
<html lang="en"     class="pb-page"  data-request-id="b2aeaa70-96d5-448e-bd8a-bc8538b23f69"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/jm200326p;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2011.54.issue-13;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma" /></meta><meta name="dc.Creator" content="Anthony D.  William" /></meta><meta name="dc.Creator" content="Angeline C.-H.  Lee" /></meta><meta name="dc.Creator" content="Stéphanie  Blanchard" /></meta><meta name="dc.Creator" content="Anders  Poulsen" /></meta><meta name="dc.Creator" content="Ee Ling  Teo" /></meta><meta name="dc.Creator" content="Harish  Nagaraj" /></meta><meta name="dc.Creator" content="Evelyn  Tan" /></meta><meta name="dc.Creator" content="Dizhong  Chen" /></meta><meta name="dc.Creator" content="Meredith  Williams" /></meta><meta name="dc.Creator" content="Eric T.  Sun" /></meta><meta name="dc.Creator" content="Kee Chuan  Goh" /></meta><meta name="dc.Creator" content="Wai Chung  Ong" /></meta><meta name="dc.Creator" content="Siok Kun  Goh" /></meta><meta name="dc.Creator" content="Stefan  Hart" /></meta><meta name="dc.Creator" content="Ramesh  Jayaraman" /></meta><meta name="dc.Creator" content="Mohammed Khalid  Pasha" /></meta><meta name="dc.Creator" content="Kantharaj  Ethirajulu" /></meta><meta name="dc.Creator" content="Jeanette M.  Wood" /></meta><meta name="dc.Creator" content="Brian W.  Dymock" /></meta><meta name="dc.Description" content="Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treat..." /></meta><meta name="Description" content="Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treat..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 15, 2011" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm200326p" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2011 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm200326p" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm200326p" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm200326p" /></link>
        
    
    

<title>Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm200326p" /></meta><meta property="og:title" content="Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0008.jpeg" /></meta><meta property="og:description" content="Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF). Herein, we describe the design and synthesis of a series of small molecule 4-aryl-2-aminopyrimidine macrocycles and their biological evaluation against the JAK family of kinase enzymes and FLT3. The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of 21c, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, respectively) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, respectively). Further profiling of 21c in preclinical species and mouse xenograft and allograft models is described. Compound 21c (SB1518) was selected as a development candidate and progressed into clinical trials where it is currently in phase 2 for MF and lymphoma." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm200326p"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm200326p">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm200326p&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm200326p&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm200326p&amp;href=/doi/10.1021/jm200326p" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2011</span><span class="cit-fg-volume">, 54</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 4638-4658</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/54/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm200311m" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm2003365" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony+D.++William">Anthony D. William</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Angeline+C.-H.++Lee">Angeline C.-H. Lee</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=St%C3%A9phanie++Blanchard">Stéphanie Blanchard</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anders++Poulsen">Anders Poulsen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ee+Ling++Teo">Ee Ling Teo</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Harish++Nagaraj">Harish Nagaraj</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Evelyn++Tan">Evelyn Tan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dizhong++Chen">Dizhong Chen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Meredith++Williams">Meredith Williams</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eric+T.++Sun">Eric T. Sun</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kee+Chuan++Goh">Kee Chuan Goh</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wai+Chung++Ong">Wai Chung Ong</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Siok+Kun++Goh">Siok Kun Goh</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Hart">Stefan Hart</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ramesh++Jayaraman">Ramesh Jayaraman</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mohammed+Khalid++Pasha">Mohammed Khalid Pasha</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kantharaj++Ethirajulu">Kantharaj Ethirajulu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeanette+M.++Wood">Jeanette M. Wood</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+W.++Dymock">Brian W. Dymock</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div><div class="corresp-info">Tel: (0065) 6827-5021. Fax: (0065) 6827-5005. E-mail: <a href="/cdn-cgi/l/email-protection#d6b7b8a2beb9b8af89a1bfbababfb7bb96a5b4bfb9f8b5b9bb"><span class="__cf_email__" data-cfemail="bcddd2c8d4d3d2c5e3cbd5d0d0d5ddd1fccfded5d392dfd3d1">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm200326p&amp;href=/doi/10.1021%2Fjm200326p" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2011</span></span><span class="cit-volume">, 54</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 4638–4658</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 23, 2011</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 March 2011</li><li><span class="item_label"><b>Published</b> online</span>15 June 2011</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 July 2011</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm200326p" title="DOI URL">https://doi.org/10.1021/jm200326p</a></div><div class="article_header-article-copyright"><strong>Copyright © 2011 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4638%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAnthony%2BD.%2BWilliam%252C%2BAngeline%2BC.-H.%2BLee%252C%2BSt%25C3%25A9phanie%2BBlanchard%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D54%26issueNum%3D13%26contentID%3Djm200326p%26title%3DDiscovery%2Bof%2Bthe%2BMacrocycle%2B11-%25282-Pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2B%2528SB1518%2529%252C%2Ba%2BPotent%2BJanus%2BKinase%2B2%252FFms-Like%2BTyrosine%2BKinase-3%2B%2528JAK2%252FFLT3%2529%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BMyelofibrosis%2Band%2BLymphoma%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4658%26publicationDate%3DJuly%2B2011">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm200326p"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5388</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">96</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm200326p" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;D. William&quot;},{&quot;first_name&quot;:&quot;Angeline&quot;,&quot;last_name&quot;:&quot;C.-H. Lee&quot;},{&quot;first_name&quot;:&quot;Stéphanie&quot;,&quot;last_name&quot;:&quot;Blanchard&quot;},{&quot;first_name&quot;:&quot;Anders&quot;,&quot;last_name&quot;:&quot;Poulsen&quot;},{&quot;first_name&quot;:&quot;Ee&quot;,&quot;last_name&quot;:&quot;Ling Teo&quot;},{&quot;first_name&quot;:&quot;Harish&quot;,&quot;last_name&quot;:&quot;Nagaraj&quot;},{&quot;first_name&quot;:&quot;Evelyn&quot;,&quot;last_name&quot;:&quot;Tan&quot;},{&quot;first_name&quot;:&quot;Dizhong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Meredith&quot;,&quot;last_name&quot;:&quot;Williams&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;T. Sun&quot;},{&quot;first_name&quot;:&quot;Kee&quot;,&quot;last_name&quot;:&quot;Chuan Goh&quot;},{&quot;first_name&quot;:&quot;Wai&quot;,&quot;last_name&quot;:&quot;Chung Ong&quot;},{&quot;first_name&quot;:&quot;Siok&quot;,&quot;last_name&quot;:&quot;Kun Goh&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Hart&quot;},{&quot;first_name&quot;:&quot;Ramesh&quot;,&quot;last_name&quot;:&quot;Jayaraman&quot;},{&quot;first_name&quot;:&quot;Mohammed&quot;,&quot;last_name&quot;:&quot;Khalid Pasha&quot;},{&quot;first_name&quot;:&quot;Kantharaj&quot;,&quot;last_name&quot;:&quot;Ethirajulu&quot;},{&quot;first_name&quot;:&quot;Jeanette&quot;,&quot;last_name&quot;:&quot;M. Wood&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;W. Dymock&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2011&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;54&quot;,&quot;pages&quot;:&quot;4638-4658&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm200326p&quot;},&quot;abstract&quot;:&quot;Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF). Herein, we describe the design and synthesis of a series of small molecule 4-aryl-2-aminopyrimidine macrocycles and their biological evaluation against the JAK family of kinase enzymes and FLT3. The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of 21c, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, respectively) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, respectively). Further profiling of 21c in preclinical species and mouse xenograft and allograft models is described. Compound 21c (SB1518) was selected as a development candidate and progressed into clinical trials where it is currently in phase 2 for MF and lymphoma.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200326p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200326p" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200326p&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200326p" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm200326p&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200326p" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm200326p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm200326p&amp;href=/doi/10.1021/jm200326p" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm200326p" /></input><a href="/doi/pdf/10.1021/jm200326p" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26pmid%3D21604762%26genre%3Darticle%26aulast%3DWilliam%26date%3D2011%26atitle%3DDiscovery%2Bof%2Bthe%2BMacrocycle%2B11-%25282-Pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2B%2528SB1518%2529%252C%2Ba%2BPotent%2BJanus%2BKinase%2B2%252FFms-Like%2BTyrosine%2BKinase-3%2B%2528JAK2%252FFLT3%2529%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BMyelofibrosis%2Band%2BLymphoma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D54%26issue%3D13%26spage%3D4638%26epage%3D4658%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/54/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jmcmar.2011.54.issue-13/production/jmcmar.2011.54.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2<sup>V617F</sup>), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF). Herein, we describe the design and synthesis of a series of small molecule 4-aryl-2-aminopyrimidine macrocycles and their biological evaluation against the JAK family of kinase enzymes and FLT3. The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of <b>21c</b>, a potent JAK2 (IC<sub>50</sub> = 23 and 19 nM for JAK2<sup>WT</sup> and JAK2<sup>V617F</sup>, respectively) and FLT3 (IC<sub>50</sub> = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC<sub>50</sub> = 1280 and 520 nM, respectively). Further profiling of <b>21c</b> in preclinical species and mouse xenograft and allograft models is described. Compound <b>21c</b> (SB1518) was selected as a development candidate and progressed into clinical trials where it is currently in phase 2 for MF and lymphoma.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87016" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87016" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Janus family of kinases (JAK1, JAK2, JAK3, and TYK2) are intracellular nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT (signal transducer and activator of transcription) pathway and hence play an important role in the control of cell proliferation, cell differentiation, and survival.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> In 2005, the discovery of the V617F mutation in JAK2 (JAK2<sup>V617F</sup>) catalyzed significant efforts in our laboratories to bring a new small molecule JAK2 inhibitor therapy to the clinic for the treatment of a wide spectrum of hematological malignancies, particularly the myeloproliferative neoplasms (MPNs) and lymphoma.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7">(3-7)</a> The MPNs are a spectrum of poorly treated diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary, post-PV, and post-ET myelofibrosis (MF). MF is the most serious disease with the most severe patients having a life expectancy of between 1.5 to 5 years. The MF disease course is characterized by symptomatic splenomegaly, progressive anemia leading to fatigue, and severe constitutional symptoms including night sweats, fever, bleeding, bone pain, and frequent infections.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Inhibition of the JAK-STAT signaling pathways<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> in MF patients has given encouraging initial responses in recent clinical trials,<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10-12)</a> and <b>21c</b> (SB1518) described herein, has demonstrated an ability to reduce splenomegaly and improve symptoms in phase 1 and 2 clinical trials in MF patients.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13-15)</a></div><div class="NLM_p">Rationale for use of JAK2 inhibitors in lymphoma is supported by a number of studies: activation of wild-type JAK2 in lymphoma cells by a mutation in the SOCS-1 gene (suppressor of cytokine signaling); discovery that a high level of a micro-RNA species targeting JAK2 (miR-135a) correlates with a favorable prognosis in classical Hodgkin lymphoma patients; and increased JAK2 gene expression in a number of lymphoma subtypes.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16-19)</a> Furthermore, JAK2 has been implicated in inflammatory disease such as rheumatoid arthritis and psoriasis with encouraging initial clinical data.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a></div><div class="NLM_p">Selectivity for JAK2 over JAK3 was strongly desirable due to the reported immunosuppressive effects of inhibiting JAK3. Deficient JAK3 signaling in humans and mice causes severe combined immunodeficiency (SCID).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The effects of adding JAK1 and/or TYK2 activity to a JAK2 inhibitor are still not well understood.</div><div class="NLM_p">Overexpression and activating mutations of receptor tyrosine kinases (RTKs) are known to be involved in the pathophysiology of diverse human cancers. Further to JAK-STAT driven disease, we sought to broaden the potential application of a JAK2 inhibitor by refining additional RTK activity discovered in our leads.  FLT3 (fms-like tyrosine kinase-3), a class III RTK, is the most frequently mutated gene in acute myeloid leukemia (AML) and plays an important role in the maintenance, growth, and development of hematopoietic and nonhematopoietic cells. Mutations of the FLT3 receptor can lead to the development of AML.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26 ref27">(23-27)</a> Hence, we were attracted to the potential of a JAK2/FLT3 combined inhibitor profile. As MF, lymphoma, and AML continue to present as unmet medical needs in hematology, JAK2/FLT3 inhibitor therapy could offer new hope for the development of a safe and effective therapy.</div><div class="NLM_p last">At the time of the first reports of the JAK2<sup>V617F</sup> mutation,<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4-6)</a> we were engaged in a search for novel kinase inhibitor motifs. We were evaluating a series of compounds which exhibited a unique kinase inhibitory spectrum with JAK2 and FLT3 inhibition being prominent. Rationale for JAK2 inhibitor therapy in the MPNs was strengthening, and encouraged by the additional desirable FLT3 activity we were seeing in our leads, we focused our attention on the rapid identification of a clinical candidate which would meet the desired requirements for MF and lymphoma therapy with potential for activity in other JAK2 and FLT3-driven diseases: potent and selective JAK2/FLT3 inhibition with an excellent safety profile and oral daily dosing. Herein, we describe the discovery and structure–activity relationship (SAR) of a series of small molecule macrocycles culminating in the identification of <b>21c</b>, the compound that we selected for preclinical development and then progressed into clinical trials. Compound <b>21c</b> is showing clinical benefit in patients with MF and lymphoma with many patients remaining on therapy in ongoing phase 1 and 2 trials in these indications.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50317" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50317" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In-house library screening revealed compound <b>1</b> which showed broad kinase inhibition with reasonable activity in cell lines tested; however, these rather ubiquitous pyrimidine-based motifs are heavily patented with very narrow possibilities for developing proprietary compounds.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> We envisioned that by connecting the open ends of <b>1</b>, to form macrocycles <b>2</b>, the binding mode to the kinase hinge region is not compromised (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Thus, we embarked on the synthesis of small molecule macrocycles by exploiting the powerful ring-closing metathesis (RCM) reaction as a synthetic tool.<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30-32)</a> We were inspired by macrocyclic natural products which, although usually complex and difficult to synthesize, have evolved to specifically interact with biological systems in ways not easily achievable with the much simpler small molecule compounds found in screening libraries.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33-35)</a> It seemed attractive to us to explore the potential for diverse but specific functionalization possible within the ring structure of <b>2</b>, conformationally defined by the semirigid arrangement of the A, B, and C rings. Whereas open chain compounds will adopt energetically favorable conformations that are not necessarily complementary to the target binding site, the ability to position a chosen group at a desired point in space with limited conformational freedom using a constrained macrocyclic structure could have benefits leading to greater specificity between kinases. The choice of initial linkers, Z, was driven by synthetic concerns and our desire to avoid very lipophilic and flexible linkers of straight carbon chains which would dramatically increase log <i>P</i> and likely be vulnerable to phase 1 metabolism. Solubility and metabolic stability were primary concerns from the early stages; therefore, linkers with some hydrophilic character (use of oxygen atoms) and not containing any groups known to be rapidly metabolized were prioritized.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Inception of macrocyclization from an in-house library screening hit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Synthesis of the macrocycles is made possible by taking advantage of the RCM reaction pioneered by Grubbs. Synthesis of the precursors for RCM was achieved by the coupling of the two halves of the molecules via acidic displacement between the chloropyrimidines and anilines.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In general, RCM of the dienes was achieved by employing either Grubbs second generation catalyst ((C<sub>46</sub>H<sub>65</sub>Cl<sub>2</sub>N<sub>2</sub>PRu): [1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro(phenylmethylene)(tricyclohexylphosphine)ruthenium) or Zhan-1B catalyst ((RuCl<sub>2</sub>[C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>][C<sub>12</sub>H<sub>17</sub>NO<sub>3</sub>S]): 1,3-Bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene[2-(i-propoxy)-5-(<i>N</i>,<i>N</i>-dimethylaminosulfonyl)phenyl]methyleneruthenium(II) dichloride).<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a> All products were isolated as inseparable mixtures of approximately 85:15 <i>trans</i>:<i>cis</i> double bond geometry. Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> illustrates the synthetic routes for compounds <b>16a</b>–<b>f</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,2-dimethoxyethane, water, 80 °C, 52–64%. (b) Allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 38–68%. (c) 4-Bromobut-1-ene, CsCO<sub>3</sub>, DMF, 40 °C, 52–64%. (d) Fe powder, NH<sub>4</sub>Cl, EtOH, water, 80 °C, 71–96%. (e) 4 M HCl, <i>n</i>-butanol, 80–100 °C, 21–56%. (f) Grubbs second generation catalyst, HCl, CH<sub>2</sub>Cl<sub>2</sub>, 40–45 °C, 43–51%. (g) NaSEt, DMF, 120 °C, 30%.</p></p></figure><div class="NLM_p">Left-hand fragments were constructed by Suzuki coupling of commercially available 2,4-dichloropyrimidine (<b>3a</b>) and boronic acids <b>4a</b>–<b>b</b> affording the corresponding biaryl alcohols <b>5a</b>–<b>b</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39, 40)</a> Alkylation of the alcohols was achieved either under phase transfer conditions with allyl bromide, giving allylethers <b>6a</b>–<b>b</b>, or with cesium carbonate assisted displacement with 4-bromo-but-1-ene furnishing homoallyl ether, <b>7</b>.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41, 42)</a></div><div class="NLM_p">Because of their diversity, right-hand fragments were prepared using a wide variety of methods, as illustrated in Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Commercially available alcohols <b>10a</b>–<b>b</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) were alkylated as described above by either allyl bromide or 4-bromo-but-1-ene to produce the corresponding <b>11a</b>–<b>b</b> and <b>13</b>, respectively. Iron-assisted reduction of the nitro group gave key anilines <b>12a</b>–<b>b</b> and <b>14</b>, respectively, in good to excellent yields.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Precursors of the RCM reaction, dienes <b>15a</b>–<b>e</b>, were prepared in moderate yield from coupling of Suzuki products <b>6a</b>–<b>b</b> and <b>7</b> and anilines <b>12a</b>–<b>b</b> and <b>14</b> in the presence of HCl under reflux conditions. Macrocyclization of <b>15a</b>–<b>e</b> proceeded efficiently in the presence of Grubbs second generation catalyst with hydrochloric acid as an additive to afford products <b>16a</b>–<b>f</b> in moderate yields.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, quantitative. (b) NaBH<sub>4</sub>, THF, water, 0 °C, quantitative. (c) Allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 38–68%. (d) Fe powder, NH<sub>4</sub>Cl, EtOH, water, 80 °C, 71–96%. (e) 1,2-Dichloroethane, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 54–72%. (f) Fmoc-Cl, DIEA, 1,4-dioxane, rt, 95%. (g) 4 M HCl, <i>n</i>-butanol, 80–100 °C, 21–92%. (h) Either Grubbs second generation catalyst or Zhan catalyst-1B, HCl, CH<sub>2</sub>Cl<sub>2</sub>, 40–45 °C, 43–96%. (i) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 73%. (j) 2-Bromoethanol, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 34%. (k) Acetyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 63%. (l) Ethanesulfonyl chloride, K<sub>2</sub>CO<sub>3</sub>, THF, 70 °C, 41%. (m) DMA, microwave 80 °C, 72–90%. (n) 20% v/v piperidine in CH<sub>2</sub>Cl<sub>2</sub>, rt, 82%. (o) 3-(Diethylamino)propionic acid hydrochloride, HOBt, EDCI, CH<sub>2</sub>Cl<sub>2</sub>, 55%.</p></p></figure><div class="NLM_p">Sequences (1–8) in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a> show the synthetic routes to obtain <b>12c</b>–<b>i</b>. The displacement reaction of <b>8b</b> with corresponding secondary amines afforded <b>9a</b>–<b>d</b> in quantitative yields. Alkylation of <b>8c</b>–<b>d</b> proceeded smoothly with 1,2-dichloroethane to afford <b>9e</b>–<b>f</b>.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Benzaldehydes <b>9a</b>–<b>f</b> were efficiently reduced to the corresponding benzylic alcohols <b>10c</b>–<b>h</b> using sodium borohydride. By employing phase transfer conditions with allyl bromide, the alkylated intermediates were then reduced via the aforementioned iron conditions to afford anilines <b>12c</b>–<b>h</b> in good to excellent yields. Aniline <b>12i</b> was prepared by alkylation of the benzylic alcohol <b>18</b> using phase transfer conditions. Reduction of both nitro groups gave bis-aniline <b>20</b>, which was monoprotected using Fmoc-Cl affording a quantitative yield of <b>12i</b>. Phenol <b>16f</b> was obtained though demethylation of <b>16e</b> using NaSEt.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_p">Biaryl <b>6b</b> underwent chloride displacement with anilines <b>12c</b>–<b>f</b> to furnish the respective dienes that were macrocyclized with either Grubbs second generation or Zhan-1B catalyst to afford macrocyles <b>17a</b>,<b>b</b>,<b>d</b>, and <b>h</b> in moderate yield. Compound <b>17c</b> was obtained via the removal of the Boc group from <b>17b</b>. The free amine on the piperazine ring was further derivatized by alkylation, acetylation, and sulfonylation to afford <b>17e</b>–<b>g</b>, respectively, with moderate yields. The intermediate <b>21a</b>, formed from coupling of <b>6b</b> and <b>12g</b> under reflux conditions in the presence of <i>n</i>-butanol, was further derivatized by displacement reactions with various secondary amines employing microwave conditions in DMA solvent, affording the more soluble products <b>21b</b>–<b>f</b>. Similarly, <b>21 h</b>–<b>i</b> were obtained from <b>21g</b> using the same displacement method. The intermediate <b>21g</b> was made in moderate yield by the coupling of <i>meta</i>-aniline <b>12h</b> and <b>6b</b>. Compounds <b>21k</b>–<b>l</b> were prepared first by basic removal of the Fmoc group from <b>21j</b>, prepared as described for <b>21g</b>, followed by amidation with 3-diethylamino-propionic acid (sequence 8 in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>).</div><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a> illustrates the synthetic route toward the preparation of diversely substituted compounds <b>22a</b>–<b>g</b>. Commercially available <b>8c</b> and <b>8e</b> were subjected to the aforementioned alkylation conditions with 1,2-dichloroethane, followed by NaBH<sub>4</sub> reduction and phase transfer allylation with allyl bromide to give <b>11g</b> and <b>11i</b>, respectively. Pyrrolidine displacement gave <b>11j</b>–<b>k</b>, which were then reduced to the anilines <b>12j</b>–<b>k</b> in excellent yields.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The right-hand fragments were obtained from different commercially available pyrimidines <b>3a</b>–<b>c</b> and boronic acids <b>4b</b>–<b>f</b>. Following standard Suzuki couping, aldehydes <b>5d</b> and <b>5h</b> and ester <b>5f</b> were readily reduced to the corresponding benzyl alcohols, which were alkylated using phase transfer conditions with allyl bromide to give <b>6b</b>–<b>h</b> in moderate yields. Compounds <b>22a</b>–<b>g</b> were then prepared using the above-described displacement and RCM.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0013.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) 1,2-dichloroethane, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 54–72%. (b) NaBH<sub>4</sub>, THF, water, 0 °C, quantitative. (c) Allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 38–68%. (d) Pyrrolidine, DMA, 90 °C, 66–76%. (e) Fe powder, NH<sub>4</sub>Cl, EtOH, water, 80 °C, 74–90%. (f) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,2-dimethoxyethane, water, 80 °C, 40–66%. (g) DIBAL, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 48%. (h) 4 M HCl, <i>n</i>-butanol, 80–100 °C, 21–91%. (i) Either Grubbs second generation catalyst or Zhan catalyst-1B, HCl, CH<sub>2</sub>Cl<sub>2</sub>, 40–45 °C, 32–79%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87161" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87161" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Selection of the Preferred Linker</h3><div class="NLM_p">Macrocycles as protein kinase inhibitors have been explored by few other groups with no advanced candidates being reported to our knowledge. We aimed to identify a distinct core structure with clear novelty and structural rigidity which would in turn reduce conformational freedom, potentially increasing the likelihood of finding compounds with specific selectivity profiles. Hence, we decided to focus on linkers retaining the double bond conveniently installed directly from the RCM reaction. A study of various linkers with and without R1 groups demonstrated that these templates inhibited JAK2/FLT3 with selectivity against JAK1/3 and CDK2 (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In general, the most potent JAK2 linkers were 8 atoms in length with at least one benzylic ether, as in compounds <b>16c</b>, <b>e</b>, and <b>f</b>. Very good selectivity over JAK1, JAK3, and CDK2 was already apparent especially with bis-phenolic ether <b>16a</b> and phenolic-benzylic ether <b>16c</b>. Symmetrical dibenzylic linkers, as employed in compounds <b>16e</b> and <b>16f</b>, were quite potent against JAK2 and retained good selectivity over JAK1 and 3 as well as CDK2. For example, <b>16e</b> has a JAK2 IC<sub>50</sub> of 70 nM and is 27-, 17-, and 12-fold selective against JAK1, JAK3, and CDK2, respectively. TYK2 SAR tended to broadly track with JAK2. We decided to focus on progression of the most potent dibenzylic compounds <b>16e</b> and <b>16f</b>. At this early stage, we were already concerned about very low solubility in these high cLogP compounds (<b>16b</b> and <b>16d</b> were <10 μg/mL in PBS buffered at pH 7.0); hence, the search for locations to install a solubilizing group was paramount.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Lead Identification: Search for a Suitable Linker for Selectivity toward JAK2</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0014.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0015.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All compounds were isolated as inseparable c.85:15 trans/cis mixtures.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">All IC<sub>50</sub> values are the mean ± SD (of at least two independent experiments). The assays were run at S*BIO using TG101348 as a reference: JAK1 IC<sub>50</sub> = 120 nM, JAK2 IC<sub>50</sub> = 7 nM, JAK3 IC<sub>50</sub> = 2650 nM (published values:<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> JAK1 IC<sub>50</sub> = 105 nM, JAK2 IC<sub>50</sub> = 3 nM, JAK3 IC<sub>50</sub> = 996 nM).</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Not determined.</p></div></div><div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Development of More Soluble Compounds: Exploration of Substituents on the C-Ring Oriented toward Solvent</h3><div class="NLM_p">Docking of <b>16e</b> into the JAK2 ATP binding site supported the hypothesis that the expected hinge binding mode is preferred with hydrogen bonding between the amino-pyrimidine and the backbone Leu932 residue (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A). An additional hydrogen bond between the benzylic ether oxygen and Ser936 could explain the higher potency of <b>16c</b>–<b>f</b> compared to that of phenolic <b>16a</b>–<b>b</b>. Clearly, the macrocycle structure fills out the available space in the binding site quite well but with opportunities for building additional interactions with the protein from various sites such as the pyrimidine, which we hypothesized could potentially accommodate small lipophilic groups to interact with the gatekeeper methionine residue Met929. Another possibility for additional interactions and to attach a solubilizing group is from the R1 position. Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B shows that the R1 substituent points directly toward a channel out to the solvent which may offer potential for additional interactions as well as increase in solubility by installation of a basic center.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0016.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>16e</b> docked into the ATP-binding site of JAK2. Compound <b>16e</b> is shown as a thick tube with green carbon. Hydrogen bonds between <b>16e</b> and JAK2 are shown as purple/black dashed lines. (A) JAK2 is shown in thin tube with gray carbon. The backbone of Leu932 forms two hydrogen bonds with <b>16e</b> and the side chain of Ser936 hydrogen bonds with an ether-oxygen in the macrocyclic linker. Leu855, Val863, Ala880, and Leu983 (in the bottom of the binding site) have hydrophobic contacts with the aromatic rings of <b>16e</b>. (B) JAK2 is shown as a surface. The methoxy group of <b>16e</b> is pointing toward a groove on the JAK2 surface that may accommodate a solubility-tag enabling fine-tuning of molecular properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Exploration of this solvent channel from both the R1 and R2 positions proved to be quite fruitful (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). A range of N- and O-substituents were very well tolerated with, on the whole, sub-100 nM IC<sub>50</sub> values against the primary targets JAK2 and FLT3. Sterically large groups such as morpholine <b>17a</b> and piperazines <b>17c</b>–<b>d</b> were potent and selective, although sparingly soluble in aqueous media. Improved solubility was achieved with the polar hydroxyethyl piperazine <b>17e</b>; however, improvement in JAK2 activity seemed elusive with nitrogen-linked compounds, even with the less sterically encumbered open-chain analogues <b>17h</b> and amide <b>21l</b>. Compound <b>17h</b> is noteworthy due to its surprising CDK2 potency, likely due to a salt bridge interaction with Asp86 made possible by the methyl substitution on the nitrogen of the side-chain, which allows the side-chain to adopt an energetically favorable conformation for interaction between Asp86 and the charged dimethylamine (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Figure S1). However, improved potency was achieved with oxygen-linked substituents: compounds <b>21b</b>–<b>f</b>, containing an aminoethylether side-chain, were uniformly potent against JAK2 and selective against JAK1/3 and CDK2 whether or not they contained a basic center. Nonbasic <b>21e</b> suffered a reduction in FLT3 as well as TYK2 activity and was likely to be less soluble than analogues with charged side chains at physiological pH; hence, the preferred compounds from this series were <b>21b</b>,<b>c</b>,<b>d</b> and <b>f</b>. The direct R2 analogue of <b>21c</b>, <b>21h</b>, was also potent against JAK2 but with submicromolar CDK2 activity. Morpholine analogue <b>21i</b>, however, was less CDK2 potent but suffered a 5-fold reduction in JAK2 potency over the most potent R<sub>1</sub> compounds. Nitrogen-linked anline <b>21k</b> and amide <b>21l</b> were also potent JAK2/FLT3 inhibitors but had reduced selectivity against CDK2. TYK2 SAR was in general quite flat for these compounds with the notable exception of <b>21l</b> (TYK2 IC<sub>50</sub> = 18 nM). Hence, only a limited study of R<sub>2</sub> substituents was carried out. Aminoethylethers <b>21b</b>–<b>d</b> containing side-chains were prioritized for further evaluation in DMPK assays.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Optimization: Study of Suitable Solubilizing Groups</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0017.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0001.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">All IC<sub>50</sub> values are the mean ± SD (of at least two independent experiments).</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">High throughput solubility in PBS buffered at pH 7.0.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Not determined.</p></div></div><div></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Development of More Potent Compounds: Exploration of A-Ring and B-Ring SARs</h3><div class="NLM_p">Docking of <b>21c</b> into the JAK2 ATP binding site confirmed the expected hinge binding mode between the amino-pyrimidine and the backbone Leu932 residue as well as the hydrogen bond to Ser936 from one of the oxygens in the macrocyclic linker. An additional notable interaction between the basic nitrogen of the pyrrolidine, forming a salt bridge to Asp939, could explain the improved potency against JAK2 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A). The macrocyclic structure of <b>21c</b> with the pendant side-chain fills out the available space in the binding site with opportunities to fine-tune hydrophobic interactions with the protein from various sites of the molecule, such as the A-ring (biaryl phenyl) and B-ring (pyrimidine). From the docking analysis, we hypothesized that these two rings could potentially accommodate small lipophilic groups that could complement the hydrophobic area bound by the gatekeeper Met929, Glu930, Ala880, and Val863 (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B).</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>21c</b> docked into the ATP-binding site of JAK2. Compound <b>21c</b> forms the same hydrogen bonds with JAK2 as <b>16e</b>. In addition, the solubilizing pyrrolidine side-chain forms a salt bridge with Asp939. There are opportunities for hydrophobic interactions with (A) Met929 through derivatization of the 5′-pyrimidine position and (B) with Gly993/Asp994 and Lys857 accessible from the A-ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Indeed 5′-methyl substituted pyrimidine <b>22b</b> exhibited 4-fold higher potency for JAK2 (IC<sub>50</sub> 6 nM) as compared to <b>21c</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). The methyl group in the 5-position of the pyrimidine fits snugly into the hydrophobic area bound by the gatekeeper Met929, Glu930, Ala880, and Val863. Although having good solubility, this compound was compromised somewhat by its selectivity against JAK3 which had dropped to about 15-fold. This may be due to the increase in torsion angle between the two aromatic rings leading to a binding conformation favorable for JAK3. Furthermore, this conformation docks less well into the CDK2 binding site with the compound fitting less well into the hydrophobic area.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR Exploration of Aromatic Ring Substitutions with Small Groups</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0005.gif" alt="" id="_i13" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd</th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">R<sub>4</sub></th><th class="colsep0 rowsep0" align="center">R<sub>5</sub></th><th class="colsep0 rowsep0" align="center">R<sub>6</sub></th><th class="colsep0 rowsep0" align="center">JAK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">JAK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">JAK3 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">TYK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">FLT3 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CDK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">cLogP</th><th class="colsep0 rowsep0" align="center">solubility (μg/mL)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22a</b></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.036 ± 0.003</td><td class="colsep0 rowsep0" align="left">1.7 ± 0.28</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.17 ± 0.021</td><td class="colsep0 rowsep0" align="left">0.006 ± 0.001</td><td class="colsep0 rowsep0" align="left">3.4 ± 1.1</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">154</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.007 ± 0.000</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.0</td><td class="colsep0 rowsep0" align="left">0.089 ± 0.004</td><td class="colsep0 rowsep0" align="left">0.057 ± 0.004</td><td class="colsep0 rowsep0" align="left">0.019 ± 0.001</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" align="left">178</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.017 ± 0.000</td><td class="colsep0 rowsep0" align="left">0.83 ± 0.085</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.00</td><td class="colsep0 rowsep0" align="left">0.14 ± 0.028</td><td class="colsep0 rowsep0" align="left">0.015 ± 0.003</td><td class="colsep0 rowsep0" align="left">1.55 ± 0.071</td><td class="colsep0 rowsep0" align="left">4.7</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22d</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.33 ± 0.00</td><td class="colsep0 rowsep0" align="left">4.9 ± 0.85</td><td class="colsep0 rowsep0" align="left">7.2 ± 0.21</td><td class="colsep0 rowsep0" align="left">0.62 ± 0.064</td><td class="colsep0 rowsep0" align="left">0.012 ± 0.001</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22e</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.024 ± 0.002</td><td class="colsep0 rowsep0" align="left">0.38 ± 0.014</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">0.036 ± 0.003</td><td class="colsep0 rowsep0" align="left">0.008 ± 0.004</td><td class="colsep0 rowsep0" align="left">2.0 ± 0.42</td><td class="colsep0 rowsep0" align="left">5.2</td><td class="colsep0 rowsep0" align="left">2.61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22f</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.019 ± 0.002</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.89 ± 0.042</td><td class="colsep0 rowsep0" align="left">0.18 ± 0.00</td><td class="colsep0 rowsep0" align="left">0.092 ± 0.011</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">60.83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22g</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">0.025 ± 0.001</td><td class="colsep0 rowsep0" align="left">4.6 ± 0.35</td><td class="colsep0 rowsep0" align="left">0.72 ± 0.11</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">0.040 ± 0.015</td><td class="colsep0 rowsep0" align="left">3.25 ± 0.071</td><td class="colsep0 rowsep0" align="left">4.7</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">All IC<sub>50</sub> values are the mean ± SD (of at least two independent experiments).</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">High throughput solubility in PBS buffered at pH 7.0.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Not determined.</p></div></div></div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>22b</b> docked into the ATP-binding site of JAK2 (A) and with the surface shown (B). The solvent-accessible surface of JAK2 surrounding the methyl-pyrimidine substituent is shown in peach. The methyl is an excellent fit to this part of the binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Replacing the 5′-methyl group with electron-withdrawing fluoro (<b>22c</b>) reduced JAK2 activity by 3-fold, confirming that hydrophobic groups are ultimately preferred, but selectivity toward JAK1 and JAK3 was retained (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). This compound was also more potent against CDK2 but retained selectivity of 91-fold. Substitution on the A ring was studied with a small group of synthetically accessible compounds. Substitution with methoxy at R<sub>4</sub> (<b>22d</b>) is unfavorable for JAK family activity but suggests that this area could be an avenue for the preparation of selective FLT3 inhibitors (<b>22d</b> FLT3 IC<sub>50</sub> 12 nM). In contrast, substitution with electron-withdrawing fluoro at R<sub>5</sub> (<b>22e</b>) is well tolerated but reduces selectivity over JAK1 as well as being of very low solubility. Small lipophilic groups at the R<sub>6</sub> position, such as methoxy <b>22f</b>, appear to be well tolerated on this ring exhibiting excellent potency and selectivity for JAK2 over JAK1. Although the effects of adding JAK1 activity to a JAK2 inhibitor are poorly understood, we prioritized more selective compounds in the expectation that they would have reduced off-target toxicity. In general, solubility seems to be lower with substitutions on this ring, possibly as a result of high log <i>P</i>. The favorable potency and excellent selectivity of <b>22f</b> were suggested from Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B and explained in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> where the extra methoxy group makes favorable hydrophobic interactions with JAK2 but has unfavorable clashes with Lys33 and Asp145 of CDK2.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>22f</b> docked into JAK2 (A) and CDK2 (B). The 4-methoxy substituent of the A-ring points up into the hydrophobic area in JAK2 while it is in the plane of the A-ring in the CDK2 pose making unfavorable contact with the charged side chains of Lys33 and Asp145.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Adding an additional substituent to the right-hand side aniline ring of <b>21c</b>, to give the electron rich <b>22a</b> did not compromise JAK2 activity or selectivity and showed improved FLT3 activity as compared with <b>21c</b> and, curiously, solubility. It is not apparent why there are such solubility differences within the series. Generally all compounds in this series were satisfactorily selective against CDK2 with TYK2 activity being up to 10-fold less active than JAK2.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Further in Vitro Profiling of Preferred Compounds</h3><div class="NLM_p">Compounds with JAK2 and FLT3, IC<sub>50</sub> <25 nM, SI >25 for JAK1/3 and SI >100 for CDK2, were shortlisted for further celluar and in vitro ADME profiling (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Inhibition of the major metabolizing cytochrome P450 isozymes 3A4 and 2D6 were determined to identify any potential drug–drug interaction liabilities. Human and mouse liver microsomal stabilities give an indication of significant phase 1 metabolism events in target species. Physicochemical measurements assessing solubility and permeability were included as important indicators of oral absorption as well as cell penetration. Pharmacological activity in cell lines reflective of the target enzymes focused initially on cell proliferation using a Ba/F3 cell line harboring the JAK2 V617F mutation and MV4–11 cells harboring the drug resistant FLT3 D835Y mutation. Good potency in these cell lines was observed for all compounds with IC<sub>50</sub> values in the range of 100–180 nM in Ba/F3 cells and 37–85 nM in MV4–11 cells. Furthermore, <b>21c</b> inhibited the JAK2-mediated production of p-STAT5 and p-STAT3 dose dependently in Ba/F3 cells, and the production of p-FLT3 and p-STAT5 in MV4–11 cells (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, Figures S2 ansd S3). This evidence of intracellular target inhibition was further supported by high permeability and solubility. Differences in metabolic parameters were more apparent between compounds: CYP 3A4 was a particular area of differentiation where <b>22b</b>, although exhibiting desirable single digit nanomolar potency toward JAK2, had an IC<sub>50</sub> of 2.5 μM for CYP3A4. Although stable in liver mircosomes, <b>22b</b> had lower selectivity for JAK3. CYP3A4 inhibition was clearly an undesirable feature of piperidine analogue <b>21d</b>, reducing our interest in further studies with this compound. Diethylamine analogue <b>21b</b> suffered from low stability in mouse and moderate stability in human microsomes in addition to significant CYP3A4 inhibition. Although the CYP inhibition for <b>21b</b> and <b>22b</b> was moderate, it could not be excluded as these plasma concentrations could be reached in human subjects, and the compounds were therefore not further tested. However, <b>21c</b> and <b>22f</b> were much less active against CYP3A4 (20% inhibition at 5 μM and IC<sub>50</sub> >10 μM, respectively), and both compounds had good selectivity and microsomal stability. Compound <b>22f</b>, although possessing excellent enzyme selectivity, was less active against FLT3. Methyl pyrimidine <b>22b</b> and <b>21c</b> are differentiated by a single methyl group which generates subtle, but important, differences in the compound profiles. Compound <b>21c</b> exhibits an overall balanced profile meeting all target criteria. It was also shown to be active against the V617F mutant of JAK2 with IC<sub>50</sub> = 19 nM and the D835Y mutant of FLT3 with IC<sub>50</sub> = 6 nM, and its protein kinase selectivity was confirmed by testing against more than 50 other protein kinases covering all major families of the human protein kinome.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Profiling Leading to Selection of in Vivo Candidate <b>21c</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">IC<sub>50</sub> Selectivity Index</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd</th><th class="colsep0 rowsep0" align="center">JAK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">JAK1/JAK2</th><th class="colsep0 rowsep0" align="center">JAK3/JAK2</th><th class="colsep0 rowsep0" align="center">TYK2/JAK2</th><th class="colsep0 rowsep0" align="center">CDK2/JAK2</th><th class="colsep0 rowsep0" align="center">FLT3 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">solubility (μg/mL)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">CYP3A4 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">CYP2D6 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">HLM <i>t</i><sub>1/2</sub>(min)</th><th class="colsep0 rowsep0" align="center">MLM <i>t</i><sub>1/2</sub>(min)</th><th class="colsep0 rowsep0" align="center">Ba/F3-JAK2V617F GI<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">MV4–11 GI<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">PAMPA <i>P</i><sub>app</sub> (x 10<sup>–6</sup> cm/s)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21b</b></td><td class="colsep0 rowsep0" align="left">0.024</td><td class="colsep0 rowsep0" align="left">146</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">196</td><td class="colsep0 rowsep0" align="left">0.029</td><td class="colsep0 rowsep0" align="left">147</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">0.15</td><td class="colsep0 rowsep0" align="left">0.037</td><td class="colsep0 rowsep0" align="left">15.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21c</b></td><td class="colsep0 rowsep0" align="left">0.023</td><td class="colsep0 rowsep0" align="left">56</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">170</td><td class="colsep0 rowsep0" align="left">0.022</td><td class="colsep0 rowsep0" align="left">>150</td><td class="colsep0 rowsep0" align="left">>5<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">>5<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left">0.047</td><td class="colsep0 rowsep0" align="left">9.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21d</b></td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">63</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">5.6</td><td class="colsep0 rowsep0" align="left">180</td><td class="colsep0 rowsep0" align="left">0.026</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">0.37</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">3.93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22b</b></td><td class="colsep0 rowsep0" align="left">0.007</td><td class="colsep0 rowsep0" align="left">143</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">0.019</td><td class="colsep0 rowsep0" align="left">>150</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">0.18</td><td class="colsep0 rowsep0" align="left">0.051</td><td class="colsep0 rowsep0" align="left">16.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22f</b></td><td class="colsep0 rowsep0" align="left">0.019</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">47</td><td class="colsep0 rowsep0" align="left">9.5</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">0.15</td><td class="colsep0 rowsep0" align="left">60.83</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">0.10</td><td class="colsep0 rowsep0" align="left">0.085</td><td class="colsep0 rowsep0" align="left">10.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">All IC<sub>50</sub> values are the means (of at least two independent experiments).</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">High throughput solubility in PBS buffered at pH 7.0.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">CYP activity determined in the human liver microsome system, see experimental section for details.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">20% inhibition at 5 μM.</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last">Not determined.</p></div></div></div><div class="NLM_p">Thus, <b>21c</b> was selected for further profiling (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Preferred properties for an orally administered drug are all exhibited by <b>21c</b>: molecular weight <500, number of hydrogen bond donors <5 and acceptors <10, and cLogP <5 and polar surface area <120 Å<sup>2</sup>. None of the five major drug metabolizing human CYP450s (1A, 3A4, 2D6, 2C9, and 2C19) is inhibited by <b>21c</b> implying low drug–drug interaction potential. A Caco-2 bidirectional permeability assay confirmed that <b>21c</b> has high permeability and was not a substrate for <i>P</i>-glycoprotein (efflux ratio of 0.8), hence predicting high intestinal absorption. In vitro plasma protein binding to human plasma was high (99.9%), but taken together, the in vitro ADME profile of <b>21c</b> supports daily oral dosing.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Physico-Chemical Properties and in Vitro ADME of <b>21c</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">property</th><th class="colsep0 rowsep0" align="center">value</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mol. wt.</td><td class="colsep0 rowsep0" align="left">472.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of HBD</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of HBA</td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cLogP</td><td class="colsep0 rowsep0" align="left">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PSA (Å<sup>2</sup>)</td><td class="colsep0 rowsep0" align="left">69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HLM (<i>t</i><sub>1/2</sub>, min)</td><td class="colsep0 rowsep0" align="left">>60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DLM (<i>t</i><sub>1/2</sub>, min)</td><td class="colsep0 rowsep0" align="left">41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RLM (<i>t</i><sub>1/2</sub>, min)</td><td class="colsep0 rowsep0" align="left">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MLM (<i>t</i><sub>1/2</sub>, min)</td><td class="colsep0 rowsep0" align="left">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human CYP inhibition IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">>5<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">permeability (<i>P</i><sub>app, A→B</sub>, ×10<sup>–6</sup> cm/s)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding (%)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> in human</td><td class="colsep0 rowsep0" align="left">99.88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding (%) in dog</td><td class="colsep0 rowsep0" align="left">99.63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding (%) in mouse</td><td class="colsep0 rowsep0" align="left">99.41</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Human CYP3A4, 1A2, 2D6, 2C9, 2C19.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Precipitation observed at highest concentration of 25 μM. No significant inhibition observed at 5 μM.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Caco-2 bidirectional permeability assay.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Equilibrium dialysis assay in human plasma at 1000 ng/mL.</p></div></div></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Pharmacokinetics of <b>21c</b> in Multiple Species</h3><div class="NLM_p">The PK properties of <b>21c</b> are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>. Compound <b>21c</b> showed rapid absorption in mice (<i>t</i><sub>max</sub> =1.0 h), a mean <i>C</i><sub>max</sub> and AUC of 292 ng/mL and 399 ng·h/mL, respectively, with a mean terminal half-life of 0.8 h following a single oral dose of 30 mg/kg. The promising efficacy of <b>21c</b> in several preclinical pharmacology models (see below) was consistent with this exposure. In rats, <b>21c</b> showed moderately fast absorption (<i>t</i><sub>max</sub> = 4 h), with a peak concentration of 114 ng/mL, AUC of 599 ng·h/mL, and a terminal half-life of ∼6 h following a single oral dose of 10 mg/kg. In dogs, <b>21c</b> was rapidly absorbed (<i>t</i><sub>max</sub> = 2.0 h), with a peak concentration of ∼12 ng/mL, AUC of 53 ng·h/mL, and a terminal half-life of 3.4 h following a single oral dose of 3 mg/kg.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Oral Pharmacokinetic Parameters of <b>21c</b> in Mice, Rats, and Dogs<a class="ref internalNav" href="#tbl6-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">mouse<a class="ref internalNav" href="#t6fn1" aria-label="b">b</a> (<i>n</i> = 3/time point)</th><th class="colsep0 rowsep0" align="center">rat<a class="ref internalNav" href="#t6fn2" aria-label="c">c</a> (<i>n</i> = 3)</th><th class="colsep0 rowsep0" align="center">dog<a class="ref internalNav" href="#t6fn2" aria-label="c">c</a> (<i>n</i> = 4)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">292</td><td class="colsep0 rowsep0" align="left">114 ± 25</td><td class="colsep0 rowsep0" align="left">11.5 ± 11.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">4 ± 0</td><td class="colsep0 rowsep0" align="left">2.0<a class="ref internalNav" href="#t6fn3" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.84</td><td class="colsep0 rowsep0" align="left">5.7 ± 1.3</td><td class="colsep0 rowsep0" align="left">3.4 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0-t</sub> (ng·h/mL)<a class="ref internalNav" href="#t6fn4" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">399</td><td class="colsep0 rowsep0" align="left">599 ± 111</td><td class="colsep0 rowsep0" align="left">53 ± 53</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup>a</sup><p class="last">Note: In preliminary PK screening studies, <b>21c</b> showed oral bioavailability of 39%, 24%, and 10% in mice, dogs, and rats, respectively.</p></div><div class="footnote" id="t6fn1"><sup>b</sup><p class="last">Mean.</p></div><div class="footnote" id="t6fn2"><sup>c</sup><p class="last">Mean ± SD.</p></div><div class="footnote" id="t6fn3"><sup>d</sup><p class="last">Median.</p></div><div class="footnote" id="t6fn4"><sup>e</sup><p class="last"><i>t</i> = 8 h.</p></div></div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Efficacy of <b>21c</b> in Mouse Models</h3><div class="NLM_p">On the basis of its efficacy on JAK2 and FLT3 dependent tumor cell lines<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and good oral bioavailability, <b>21c</b> was selected for evaluation in mouse tumor models. Two models were selected on the basis of their relevance to the molecular targets: Ba/F3-JAK2<sup>V617F</sup> and MV4–11 allograft and xenograft studies representing cell lines dependent on mutant JAK2 and FLT3 signaling, respectively.</div><div class="NLM_p">The Ba/F3-JAK2<sup>V617F</sup> mouse allograft represents a model for a JAK2-driven disease exhibiting hallmark symptoms of myeloproliferative diseases such as splenomegaly and hepatomegaly. In this model, murine Ba/F3-JAK2<sup>V617F</sup> cells were engrafted by tail vein injection. Treatment with <b>21c</b> at doses of 75 and 150 mg/kg p.o. b.i.d. was started 4 days after cell inoculation for 13 consecutive days. At study termination, vehicle control mice exhibited splenomegaly and hepatomegaly (∼7-fold and 1.6-fold respectively); <b>21c</b> treatment at 150 mg/kg p.o. b.i.d. significantly ameliorated the disease symptoms, with 42% normalization of spleen weight and 99% normalization of liver weight (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>21c</b> reduces splenomegaly and hepatomegaly in a Ba/F3-JAK2<sup>V617F</sup> model of leukemia. Ba/F3-JAK2<sup>V617F</sup>-bearing nude mice were dosed p.o., b.i.d., with 75 and 150 mg/kg <b>21c</b> (HCl salt) for 13 consecutive days. On day 13, mice were sacrificed and spleen and liver weights determined (<i>n</i> = 8; * <i>p</i> < 0.05, **<i>p</i> < 0.01 ANOVA, Dunnett’s post test). The dotted line represents baseline weights.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For evaluation of the in vivo efficacy of <b>21c</b> on FLT3-ITD driven tumors, MV4–11 xenografts were established in nude mice. To identify effects on tumor growth delay, MV4–11 tumor bearing mice (average starting tumor size of 130 mm<sup>3</sup>) were treated orally once daily at doses of 25, 50, or 100 mg/kg for 21 consecutive days. After termination of the treatment, tumor growth was measured up to day 55, and median time-to-end point (= median survival) was calculated. The end point of the experiment for an individual mouse was reached on day 55 or when the tumor reached a size of 1000 mm<sup>3</sup>, whichever occurred earlier. Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a> shows the Kaplan–Meier survival curves for the different groups. The median survival was 33.0 days for the vehicle group. The lowest dose-treated group (25 mg/kg <b>21c</b>) did not show statistically significant activity with survival of 35.0 days. However, the 50 mg/kg and 100 mg/kg <b>21c</b> treatment groups showed a significantly increased median survival of 55 days (<i>p</i> < 0.01) with no significant body weight loss in the treated animals at the termination of the study. Clearly, <b>21c</b> is effective at lower doses in the MV4–11 model than in the more aggressive Ba/F3 JAK2<sup>V617F</sup> model. This is partly explained by differences in the degree of oncogene addiction in the two models, reflected in the cell viability IC<sub>50</sub> of both cell lines: the MV4–11 cell line is more sensitive than the Ba/F3 JAK2<sup>V617F</sup> cell line (MV4–11 showed an approximately 4-fold difference in sensitivity compared to that of Ba/F3 JAK2<sup>V617F</sup>); this may account for the difference in dose required in vivo. Both 75 mg/kg and 150 mg/kg bid doses are well tolerated in the Ba/F3 inoculated animals with no significant body weight loss.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>21c</b> is efficacious in a xenograft derived from a cell line harboring FLT3-ITD. MV4–11 tumor bearing nude mice were randomized into 4 groups of 8–10 animals each. Mice were treated orally (p.o.) once daily at doses of 25, 50, or 100 mg/kg of <b>21c</b> for 21 consecutive days, and median time to end point (= median survival) was determined on day 55. The figures given indicate doses calculated using the molecular weight of the free base. The Log-rank (Mantel-Cox) test was used for statistical analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10250" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10250" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described the discovery of a series of small molecule macrocycles as potent inhibitors of JAK2 and FLT3 kinases. SAR studies using data from biochemical and ADME assays led to potent JAK2 inhibitors with an appropriate balance of physicochemical and ADME properties suitable for daily oral dosing. Our original hypothesis of using a macrocyclic structure with limited conformational options by constraining the binding moieties at specific points in space has produced a novel series of JAK2/FLT3 selective inhibitors able to achieve interactions in the active sites of the target enzymes not easily accomplished with an acyclic structure. A subset of diverse compounds showed good potency and selectivity for JAK2 within the JAK family, good potency for FLT3, and also retaining potency for TYK2. Importantly, selectivity for CDK2 was assured in this series, which is not the case with at least one reported clinical-stage JAK1/2 inhibitor.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Cell proliferation was potently inhibited in cell lines driven by mutant JAK2 and FLT3, and target inhibition in the cell has been demonstrated. The favorable oral pharmacokinetic properties of <b>21c</b> prompted us to explore its pharmacodynamic effects in relevant mouse models in a dose-dependent manner. An efficacy study in a model of JAK2<sup>V617F</sup>-driven disease demonstrated dose-dependent tumor growth inhibition<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and normalization of splenomegaly and hepatomegaly at well-tolerated doses. In a second study in a model of FLT3-ITD driven leukemia, <b>21c</b> demonstrated significant survival benefits at very well-tolerated doses. Extensive cellular profiling of <b>21c</b> on myeloid and lymphoid cells and its activity in the JAK2<sup>V617F</sup>-driven SET-2 model have been reported elsewhere.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Its attractive preclinical profile led to the selection of <b>21c</b> for preclinical development, which in turn resulted in progression into the clinic where it has shown clinical benefit in myelofibrosis<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> and lymphoma patients in two completed phase 2 trials.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33781" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33781" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Chemistry</h3><div class="NLM_p">Workup for chemical reactions was typically done by diluting the reaction mixture or residue with the reaction solvent or extraction solvent and then washing with the indicated aqueous solution(s). Product solutions were dried over anhydrous sodium sulfate prior to filtration, and the solvents were removed under reduced pressure using a rotary evaporator. All compounds were purified by either flash or reversed phase chromatography. Flash column chromatography was conducted using Silica gel 60 (Merck KGaA, 0.040–0.063 mm, 230–400 mesh ASTM). Reverse-phase preparative high performance liquid chromatography (rpHPLC) was operated on a Phenomenex column (Luna 5 μm C18 (2) 100A 150 × 21.2 mm) with adjustable solvent gradients, usually 5 to 95% acetonitrile in water + 0.1% trifluoroacetic acid (TFA), with a run time of 18 min, at a flow rate of 20 mL/min were used for routine purification. Fractions containing the desired product were lyophilized or evaporated to dryness under vacuum to provide the dry compound, or evaporated to remove volatile organic solvents, then extracted with a suitable organic solvent (ethyl acetate or dichloromethane were commonly used; if necessary, the pH of the aqueous solution was adjusted in order to get free base, acid, or the neutral compound).</div><div class="NLM_p">The preliminary purity and identity of all compounds was assessed post-purification by tandem HPLC/mass spectral (LC/MS) analyses on a Waters Micromass ZQ mass spectrometer in electrospray ionization (ESI) positive mode after separation on Waters 2795 Separations Module. The HPLC separations were performed on a Phenomenex column (Luna 5 μm C18 (2) 100A 50 × 2.00 mm) with a flow rate of 0.8 mL/min and a 4 min gradient of <i>x</i>–100% acetonitrile in water + 0.05% TFA (<i>x</i> = 5, or 30, or 50), using a Waters 2996 photodiode array detector. Purity and identity were assessed on the integrated UV chromatogram (220–400 nm) and the mass spectrum (homogeneity of the product peak and its fragmentation(s)). The final purity was determined using Waters 2695 Separations Module on a Waters Xterra RP18 3.5 mm 4.6 × 20 mm IS column with a flow rate of 2.0 mL/min, gradient 5–65% B over 4 min, then 65–95% B over 1 min, and 95% B for an additional 0.1 min (solvent A, H<sub>2</sub>O with 0.1% TFA; solvent B, acetonitrile with 0.1% TFA), and a Waters 2996 photodiode array detector. For compounds not suitable for the above HPLC methods either due to polarity or poor peak separation, a longer column (Phenomenex Gemini 5 μm C18, 110A, 4.6 × 150 mm) together with a flow rate of 1.0–1.2 mL/min and a 15 min gradient of 5–95% acetonitrile in water + 0.1% TFA was used for purity determination. Purity was >95% for all test compounds except those indicated in their respective synthesis descriptions.</div><div class="NLM_p">All the 1D and 2D NMR experiments for <sup>1</sup>H (400.13 MHz), <sup>13</sup>C (100.61 MHz), <sup>15</sup>N (40.55 MHz), and <sup>19</sup>F (376.47 MHz) nuclei were performed on a Bruker AVANCE-400 digital NMR spectrometer. <sup>1</sup>H–<sup>1</sup>H, <sup>1</sup>H–<sup>13</sup>C, and <sup>1</sup>H–<sup>15</sup>N 2D experiments (COSY, HMQC, HSQC, and HMBC) were run with Z-gradient selection. NMR spectra are reported in ppm with reference to an internal tetramethylsilane standard (0.00 ppm for <sup>1</sup>H and <sup>13</sup>C) or solvent peak(s) of CDCl<sub>3</sub> (7.26 and 77.1 ppm) or CD<sub>3</sub>OD (3.31 and 49.0 ppm), or DMSO-<i>d</i><sub>6</sub> (2.50 and 39.5 ppm). Other NMR solvents were used as needed. When peak multiplicities are reported, the following abbreviations are used: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broadened, dd = doublet of doublets, dt = doublet of triplets, and bs = broadened singlet. Coupling constants, when given, are reported in Hertz.</div><div class="NLM_p">All melting points are uncorrected. Elemental analyses of CHN were performed on Perkin-Elmer 2400 CHN/CHNS Elemental Analyzers. HRMS was obtained from a Bruker microTOF-Q II with direct injection.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 3-(2-Chloro-pyrimidin-4-yl)-phenol (<b>5a</b>)</h4><div class="NLM_p last">To a degassed (nitrogen) solution of 2,4-dichoropyrimidine (<b>3a</b>) (1.0 g, 6.71 mmol) and 3-hydroxylphenyl boronic acid (<b>4a</b>) (1.1 g, 8.05 mmol) in 1,2 dimethoxyethane (10 mL) was sequentially added aqueous Na<sub>2</sub>CO<sub>3</sub> (1.06 g, 10.06 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (0.387 g, 0.335 mmol). The resultant mixture was stirred at 80–85 °C for 4 h, cooled to 0 °C, and quenched with saturated NH<sub>4</sub>Cl. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> thrice and the combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude mixture was column purified (EtOAc/Hexane) to furnish 0.550 g of <b>5a</b> (yield, 40%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 207 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.74 (s, 1H), 9.23 (d, 1H), 8.83 (d, 1H), 8.01 (dd, 1H), 7.60–7.65 (m, 1H), 7.35 (t, 1H), 6.94–6.99 (m, 1H).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> [3-(2-Chloro pyrimidine-4-yl) phenyl] Methanol (<b>5b</b>)</h4><div class="NLM_p">The synthesis for this intermediate has been improved for scale-up and was prepared using a different Suzuki coupling procedure as compared to that of <b>5a</b>. To a degassed (nitrogen) solution of <b>3a</b> (50 g, 335 mmol) and 3-(hydroxymethyl)phenylboronic acid (<b>4b</b>) (48.5 g, 318 mmol) in THF (500 mL, 10 vol) was added saturated Na<sub>2</sub>CO<sub>3</sub> (88.6 g, 838 mmol), palladium acetate (0.15 g, 0.67 mmol), and triphenylphosphine (0.35 g, 1.34 mmol). The resultant mixture was stirred at 70 °C for 6 h, and filtered. Water was added to the filtrate and extracted with ethyl acetate (3 × 250 mL). The combined organic extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and filtered. The filtrate was treated with activated charcoal, and the mixture was filtered and the filtrate concentrated under reduced pressure, and the crude product was slurried in isopropyl alcohol (300 mL). The mixture was filtered, and the solid was slurried in cold <i>n</i>-heptane and filtered to furnish <b>5b</b> (42.8 g; yield, 61%). This material was taken up for the next step without any purification. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 221 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (DMSO-<i>d</i><sub><i>6</i></sub>) δ 8.81 (d, 1H), 8.15 (br, 1H), 8.10 (d, 1H), 8.04 (dt, 1H), 7.57–7.54 (m, 1H), 4.63 (s, 2H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub><i>6</i></sub>) δ 166.7, 161.4, 160.8, 143.9, 134.7, 130.5, 129.4, 126.1, 125.4, 116.4, 62.9.</div><div class="NLM_p last">Following a procedure similar to that of <b>5a</b>, the following intermediates were synthesized:</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> [5-(2-Chloro-pyrimidin-4-yl)-2-fluoro-phenyl]-methanol (<b>5c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>3a</b> and [4-fluoro-3-(hydroxymethyl)phenyl] boronic acid (<b>4c</b>) (yield, 66%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 239 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 5-(2-Chloro-pyrimidin-4-yl)-2-methoxy-benzaldehyde (<b>5d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>3a</b> and 3-formyl-4-methoxyphenylboronic acid (<b>4d</b>) (yield, 58%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 249 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 3-(2-Chloro-pyrimidin-4-yl)-5-fluoro-benzoic Acid Ethyl Ester (<b>5f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>3a</b> and (3-fluoro-5-ethoxycarbonylphenyl) boronic acid (<b>4e</b>) (yield, 89%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 281 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 3-(2-Chloro-pyrimidin-4-yl)-4-methoxy-benzaldehyde (<b>5h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>3a</b> and 5-formyl-2-methoxyphenyl boronic acid (<b>4f</b>) (yield, 84%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 249 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> [3-(2-Chloro-5-methyl-pyrimidin-4-yl)-phenyl]-methanol (<b>5j</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2,4-dichloro-5-methylpyrimidine (<b>3b</b>) and <b>4b</b> (yield, 56%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 235 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> [3-(2-Chloro-5-fluoro-pyrimidin-4-yl)-phenyl]-methanol (<b>5k</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2,4-dichloro-5-fluoropyrimidine (<b>3c</b>) and <b>4b</b> (yield, 74%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 239 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> [5-(2-Chloro-pyrimidin-4-yl)-2-methoxy-phenyl]-methanol (<b>5e</b>)</h4><div class="NLM_p last">To a solution of <b>5d</b> (5 g, 20.1 mmol) in THF (25 mL, 5 vol) at 0 °C was added NaBH<sub>4</sub> (0.76 g, 20.1 mmol), and the resulting mixture was stirred for 30 min before warming to rt. The reaction mixture was quenched with water. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> thrice, and the combined organic extracts were washed with H<sub>2</sub>O followed by brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to furnish without purification 5 g of compound <b>5e</b> (yield, quantitative). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 251 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> [3-(2-Chloro-pyrimidin-4-yl)-5-fluoro-phenyl]-methanol (<b>5g</b>)</h4><div class="NLM_p last">To a cooled mixture of <b>5f</b> (560 mg, 2.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (6 mL, 10 vol) at 0 °C, 1.0 M DIBAL solution (4 mL, 4.00 mmol) was added dropwise. The resulting mixture was stirred for 1 h and allowed to warm to rt. Water was added, and the product was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure to obtain the crude residue, which was purified by column chromatography (using 35% ethyl acetate in hexane) to furnish <b>5g</b> (230 mg; yield, 48%) as a colorless oil. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 239 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> [3-(2-Chloro-pyrimidin-4-yl)-4-methoxy-phenyl]-methanol (<b>5i</b>)</h4><div class="NLM_p last">The title compound was synthesized following a procedure similar to that of <b>5e</b>, from <b>5h</b> (yield, quantitative). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 251 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-(3-Allyloxymethyl phenyl)-2-chloro Pyrimidine (<b>6b</b>)</h4><div class="NLM_p">A mixture of <b>5b</b> (20 g, 90.6 mmol), KOH (23.8 g, 172 mmol), and tetrabutyl ammonium hydrogen sulfate (1.5 g, 4.53 mmol) in allyl bromide (80 mL, 4 vol) was stirred at rt for 12 h. The reaction mixture was quenched with water and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 25 mL). The combined organic extracts were washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure to obtain the crude residue, which was purified by column chromatography (using 15% ethyl acetate in hexane) to furnish <b>6b</b> (13 g; yield, 55%) as a pale yellow oil. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 261 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.62 (d, 1H), 8.06 (br, 1H), 8.00 (dt, 1H), 7.66 (d, 1H), 7.54–7.46 (m, 2H), 6.02–5.93 (m, 1H), 5.27 (ddq, 2H), 4.60 (s, 2H), 4.08 (dq, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 167.1, 161.9, 159.9, 139.7, 135.3, 134.6, 131.2, 129.7, 129.3, 126.6, 117.5, 115.4, 71.7, 71.6; IR (KBr pellet): 1568, 1535, 1344, 1186, 1079 cm<sup>–1</sup>.</div><div class="NLM_p last">Following a procedure similar to that of <b>6b</b>, the following intermediates were synthesized:</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 4-(3-Allyloxy-phenyl)-2-chloro-pyrimidine (<b>6a</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5a</b> and allyl bromide (yield, 59%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 247 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 4-(3-Allyloxymethyl-4-fluoro-phenyl)-2-chloro-pyrimidine (<b>6c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5c</b> and allyl bromide (yield, 63%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 279 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 4-(3-Allyloxymethyl-4-methoxy-phenyl)-2-chloro-pyrimidine (<b>6d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5e</b> and allyl bromide (yield, 51%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 291 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 4-(3-Allyloxymethyl-5-fluoro-phenyl)-2-chloro-pyrimidine (<b>6e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5g</b> and allyl bromide (yield, 71%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 279 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-(5-Allyloxymethyl-2-methoxy-phenyl)-2-chloro-pyrimidine (<b>6f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5i</b> and allyl bromide (yield, 55%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 291 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-(3-Allyloxymethyl-phenyl)-2-chloro-5-methyl-pyrimidine (<b>6g</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5j</b> and allyl bromide (yield, 42%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 275 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-(3-Allyloxymethyl-phenyl)-2-chloro-5-fluoro-pyrimidine (<b>6h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5k</b> and allyl bromide (yield, 67%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 279 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-(3-But-3-enyloxy-phenyl)-2-chloro-pyrimidine (<b>7</b>)</h4><div class="NLM_p last">To a mixture of <b>5a</b> (2.0 g, 9.68 mmol) and 4-bromo-but-1-ene (7.8 g, 5.80 mmol) in dry DMF (10 mL) at ambient temperature was added cesium carbonate (14.19 g, 43.55 mmol), and the resulting mixture was stirred at 40 °C for 6 h. The reaction mixture was cooled to 0 °C and quenched with water. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> thrice, and the combined organic extracts were washed with water followed by brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to furnish an oil, which was purified by column (EtOAc/hexane) to obtain 1.61 g of <b>7</b> (yield, 64%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 261 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub><i>6</i></sub>): δ 8.82 (d, 1H), 8.12 (d, 1H), 7.77 (d, 1H), 7.70 (br s, 1H), 7.48 (t, 1H), 7.18 (dd, 1H), 5.86–5.98 (m, 1H), 5.16–5.24 (m, 1H), 5.09–5.13 (m, 1H), 4.13 (t, 2H), 2.49–2.56 (m, 2H).</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-(4-Methyl-piperazin-1-yl)-5-nitro-benzaldehyde (<b>9c</b>)</h4><div class="NLM_p">To a mixture of 2-chloro-5-nitrobenzaldehyde <b>8b</b> (3 g, 16.2 mmol) and 1-methylpiperazine (3.5 mL, 31.6 mmol) in DMF (30 mL, 10 vol) was added K<sub>2</sub>CO<sub>3</sub> (4 g, 28.9 mmol), and the resulting mixture was stirred at 90 °C for 4 h. The reaction mixture was cooled to rt, and water (60 mL) was added to quench. The aqueous layer was extracted thrice with EtOAc (40 mL each), and the combined organic extract was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure. Product <b>9c</b> (3.6 g; yield, 90%) was taken forward for the next step without any purification. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 250 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 10.10 (s, 1H), 8.62 (d, 1H), 8.30 (dd, 1H), 7.09 (d, 1H), 3.35–3.32 (m, 4H), 2.64–2.63 (m, 4H), 2.39 (s, 3H).</div><div class="NLM_p last">Following a procedure similar to that of <b>9c</b>, the following intermediates were synthesized:</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2-Morpholin-4-yl-5-nitro-benzaldehyde (<b>9a</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>8b</b> and morpholine (yield, quantitative). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 237 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 4-(2-Formyl-4-nitro-phenyl)-piperazine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>9b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>8b</b> and 1-Boc-piperazine (yield, quantitative). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 336 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-[(2-Dimethylamino-ethyl)-methyl-amino]-5-nitro-benzaldehyde (<b>9d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>8b</b> and <i>N</i>,<i>N</i>,<i>N</i>′-trimethyl-ethane-1,2-diamine (yield, 96%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 252 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 2-(2-Chloro ethoxy)-5-nitro-benzaldehyde (<b>9e</b>)</h4><div class="NLM_p">To a mixture of 2-hydroxy-4-nitrobenzaldehyde (<b>8c</b>) (50 g, 299 mmol) and 1,2-dichloroethane (300 mL, 6 vol) in DMF (600 mL, 12 vol)) was added K<sub>2</sub>CO<sub>3</sub> (62.5 g, 450 mmol), and the resulting mixture was stirred at 100–105 °C for 6 h. The reaction mixture was quenched with water (500 mL), and the product was extracted four times with CH<sub>2</sub>Cl<sub>2</sub> (200 mL each). The combined organic extracts were washed with water (500 mL), brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure, and <i>n</i>-hexane (500 mL) was added to the crude product. The resulting mixture was stirred for 30 min and evaporated to dryness under reduced pressure, and one more hexane washing was repeated. A third aliquot of cold <i>n</i>-hexane (500 mL) was added, and the yellow solid was collected by filtration and washing with cold <i>n</i>-hexane. Product <b>9e</b> (49.3 g; yield, 72%) was taken forward for the next step without any purification. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 230 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.52 (s, 1H), 8.71 (d, 1H), 8.45 (dd, 1H), 7.14 (d, 1H), 4.51 (t, 2H), 3.96 (t, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 187.3, 164.2, 142.1, 130.6, 125.0, 124.6, 113.2, 69.4, 41.3.</div><div class="NLM_p last">Following a procedure similar to that of <b>9e</b>, the following intermediates were synthesized:</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 3-(2-Chloro-ethoxy)-5-nitro-benzaldehyde (<b>9f</b>)</h4><div class="NLM_p last">The title compound was synthesized from 3-hydroxy-5-nitrobenzaldehyde (<b>8d</b>) and 1,2-dichloroethane (yield, 66%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 230 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 2-(2-Chloro-ethoxy)-3-methoxy-5-nitro-benzaldehyde (<b>9g</b>)</h4><div class="NLM_p">The title compound was synthesized from 2-hydroxy-3-methoxy-5-nitro-benzaldehyde (<b>8e</b>) and 1,2-dichloroethane (yield, 64%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 260 ([M + H]<sup>+</sup>).</div><div class="NLM_p last">Following a procedure similar to that of <b>5e</b>, the following intermediates were synthesized:</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (2-Methoxy-5-nitro-phenyl)-methanol (<b>10b</b>)</h4><div class="NLM_p last">The title compound was synthesized from 2-methoxy-3-nitrobenzaldehyde <b>8a</b> (yield, quantitative). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 184 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (2-Morpholin-4-yl-5-nitro-phenyl)-methanol (<b>10c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>9a</b> (yield, quantitative). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 239 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 4-(2-Hydroxymethyl-4-nitro-phenyl)-piperazine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>10d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>9b</b> (yield, quantitative). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 338 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> [2-(4-Methyl-piperazin-1-yl)-5-nitro-phenyl]-methanol (<b>10e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>9c</b> (yield, quantitative). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 252 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> {2-[(2-Dimethylamino-ethyl)-methyl-amino]-5-nitro-phenyl}-methanol (<b>10f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>9d</b> (yield, quantitative). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 254 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> [2-(2-Chloro ethoxy)-5-nitro-phenyl-methanol (<b>10g</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>9e</b> (yield, quantitative). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 232 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (DMSO-<i>d</i><sub><i>6</i></sub>) δ 8.27–8.26 (m, 1H), 8.17 (dd, 1H), 7.19 (d, 1H), 4.60 (s, 2H), 4.44 (t, 2H), 4.00 (t, 2H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub><i>6</i></sub>) δ 160.0, 141.4, 132.6, 124.4, 122.0, 111.8, 69.2, 57.5, 43.1.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> [3-(2-Chloro-ethoxy)-5-nitro-phenyl]-methanol (<b>10h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>9f</b> (yield, quantitative). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 232 ([M + H]<sup>+</sup>);</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> [2-(2-Chloro-ethoxy)-3-methoxy-5-nitro-phenyl]-methanol (<b>10i</b>)</h4><div class="NLM_p">The title compound was synthesized from <b>9g</b> (yield, quantitative). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 262 ([M + H]<sup>+</sup>).</div><div class="NLM_p last">Following a procedure similar to that of <b>6a</b>, the following intermediates were synthesized:</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 1-Allyloxy-3-nitro-benzene (<b>11a</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>10a</b> and allyl bromide (yield, 62%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 180 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 2-Allyloxymethyl-1-methoxy-4-nitro-benzene (<b>11b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>10b</b> and allyl bromide (yield, 68%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 224 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4-(2-Allyloxymethyl-4-nitro-phenyl)-morpholine (<b>11c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>10c</b> and allyl bromide (yield, 55%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 279 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 4-(2-Allyloxymethyl-4-nitro-phenyl)-piperazine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>11d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>10d</b> and allyl bromide (yield, 60%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 378 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 1-(2-Allyloxymethyl-4-nitro-phenyl)-4-methyl-piperazine (<b>11e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>10e</b> and allyl bromide (yield, 48%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 292 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>N</i>-(2-Allyloxymethyl-4-nitro-phenyl)-<i>N</i>,<i>N</i>′,<i>N</i>′-trimethyl-ethane-1,2-diamine (<b>11f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>10f</b> and allyl bromide (yield, 42%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 294 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.35 (d, 1H), 8.12 (dd, 1H), 7.09 (d, 1H), 6.01–5.94 (m, 1H), 5.37–5.24 (m, 2H), 4.53 (s, 2H), 4.13–4.11 (m, 2H), 3.63–3.59 (m, 2H), 2.90–2.84 (m, 2H), 2.88 (s, 3H), 2.60 (s, 6H).</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 2-Allyloxymethyl-1-(2-chloro ethoxy)-4-nitro Benzene (<b>11g</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>10g</b> and allyl bromide (yield, 63%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 272 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.37 (t, 1H), 8.17 (dd, 1H), 6.88 (dd, 1H), 6.04–5.91 (m, 1H), 5.43–5.21 (m, 2H), 4.35 (t, 2H), 4.15–4.13 (m, 2H), 3.87 (t, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 160.2, 142.0, 134.5, 129.1, 124.8, 124.2, 117.5, 110.7, 72.1, 68.9, 66.0, 41.7. Anal. Calcd. for C<sub>12</sub>H<sub>14</sub>ClNO<sub>4</sub>: C, 53.05; H, 5.19; N, 5.16; Cl: 13.05. Found: C, 53.09; H, 5.30; N, 5.14; Cl, 13.37. IR (KBr pellet): 1593, 1519, 1341, 1270, 1077 cm<sup>–1</sup>.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 1-Allyloxymethyl-3-(2-chloro-ethoxy)-5-nitro-benzene (<b>11h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>10h</b> and allyl bromide (yield, 59%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 272 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 1-Allyloxymethyl-2-(2-chloro-ethoxy)-3-methoxy-5-nitro-benzene (<b>11i</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>10i</b> and allyl bromide (yield, 38%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 302 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 1-Allyloxymethyl-3,5-dinitro-benzene (<b>19</b>)</h4><div class="NLM_p last">The title compound was synthesized from 3,5-dinitrobenzyl alcohol <b>18</b> and allyl bromide (yield, 41%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 239 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 1-[2-(2-Allyloxymethyl-4-nitro-phenoxy] Pyrrolidine (<b>11j</b>)</h4><div class="NLM_p last">To a solution of <b>11g</b> (10 g, 36.8 mmol) in <i>N</i>,<i>N</i>-dimethylacetamide (DMA, 50 mL) was added pyrrolidine (20 mL, 2 vol), and the resulting mixture was stirred at 90 °C for 20 h. The reaction mixture was brought to rt and quenched with water (100 mL) and extracted in ethyl acetate (3 × 50 mL). The combined organic extracts were washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure to afford the crude product <b>11m</b> (8.5 g; yield, 76%) as a pale yellow oil. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 307 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.33 (d, 1H), 8.17 (dd, 1H), 6.91 (d, 1H), 6.03–5.93 (m, 1H), 5.37–5.23 (m, 2H), 4.56 (s, 2H), 4.26 (t, 2H), 4.12 (dt, 2H), 2.99 (t, 2H), 2.71–2.68 (m, 4H), 1.90–1.86 (m, 4H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.0, 141.7, 134.6, 128.6, 125.0, 124.3, 117.6, 110.7, 72.2, 68.5, 66.3, 55.1, 54.7, 23.8.</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 1-[2-(2-Allyloxymethyl-6-methoxy-4-nitro-phenoxy)-ethyl]-pyrrolidine (<b>11k</b>)</h4><div class="NLM_p last">Following a similar procedure to that of <b>11i</b>, the title compound was synthesized from <b>11h</b> and pyrrolidine (yield, 66%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 337 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 1-But-3-enyloxy-3-nitro-benzene (<b>13</b>)</h4><div class="NLM_p last">Following a similar procedure to that of <b>7</b>, the title compound was synthesized from <b>10a</b> and 4-bromo-but-1-ene (yield, 52%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 194 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 3-Allyloxy-phenylamine (<b>12a</b>)</h4><div class="NLM_p">Compound <b>11a</b> (1.0 g, 5.58 mmol) was taken in EtOH (10 mL, 10 vol), and fine Fe powder (0.93 g, 16.7 mmol) was added at 50–55 °C followed by NH<sub>4</sub>Cl solution (1.76 g, 32 mmol in 2 mL water). The reaction mixture was refluxed for 4 h, and EtOH was removed from the reaction mixture under reduced pressure. The residue was basified with NaHCO<sub>3</sub> solution (pH 7–8) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 25 mL). The combined organic extracts were washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated under reduced pressure to furnish <b>12a</b> (0.75 g; yield, 90%) as a brown oil. This material was taken up for the next step without any purification. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 150 ([M + H]<sup>+</sup>).</div><div class="NLM_p last">Following a procedure similar to that of <b>12a</b>, the following intermediates were synthesized:</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 3-Allyloxymethyl-4-methoxy-phenylamine (<b>12b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11b</b> (yield, 88%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 194 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 3-Allyloxymethyl-4-morpholin-4-yl-phenylamine (<b>12c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11c</b> (yield, 83%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 249 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 4-(2-Allyloxymethyl-4-amino-phenyl)-piperazine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>12d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11d</b> (yield, 80%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 348 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.90 (d, 1H), 6.81 (d, 1H), 6.59 (dd, 1H), 6.00–5.93 (m, 1H), 5.34–5.29 (m, 2H), 4.55 (s, 2H), 4.07–4.05 (m, 2H), 3.55–3.50 (m, 4H), 2.78–2.72 (m, 4H), 1.48 (s, 9H).</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 3-Allyloxymethyl-4-(4-methyl-piperazin-1-yl)-phenylamine (<b>12e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11e</b> (yield, 76%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 262 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 2-Allyloxymethyl-<i>N</i>1-(2-dimethylamino-ethyl)-<i>N</i>1-methyl-benzene-1,4-diamine (<b>12f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11f</b> (yield, 71%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 264 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.99 (d, 1H), 6.81 (d, 1H), 6.61 (dd, 1H), 6.00–5.93 (m, 1H), 5.34–5.19 (m, 2H), 4.51 (s, 2H), 4.07–4.05 (m, 2H), 3.58 (br, 2H), 3.28–3.24 (m, 2H), 2.81–2.60 (m, 2H), 2.60 (s, 3H), 2.51 (s, 6H).</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 3-Allyloxymethyl-4-(2-chloro-ethoxy)-phenylamine (<b>12g</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11g</b> (yield, 86%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 242 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 3-Allyloxymethyl-5-(2-chloro-ethoxy)-phenylamine (<b>12h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11h</b> (yield, 89%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 242 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 3-Allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenylamine (<b>12j</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11j</b> (yield, 90%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 277 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>) δ 6.82–6.78 (m, 2H), 6.69 (dd, 1H), 5.93–5.83 (m, 1H), 5.26–5.11 (m, 2H), 4.45 (s, 2H), 4.20 (t, 2H), 3.97 (dt, 2H), 3.56 (t, 2H); <sup>13</sup>C NMR (MeOD-<i>d</i><sub><i>4</i></sub>) δ 149.4, 140.2, 134.7, 127.6, 118.2, 116.5, 116.2, 113.9, 70.8, 67.3, 64.6, 54.5, 54.1, 22.6. IR (KBr pellet): 1626, 1502, 1225, 1084, 798 cm<sup>–1</sup>.</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 3-Allyloxymethyl-5-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenylamine (<b>12k</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>11k</b> (yield, 74%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 307 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 3-But-3-enyloxy-phenylamine (<b>14</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>13</b> (yield, 89%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 164 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 5-Allyloxymethyl-benzene-1,3-diamine (<b>20</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>19</b>, using twice the amount of Fe powder and NH<sub>4</sub>Cl solution (yield, 73%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 179 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> (3-Allyloxymethyl-5-amino-phenyl)-carbamic acid 9<i>H</i>-fluoren-9-ylmethyl Ester (<b>12i</b>)</h4><div class="NLM_p last">To a mixture of <b>20</b> (290 mg, 1.63 mmol) and Fmoc-Cl (350 mg, 1.35 mmol) in 1,2-dioxane was added di-isopropylethylamine (0.5 mL), and the resulting mixture was stirred at rt for 2 h. The reaction mixture was concentrated under reduced pressure to furnish an oil, which was purified by column (40% EtOAc/<i>n</i>-hexane) to obtain 370 mg of <b>12k</b> (yield, 95%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 401 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (3-But-3-enyloxy-phenyl)-[4-(3-but-3-enyloxy-phenyl)-pyrimidin-2-yl]-amine (<b>15a</b>)</h4><div class="NLM_p">To a mixture of <b>7</b> (100 mg, 0.38 mmol) and <b>14</b> (75 mg, 0.46 mmol) in <i>n-</i>butanol (2 mL) at ambient temperature was added 4 M HCl (0.5 mL), and the resulting mixture was stirred at 80 °C for 4 h. The reaction mixture was cooled to 0 °C and quenched with water. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> thrice, and the combined organic extracts were washed with saturated NaHCO<sub>3</sub> followed by brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to furnish an oil, which was purified by column (EtOAc/<i>n</i>-hexane) to obtain 71 mg of <b>15a</b> (yield, 48%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 388 ([M + H]<sup>+</sup>).</div><div class="NLM_p last">Following a procedure similar to that of <b>15a</b>, the following intermediates were synthesized:</div></div><div id="sec5_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> (3-Allyloxy-phenyl)-[4-(3-but-3-enyloxy-phenyl)-pyrimidin-2-yl]-amine (<b>15b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>7</b> and <b>12a</b> (yield, 21%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 374 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> (3-Allyloxymethyl-4-methoxy-phenyl)-[4-(3-but-3-enyloxy-phenyl)-pyrimidin-2-yl]-amine (<b>15c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>7</b> and <b>12b</b> (yield, 26%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 418 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> (3-Allyloxymethyl-4-methoxy-phenyl)-[4-(3-allyloxy-phenyl)-pyrimidin-2-yl]-amine (<b>15d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6a</b> and <b>12b</b> (yield, 51%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 404 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> (3-Allyloxymethyl-4-methoxy-phenyl)-[4-(3-allyloxymethyl-phenyl)-pyrimidin-2-yl]-amine (<b>15e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6b</b> and <b>12b</b> (yield, 56%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 418 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> (3-Allyloxymethyl-4-morpholin-4-yl-phenyl)-[4-(3-allyloxymethyl-phenyl)-pyrimidin-2-yl]-amine (<b>15f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6b</b> and <b>12c</b> (yield, 78%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 473 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 4-{2-Allyloxymethyl-4-[4-(3-allyloxymethyl-phenyl)-pyrimidin-2-ylamino]-phenyl}-piperazine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>15g</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6b</b> and <b>12d</b> (yield, 86%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 572 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> [3-Allyloxymethyl-4-(4-methyl-piperazin-1-yl)-phenyl]-[4-(3-allyloxymethyl-phenyl)-pyrimidin-2-yl]-amine (<b>15h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6b</b> and <b>12e</b> (yield, 88%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 486 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 2-Allyloxymethyl-<i>N</i>4-[4-(3-allyloxymethyl-phenyl)-pyrimidin-2-yl]-<i>N</i>1-(2-dimethylamino-ethyl)-<i>N</i>1-methyl-benzene-1,4-diamine (<b>15i</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6b</b> and <b>12f</b> (yield, 71%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 488 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> [3-Allyloxymethyl-4-(2-chloro-ethoxy)-phenyl]-[4-(3-allyloxymethyl-phenyl)-pyrimidin-2-yl]-amine (<b>15j</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6b</b> and <b>12g</b> (yield, 92%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 466 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> [3-Allyloxymethyl-5-(2-chloro-ethoxy)-phenyl]-[4-(3-allyloxymethyl-phenyl)-pyrimidin-2-yl]-amine (<b>15k</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6b</b> and <b>12h</b> (yield, 82%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 466 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> {3-Allyloxymethyl-5-[4-(3-allyloxymethyl-phenyl)-pyrimidin-2-ylamino]-phenyl}-carbamic Acid 9<i>H</i>-Fluoren-9-yl-methyl Ester (<b>15l</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6b</b> and <b>12i</b> (yield, 90%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 625 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> [3-Allyloxymethyl-5-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-[4-(3-allyloxymethyl-phenyl)-pyrimidin-2-yl]-amine (<b>15m</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6b</b> and <b>12k</b> (yield, 21%) LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 531 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> [4-(3-Allyloxymethyl-phenyl)-5-methyl-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (<b>15n</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6g</b> and <b>12j</b> (yield, 65%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 515 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> [4-(3-Allyloxymethyl-phenyl)-5-fluoro-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (<b>15o</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6h</b> and <b>12j</b> (yield, 65%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 519 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> [4-(5-Allyloxymethyl-2-methoxy-phenyl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (<b>15p</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6f</b> and <b>12j</b> (yield, 91%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 531 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> [4-(3-Allyloxymethyl-5-fluoro-phenyl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (<b>15q</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6e</b> and <b>12j</b> (yield, 47%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 519 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> [4-(3-Allyloxymethyl-4-methoxy-phenyl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (<b>15r</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6d</b> and <b>12j</b> (yield, 81%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 531 ([M + H]<sup>+</sup>).</div></div><div id="sec5_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> [4-(3-Allyloxymethyl-4-fluoro-phenyl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (<b>15s</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>6c</b> and <b>12j</b> (yield, 39%). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 519 ([M + H]<sup>+</sup>).</div></div><div id="sec700" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> (<b>16a</b>)</h4><div class="NLM_p">To <b>15a</b> (20 mg, 0.052 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) at ambient temperature was added 4 M HCl until the pH reached 2.0–2.2. The solution was degassed (N<sub>2</sub>), and Grubbs second generation catalyst (7 mg, 0.005 mmol) was added in two portions at 1 h intervals. The resulting mixture was stirred at 40–45 °C for 4 h. The reaction mixture was cooled and concentrated under reduced pressure to furnish an oil, which was purified by preparative HPLC to obtain 9 mg of <b>16a</b> (yield, 48%, >95% trans by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 360 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR (DMSO-<i>d</i><sub><i>6</i></sub>) δ 9.77 (s, 1H), 8.57 (d, 1H), 8.48 (t, 1H), 8.09 (t, 1H), 7.65 (d, 1H), 7.46 (d, 1H), 7.44 (t, 1H), 7.17 (t, 1H), 7.10 (dd, 1H), 6.84 (dd, 1H), 6.54 (dd, 1H), 5.60–5.68 (m, 2H), 4.12 (t, 2H), 4.06 (t, 2H), 2.56–2.61 (m, 4H).</div><div class="NLM_p last">Following a procedure similar to that of <b>16a</b>, the following compounds were synthesized:</div></div><div id="sec701" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> (<b>16b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15b</b> (yield, 51%; >95% <i>trans</i> by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 346 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 11.30 (s, 1H), 8.29 (d, 1H), 8.21 (t, 1H), 8.11 (t, 1H), 7.57 (d, 1H), 7.48 (t, 1H), 7.32–7.35 (m, 2H), 7.22–7.25 (m, 1H), 6.95 (dd, 1H), 6.82 (dd, 1H), 6.02–6.08 (m, 1H), 5.87–5.93 (m, 1H), 4.78 (d, 2H), 4.29 (t, 2H), 2.63–2.68 (m, 2H).</div></div><div id="sec702" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> (<b>16c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15c</b> (yield, 45%; >95% <i>trans</i> by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 390 ([M + H]<sup>+</sup>); <sup>1</sup>H NMR.</div></div><div id="sec703" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> (<b>16d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15d</b> (yield, 45%; >95% <i>trans</i> by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 502 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 11.76 (s, 1H), 8.16 (d, 1H), 8.14 (d, 1H), 7.66 (s, 1H), 7.40–7.42 (m, 2H), 7.28 (dd, 1H), 7.19–7.21 (m, 1H), 7.17 (d, 1H), 6.90 (d, 1H), 6.07–6.14 (m, 1H), 5.82–5.88(m, 1H), 5.67 (d, 2H), 4.60 (s, 2H), 4.14 (dd, 2H), 3.86 (s, 3H).</div></div><div id="sec704" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> (<b>16e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15e</b> (yield, 48%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 390 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (DMSO-<i>d</i><sub><i>6</i></sub>): δ 9.55 (s, 1H), 8.54–8.52 (m, 2H), 8.19 (s, 1H), 8.02 (d, 1H), 7.56 (dd, 1H), 7.40 (d, 1H), 7.15 (d, 1H), 6.98 (d, 1H), 5.84–5.72 (m, 2H), 4.57 (s, 2H), 4.49 (s, 2H), 4.06 (d, 2H), 4.01 (d, 2H), 3.78 (s, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub><i>6</i></sub>): δ 63.4, 160.7, 159.8, 152.5, 139.1, 137.3, 134.2, 131.5, 131.2, 130.3, 129.6, 127.0, 126.9, 126.2, 121.2, 120.1, 111.9, 107.8, 69.6, 69.3, 67.5, 65.7, 56.1.</div></div><div id="sec705" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> (<b>17a</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15f</b> (yield, 43%; mixture of <i>trans</i>/<i>cis</i> 85:15 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 502 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 11.56 (s, 1H), 8.45 (d, 1H), 8.29–8.27 (m, 1H), 8.22 (d, 1H), 7.90 (d, 1H), 7.76 (d, 1H), 7.59 (t, 1H), 7.31 (d, 1H), 7.26–7.21 (m, 1H), 7.10 (d, 1H), 5.91–5.69 (m, 2H), 4.66 (s, 2H), 4.64 (s, 2H), 4.17–4.15 (m, 2H), 4.06–4.04 (m, 2H), 3.89–3.82 (m, 4H), 2.30–2.96 (m, 4H).</div></div><div id="sec706" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> (<b>17b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15g</b> using 10 mol % Zhan catalyst-1B instead of the Grubbs second generation catalyst (yield, 96%, isomers ration not determined). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 502 ([M + H]<sup>+</sup>).</div></div><div id="sec707" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> (<b>17d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15h</b> (yield, 52%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 502 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 10.62 (s, 1H), 8.59 (d, 1H), 8.29–8.24 (m, 2H), 7.88 (d, 1H), 7.72 (d, 1H), 7.59–7.56 (m, 1H), 7.30 (d, 1H), 7.18–7.10 (m, 2H), 5.90–5.69 (m, 2H), 4.65 (s, 2H), 4.61 (s, 2H), 4.17–4.15 (m, 2H), 4.08–4.06 (m, 2H), 3.68–3.66 (m, 2H), 3.37–3.25 (m, 4H), 2.93–2.91 (m, 2H), 2.90 (s, 3H).</div></div><div id="sec708" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> (<b>17h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15i</b> (yield, 56%; mixture of <i>trans</i>/<i>cis</i> 85:15 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 502 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 8.87 (s, 1H), 8.48 (s, 1H), 8.29 (s, 1H), 7.98 (d, 1H), 7.64 (d, 1H), 7.54 (d, 1H), 7.40 (d, 1H), 7.37 (d, 1H), 7.20 (dd, 1H), 6.00–5.78 (m, 2H), 4.67 (s, 2H), 4.27 (d, 2H), 4.06 (d, 2H), 3.40 (t, 2H), 3.15 (t, 2H), 2.89 (s, 6H), 2.76 (s, 3H).</div></div><div id="sec709" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> (<b>21a</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15j</b> (yield, 74%; mixture of <i>trans</i>/<i>cis</i> 85:15 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 438 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.70 (d, 1H), 8.43 (d, 1H), 8.30 (s, 1H), 7.81 (d, 1H), 7.61–7.59 (m, 1H), 7.50 (t, 1H), 7.17–7.15 (m, 2H), 6.85–6.82 (m, 2H), 5.91–5.79 (m, 2H), 4.66 (s, 2H), 4.65 (s, 2H), 4.27 (t, 2H), 4.17 (d, 2H), 4.07 (d, 2H), 3.83 (t, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub><i>6</i></sub>): δ 163.4, 160.7, 159.9, 151.1, 139.1, 137.2, 134.9, 131.5, 131.3, 130.4, 129.6, 127.4, 127.0 (duplicate), 121.0, 120.1, 114.4, 107.9, 69.8, 69.7, 69.4, 67.5, 65.5, 43.8.</div></div><div id="sec800" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> (<b>21g</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15k</b> (yield, 56%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 438 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.46 (d, 1H), 8.43 (s, 1H), 8.39 (s, 1H), 7.83 (d, 1H), 7.58–7.54 (m, 2H), 7.51–7.49 (m, 1H), 7.21 (d, 1H), 6.70 (s, 1H), 6.49 (t, 1H), 5.92–5.81 (m 2H), 4.63 (s, 2H), 4.56 (s, 2H), 4.27 (t, 2H), 4.15 (d, 2H), 4.09 (d, 2H), 3.83 (t, 2H).</div></div><div id="sec801" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> (<b>21j</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15l</b> using 10 mol % Zhan catalyst-1B instead of the Grubbs second generation catalyst (yield, 73%; mixture of <i>trans</i>/<i>cis</i> 85:15 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 597 ([M + H]<sup>+</sup>).</div></div><div id="sec802" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> (<b>22a</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15m</b> (yield, 43%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 503 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.33–8.28 (m, 2H), 8.10 (d, 1H), 7.93 (d, 1H), 7.79 (d, 1H), 7.63 (t, 1H), 7.40 (d, 1H), 6.93 (d, 1H), 5.94–5.82 (m, 2H), 4.68 (s, 1H), 4.60 (s, 2H), 4.36 (m, 2H), 4.18 (d, 2H), 4.11 (d, 2H), 4.12–4.03 (m, 2H), 3.94 (s, 3H), 3.63(m, 2H), 3.19 (m, 2H), 2.34–2.22 (m, 4H).</div></div><div id="sec803" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> (<b>22b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15n</b> (yield, 79%; mixture of <i>trans</i>/<i>cis</i> 88:12 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 487 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 10.4 (s, 1H), 8.40 (s, 1H), 8.12 (s, 1H), 7.78 (s, 1H), 7.65–7.36 (m, 3H), 7.07 (d, 1H), 6.78 (d, 1H), 5.84–5.64 (m, 2H), 4.56 (s, 2H), 4.42 (s, 2H), 4.31 (br s, 2H), 4.10 (d, 2H), 3.99 (d, 2H), 3.85 (m, 2H), 3.50 (m, 2H), 2.97 (m, 2H), 2.26 (s, 3H), 2.05 (m, 4H).</div></div><div id="sec804" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> (<b>22c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15o</b> (yield, 56%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 491 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.23 (m, 1H), 8.12 (s, 1H), 7.95 (d, 1H), 7.52 (d, 1H), 7.42 (m, 1H), 7.12 (s, 1H), 6.76 (d, 2H), 5.75 (m, 2H), 4.59 (s, 2H), 4.47 (m, 2H), 4.14 (m, 2H), 4.05 (m, 2H), 4.01 (m, 2H), 2.96 (m, 2H), 2.71 (m, 4H), 1.79 (m, 4H).</div></div><div id="sec805" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> (<b>22d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15p</b> (yield, 32%; mixture of <i>trans</i>/<i>cis</i> 85:15 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 503 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 8.61 (d, 1H), 8.36 (d, 1H), 8.07 (s, 1H), 7.59 (d, 1H), 7.53 (dd, 1H), 7.19 (d, 1 H), 7.13 (dd, 1H), 7.04 (d, 1H), 5.90 (dt, 1H), 5.79 (dt, 1H), 4.61 (s, 2H), 4.59 (s, 2H), 4.37 (t, 2H), 4.11 (d, 2H), 4.08 (d, 2H), 3.95 (s, 3H), 3.80 (m, 2H); 3.68 (t, 2H), 2.17 (m, 2H), 2.08 (m, 2H), 1.30 (m, 2H).</div></div><div id="sec806" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> (<b>22e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15q</b> (yield, 42%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 491 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 8.72 (d, 1H), 8.48 (m, 1H), 8.11 (s, 1H), 7.72 (m, 1H), 7.34 (m, 2H), 7.05–7.15 (m, 2H), 5.82–5.90 (m, 2H), 4.65 (m, 2H), 4.39 (m, 2H), 4.16 (m, 2H), 4.09 (m, 2H), 3.80 (m, 2H), 3.71 (m, 2H), 3.27 (m, 4H), 2.08–2.24 (m, 4H).</div></div><div id="sec807" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> (<b>22f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15r</b> (yield, 48%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 503 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 8.50–8.48 (m, 1H), 8.37 (d, 1H), 8.27 (d, 1H), 8.07 (dd, 1H), 7.38 (d, 1H), 7.17–7.15 (m, 2H), 7.08–7.06 (m, 1H), 5.98–5.86 (m, 2H), 4.69 (s, 2H), 4.64 (s, 2H), 4.39 (t, 2H), 4.17 (d, 2H), 4.08 (d, 2H), 3.88–3.82 (m, 2H), 3.70 (t, 2H), 2.23–2.21 (m, 2H), 2.10–2.07 (m, 2H).</div></div><div id="sec808" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> (<b>22g</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>15s</b> (yield, 49%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 491 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 8.45 (m, 2H), 8.30 (m, 1H), 8.05 (m, 1H), 7.38 (m, 1H), 7.26 (m, 1H), 7.16 (m, 1H), 7.08 (m, 1H), 5.90–5.92 (m, 2H), 4.65 (m, 4H), 4.39 (m, 2H), 4.16 (m, 2H), 4.09 (m, 2H), 3.85 (m, 2H), 3.71 (m, 2H), 3.32 (m, 2H), 2.08–2.25 (m, 4H).</div></div><div id="sec809" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> (<b>16f</b>)</h4><div class="NLM_p last">To a mixture of <b>16e</b> (20 mg, 0.051 mmol) in DMF (2 mL) was added sodium ethanethiolate (5 mg, 0.061 mmol), and the resulting mixture was stirred at 120 °C for 20 h. It was cooled, and saturated NH<sub>4</sub>Cl was added. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> thrice, and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to furnish an oil which was further purified by preparative HPLC to furnish <b>16f</b> (6 mg; yield, 30%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 376 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (DMSO-<i>d</i><sub><i>6</i></sub>): δ 9.43 (s, 1H), 9.11 (br, 1H), 8.50 (d, 1H), 8.44 (d, 1H), 8.20 (s, 1H), 8.01 (dd, 1H), 7.56–7.54 (m, 2H), 7.37 (d, 1H), 6.99 (dd, 1H), 6.76 (d, 1H), 5.85–5.73 (m, 2H), 4.56 (s, 2H), 4.47 (s, 2H), 4.06 (s, 2H), 4.01 (d, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub><i>6</i></sub>): δ 163.3, 160.7, 159.8, 150.6, 139.1, 137.3, 132.8, 131.6, 131.2, 130.3, 129.6, 127.1, 126.9, 124.3, 121.3, 120.3, 115.8, 107.5, 169.5, 69.4, 67.6, 66.0.</div></div><div id="sec900" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> (<b>17c</b>)</h4><div class="NLM_p last">To a mixture of <b>17b</b> (131 mg, 0.241 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added TFA (0.5 mL), and the resulting mixture was stirred at 40 °C for 2 h. It was cooled and concentrated under reduced pressure. The crude product was further purified by preparative HPLC to furnish <b>17c</b> (70 mg; yield, 73%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR) as a pale yellow solid. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 444 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 8.77 (d, 1H), 8.46 (d, 1H), 8.31 (s, 1H), 8.00 (d, 1H), 7.65–7.63 (m, 1H), 7.56 (t, 1H), 7.41 (d, 1H), 7.19 (d, 1H), 7.11 (dd, 1H), 5.95–5.76 (m, 2H), 4.68 (s, 2H), 4.67 (s, 2H), 4.17 (d, 2H), 4.07 (d, 2H), 3.42–3.38 (m, 4H), 3.25–3.21 (m, 4H).</div></div><div id="sec901" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> (<b>17e</b>)</h4><div class="NLM_p last">To a mixture of <b>17c</b> (16 mg, 0.036 mmol) and 2-bromoethanol (5 μL, 0.072 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added Et<sub>3</sub>N (14 μL, 0.10 mmol), and the resulting mixture was stirred at rt for 2 h. It was concentrated under reduced pressure and further purified by preparative HPLC to furnish <b>17e</b> (6 mg; yield, 34%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR) as a pale yellow solid. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 488 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 11.76 (s, 1H), 8.51 (d, 1H), 8.26 (s, 1H), 8.23 (d, 1H), 7.90 (d, 1H), 7.76 (d, 1H), 7.62 (t, 1H), 7.34 (d, 1H), 7.30–7.27 (m, 1H), 7.15 (d, 1H), 5.90–5.73 (m, 2H), 4.65 (s, 2H), 4.60 (s, 2H), 4.14 (d, 2H), 4.07 (d, 4H), 3.83–3.80 (m, 2H), 3.40–3.38 (m, 2H), 3.30–3.27 (m, 4H), 3.17–3.13 (m, 2H).</div></div><div id="sec902" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> (<b>17f</b>)</h4><div class="NLM_p last">To a mixture of <b>17c</b> (9 mg, 0.020 mmol) and acetyl chloride (3 μL, 0.041 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added Et<sub>3</sub>N (9 μL, 0.060 mmol), and the resulting mixture was stirred at rt for 2 h. It was concentrated under reduced pressure and further purified by preparative HPLC to furnish <b>17f</b> (6 mg; yield, 63%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 486 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 12.00 (s, 1H), 8.46 (d, 1H), 8.28 (s, 1H), 8.25 (d, 1H), 7.92 (d, 1H), 7.78 (d, 1H), 7.59 (t, 1H), 7.36 (d, 1H), 7.31–7.28 (m, 1H), 7.09 (d, 1H), 5.91–5.75 (m, 2H), 4.67 (s, 2H), 4.65 (s, 2H), 4.17 (d, 2H), 4.07 (d, 2H), 3.83–3.67 (m, 4H), 3.06–2.93 (m, 4H), 2.22 (s, 3H).</div></div><div id="sec903" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> (<b>17g</b>)</h4><div class="NLM_p last">To a mixture of <b>17c</b> (14 mg, 0.032 mmol) and ethanesulfonyl chloride (6 μL, 0.063 mmol) in THF (1 mL) was added K<sub>2</sub>CO<sub>3</sub> (10 mg, 0.072 mmol), and the resulting mixture was stirred at 70 °C for 4 h. It was cooled and concentrated under reduced pressure. The crude product was further purified by preparative HPLC to furnish <b>17g</b> (7 mg; yield, 41%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR) as a pale yellow solid. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 536 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.50 (d, 1H), 8.29 (s, 1H), 8.22 (d, 1H), 7.90 (d, 1H), 7.75 (d, 1H), 7.57 (t, 1H), 7.32 (d, 1H), 7.25–7.21 (m, 1H), 7.10 (d, 1H), 5.90–5.73 (m, 2H), 4.65 (s, 2H), 4.64 (s, 2H), 4.15 (d, 2H), 4.06 (d, 2H), 3.07–2.99 (m, 4H), 3.02 (d, 2H), 3.25–3.21 (m, 4H), 1.45 (t, 3H).</div></div><div id="sec904" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> (<b>21b</b>)</h4><div class="NLM_p">To a microwave glass vial was added <b>21a</b> (20 mg, 0.046 mmol), diethylamine (10 μL, 0.11 mmol), and DMA (1 mL), and the resulting mixture was stirred under microwave conditions at 80 °C for 30 min. The mixture was diluted with MeOH and purified directly by preparative HPLC to furnish <b>21b</b> (18 mg; yield, 82%; mixture of <i>trans</i>/<i>cis</i> 85:15 by NMR) as a pale yellow solid. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 475 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 8.49 (s, 1H), 7.98–7.97 (m, 1H), 7.77 (s, 1H), 7.63–7.61 (m, 1H), 7.57–7.55 (m, 1H), 7.42–7.38 (m, 4H), 7.14–7.11 (m, 1H), 5.83–5.76 (m, 1H), 5.42–5.34 (m, 1H), 4.29–4.27 (m, 1H), 4.13–4.10 (m, 2H), 3.83–3.72 (m, 2H), 3.24 (s, 2H), 3.25–2.97 (m, 4H), 2.29–2.24 (m, 2H), 2.11–1.92 (m, 4H).</div><div class="NLM_p last">Following a procedure similar to that of <b>21b</b>, the following compounds were synthesized:</div></div><div id="sec905" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> (<b>21c</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>21a</b> and pyrrolidine (yield, 83%; mixture of <i>trans</i>/<i>cis</i> 85:15 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 473 ([M + H]<sup>+</sup>). HRMS: theoretical C<sub>28</sub>H<sub>32</sub>N<sub>4</sub>O<sub>3</sub> MW, 472.2474; found, 473.2547. <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 8.79 (d, 1H), 8.46 (d, 1H), 8.34–8.31 (m, 1H, CH), 7.98–7.96 (m, 1H), 7.62–7.49 (m, 2H), 7.35 (d, 1H), 7.15–7.10 (m, 1H), 7.07–7.02 (m, 1H), 5.98–5.75 (m, 2H), 4.67 (s, 2H), 4.67 (s, 2H), 4.39–4.36 (m, 2H), 4.17 (d, 2H), 4.08 (d, 2H), 3.88–3.82 (m, 2H), 3.70 (t, 2H), 2.23–2.21 (m, 2H), 2.10–2.07 (m, 2H); chloride content (titration) 7.7% (1.18 equivs); water content (Karl Fischer) 6.1% (1.85 equivs); Anal. Calcd. for C<sub>28</sub>H<sub>32</sub>N<sub>4</sub>O<sub>3</sub>·1.18HCl·1.85H<sub>2</sub>O: C, 61.46; H, 6.46; N, 10.24; Cl, 7.65. Found: C, 61.99; H, 6.91; N, 10.25; Cl, 7.45.</div></div><div id="sec906" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> (<b>21d</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>21a</b> and piperidine (yield, 84%; mixture of <i>trans</i>/<i>cis</i> 85:15 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 487 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 8.65 (d, 1H), 8.33 (d, 1H), 8.15 (s, 1H), 7.84 (d, 1H), 7.44 (m, 2H), 7.22 (d, 1H), 7.00 (m, 1H), 6.93 (d, 1H), 5.82–5.66 (m, 2H), 4.52 (s, 2H), 4.50 (s, 2H), 4.30 (t, 2H), 4.02 (d, 2H), 3.95 (d, 2H), 3.61 (br, 2H), 3.49 (t, 2H), 3.03 (m, 2H), 1.98 (m, 2H), 1.77 (m, 4H). <sup>13</sup>C NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 159.6, 152.8, 140.2, 138.6, 132.5, 132.4, 132.1, 130.4, 128.7, 128.0, 127.7, 123.0, 121.2, 114.6, 109.0, 70.8, 70.6, 68.9, 67.7, 64.7, 57.6, 55.3, 24.4, 22.7.</div></div><div id="sec907" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> (<b>21e</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>21a</b> and 2-pyrrolidinone (yield, 72%; mixture of <i>trans</i>/<i>cis</i> 85:15 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 487 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (DMSO-<i>d</i><sub><i>6</i></sub>): δ 9.55 (s, 1H), 8.57 (s, 1H), 8.52 (d, 1H), 8.19 (s, 1H), 8.01 (d, 1H), 7.56 (m, 2H), 7.39 (d, 1H), 7.13 (dd, 1H), 6.96 (d, 1H), 5.88–5.69 (m, 2H), 4.57 (s, 2H), 4.47 (s, 2H), 4.09 (m, 6H), 3.58 (t, 2H), 3.51 (t, 2H), 2.24 (t, 2H), 1.95 (t, 2H).</div></div><div id="sec908" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> (<b>21f</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>21a</b> and 3-pyrrolidinone (yield, 75%; mixture of <i>trans</i>/<i>cis</i> 85:15 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 487 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (DMSO-<i>d</i><sub><i>6</i></sub>): δ 9.55 (s, 1H), 8.57 (s, 1H), 8.52 (d, 1H), 8.19 (s, 1H), 8.01 (d, 1H), 7.56 (m, 2H), 7.39 (d, 1H), 7.13 (dd, 1H), 6.97 (d, 1H), 5.87–5.69 (m, 2H), 4.56 (s, 2H), 4.48 (s, 2H), 4.11 (t, 2H), 4.03 (m, 4H), 3.08 (s, 2H), 2.99 (t, 2H), 2.92 (t, 2H), 2.34 (t, 2H).</div></div><div id="sec909" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> (<b>21h</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>21g</b> and pyrrolidine (yield, 90%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 473 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 8.47 (d, 1H), 8.35 (d, 2H), 8.00 (d, 1H), 7.62–7.59 (m, 1H), 7.56–7.52 (m, 1H), 7.43 (d, 1H), 6.80–6.79 (m, 1H), 6.75–6.74 (m, 1H), 5.92–5.79 (m, 2H), 4.61 (s, 2H), 4.57 (s, 2H), 4.37 (t, 2H), 4.15 (d, 2H), 4.08 (d, 2H), 3.77–3.72 (m, 2H), 3.68 (t, 2H), 3.26–3.21 (m, 2H), 2.23–2.16 (m, 2H), 2.11–2.03 (m, 2H).</div></div><div id="sec910" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> (<b>21i</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>21g</b> and morpholine (yield, 79%; mixture of <i>trans</i>/<i>cis</i> 80:20 by NMR). LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 489 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 8.47 (d, 1H), 8.36 (d, 2H), 8.00 (d, 1H), 7.62–7.60 (m, 1H), 7.55–7.51 (m, 1H), 7.42 (d, 1H), 6.80–6.79 (m, 1H), 6.75–6.73 (m, 1H), 5.92–5.79 (m, 2H), 4.61 (s, 2H), 4.56 (s, 2H), 4.43 (t, 2H), 4.15 (d, 2H), 4.08 (d, 2H), 4.08–4.04 (m, 2H), 3.90–3.79 (m, 2H), 3.66 (t, 2H), 3.65–3.58 (m, 2H).</div></div><div id="sec911" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> (<b>21k</b>)</h4><div class="NLM_p last">To a mixture of <b>21j</b> (156 mg, 0.261 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added piperidine (1 mL, 20% v/v), and the resulting mixture was stirred at rt for 30 min. It was concentrated under reduced pressure and purified by preparative HPLC to furnish <b>21k</b> (80 mg; yield, 82%; mixture of <i>trans</i>/<i>cis</i> 85:15 by NMR) as a pale yellow solid. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 375 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 8.83 (s, 1H), 8.53 (d, 1H), 8.34 (s, 1H), 7.99 (dd, 1H), 7.61–7.56 (m, 1H), 7.54–7.51 (m, 1H), 7.45 (d, 1H), 7.08–7.06 (m, 2H), 5.94–5.81 (m, 2H), 4.63 (s, 4H), 4.18 (d, 2H), 4.10 (d, 2H).</div></div><div id="sec912" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> (<b>21l</b>)</h4><div class="NLM_p last">To a mixture of <b>21k</b> (20 mg, 0.053 mmol) and 3-(diethylamino)propionic acid hydrochloride (17 mg, 0.096 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added HOBt (14 mg, 0.11 mmol) and EDCI (21 mg, 0.11 mmol), and the resulting mixture was stirred at rt for 4 h. It was concentrated under reduced pressure and purified by preparative HPLC to furnish <b>21l</b> (15 mg; yield, 55%; mixture of <i>trans</i>/<i>cis</i> 85:15 by NMR) as a pale yellow solid. LC-MS (ESI positive mode) <i>m</i>/<i>z</i> 502 ([M + H]<sup>+</sup>). <sup>1</sup>H NMR (MeOD-<i>d</i><sub><i>4</i></sub>): δ 8.50–8.49 (m, 2H), 8.37 (s, 1H), 8.01 (d, 1H), 7.62–7.61 (m, 1H), 7.56 (t, 1H), 7.48–7.47 (m, 1H), 7.42 (d, 1H), 7.28 (s, 1H), 5.95–5.81 (m, 2H), 4.64 (s, 2H), 4.59 (s, 2H), 4.17 (d, 2H), 4.10 (d, 2H), 3.55 (t, 2H), 3.34 (q, 4H), 2.94 (t, 2H), 1.40 (t, 6H).</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i136" class="anchor-spacer"></div><h3 class="article-section__title" id="_i136"> Enzyme Assays</h3><div class="NLM_p last">The recombinant enzymes (CDK2/CyclinA, JAK1, JAK2, JAK3 and FLT3) were prepared by the S*BIO biochemistry group according to published procedures. All assays were carried out in 384-well white microtiter plates using the PKLight assay system from Cambrex. This assay platform is essentially a luminometric assay for the detection of ATP in the reaction using a luciferase-coupled reaction. The compounds were tested at 8 concentrations prepared from 3- or 4-fold serial dilution starting at 10 μM. For the CDK2/cyclin A assay, the reaction mixture consisted of the following components in 25 μL assay buffer (50 mM Hepes, pH 7.5, 10 mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 5 mM BGP, 1 mM DTT, and 0.1 mM sodium orthovanadate), 1.4 μg/mL of CDK2/cyclin A complex, 0.5 μM of RbING substrate (Invitrogen, cat # PV2939), and 0.5 μM of ATP. The reaction was incubated at room temperature for 2 h. Thirteen microliters of PKLight ATP detection reagent was added, and the reaction was incubated for 10 min. Luminescence signals were detected on a multilabel plate reader (Victor<sup>2</sup> V 1420, Perkin-Elmer). The other kinase assays were similar, with the following differences in reagents. For FLT3 assays, the reaction contained 2.0 μg/mL FLT3 enzyme, 5 μM of poly(Glu,Tyr) substrate (Sigma, cat # P0275), and 4 μM of ATP. For JAK1 assays, the reaction contained 2.5 μg/mL of JAK1 enzyme, 10 μM of poly(Glu,Ala,Tyr) substrate (Sigma, cat # P3899), and 1.0 μM of ATP. For JAK2 assays, the reaction contained 0.35 μg/mL of JAK2 enzyme, 10 μM of poly(Glu,Ala,Tyr) substrate (Sigma, cat # P3899), and 0.15 μM of ATP. For JAK3 assays, the reaction contained 3.5 μg/mL of JAK3 enzyme, 10 μM of poly(Glu,Ala,Tyr) substrate (Sigma, cat # P3899), and 6.0 μM of ATP. The analytical software, Prism 5.0 (GraphPad Software Pte Ltd.) was used to generate IC<sub>50</sub> values from the data.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i137" class="anchor-spacer"></div><h3 class="article-section__title" id="_i137"> Cell Proliferation Assays</h3><div class="NLM_p last">Ba/F3-JAK2<sup><i>V617F</i></sup>-GFP-Luc cells were generous gifts from Dr. Martin Sattler (Dana-Farber Cancer Institute, Boston, MA). The generation and culture of these cells has been described previously {Walz, 2006 #2}. MV4–11 cells was obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured according to the recommended guidelines. For proliferation assays in 96-well plates, 20.000 cells were seeded in 100 μL and treated the following day with compounds (in triplicates) at concentrations up to 10 μM for 48 h. Cell viability was monitored using the CellTiter-Glo cell proliferation assay (Promega, Madison, WI). Dose–response curves were plotted to determine IC<sub>50</sub> values for the compounds using the XL-fit software (IDBS Ltd., Alameda, CA).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> Allograft Studies with Ba/F3-JAK2<sup><i>V617F</i></sup> Cells</h3><div class="NLM_p">All mice were obtained from the Biological Resource Centre (Biopolis, Singapore). Female athymic BALB/c nude mice (BALB/cOlaHsd-<i>Foxn1</i><sup><i>nu</i></sup>) were 12 weeks of age; female SCID Beige mice (CB17.Cg-<i>Prkdc</i><sup><i>scid</i></sup><i>Lyst</i><sup><i>bg</i></sup>/Crl) werr 9–10 weeks of age. Standard protocols were followed, in compliance with the NIH and National Advisory Committee for Laboratory Animal Research guidelines (IACUC approval #0800371).</div><div class="NLM_p last">For the mouse model of MPD, 2 × 10<sup>6</sup> Ba/F3-JAK2<sup>V617F</sup> cells were resuspended in 100 μL serum-free culture medium and injected intravenously into the tail vein of BALB/c nude mice. Treatment was started on day 4 for 13 consecutive days for three groups of 8 mice each. Four naïve mice served to establish baseline values. Animals were sacrificed at the end of study, and the spleens and livers were harvested and weighed.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i139" class="anchor-spacer"></div><h3 class="article-section__title" id="_i139"> Xenograft Studies with MV4–11 Cells</h3><div class="NLM_p last">Female BALB/c mice and female athymic BALB/c nude mice (BALB/cOlaHsd-<i>Foxn1</i><sup><i>nu</i></sup>) were obtained from the Biological Resource Centre (BRC, Biopolis, Singapore) and were 9–16 weeks of age at the time of tumor implantation. Standard protocols were followed, in compliance with the National Institutes of Health and National Advisory Committee for Laboratory Animal Research guidelines (IACUC approval #0800371). Female BALB/c nude mice were implanted subcutaneously in the right flank with 1 × 10<sup>7</sup> MV4–11 human AML cells. Cells were resuspended in 50 μL of serum-free growth medium, mixed 1:1 with Matrigel (Cat. No:354248; BD Bioscience), and injected in a total volume of 100 μL, using a 23-gauge needle. MV4–11 tumor-bearing mice (average starting tumor size of 130 mm<sup>3</sup>) were treated orally (p.o.) once daily at doses of 25, 50, or 100 mg/kg for 21 consecutive days. After termination of the treatment, tumor growth was measured up to day 55, and the median time to end point (TTE) (median survival) was calculated. End point of experiment for an individual mouse was reached either on day 55 or when a tumor reached a size of 1000 mm<sup>3</sup>. The tumor volumes were calculated using the formula: Tumor volume (mm<sup>3</sup>) = (<i>w</i><sup>2</sup> × <i>l</i>)/2 (<i>w</i> = width, and <i>l</i> = length in mm of the tumor xenograft). All doses for in vivo experiments used in this article are given as free base equivalent.</div></div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i140" class="anchor-spacer"></div><h3 class="article-section__title" id="_i140"> Metabolic Stability in Liver Microsomes</h3><div class="NLM_p last">Test compounds (5 μM) were incubated with MLM, RLM, DLM, and HLM (final microsomal concentration of ∼0.87 mg/mL), in a reaction mix containing 50 mM potassium phosphate buffer (pH 7.4), and a NADPH regeneration system, at 37 °C, in a total reaction volume of 1 mL. Reactions were terminated at 0, 15, 30, 45, and 60 min of incubation with a chilled mixture of acetonitrile and DMSO (80:20), vortexed for 5 min, and centrifuged at 13200 rpm for 15 min at 4 °C, and the supernatants were analyzed by LC/MS/MS. Stability was assessed by plotting the percent of parent compound remaining against time on a log–linear scale and estimating the half-life from the linear portion of the log–linear curve using the first order equation <i>t</i><sub>1/2</sub> = 0.693/<i>k</i>, where <i>k</i> = slope of the curve (equal to the first order elimination rate constant).</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i141" class="anchor-spacer"></div><h3 class="article-section__title" id="_i141"> Human in vitro CYP450 Inhibition Assay</h3><div class="NLM_p last">Test compounds were incubated (at concentrations of 0.05, 0.25, 0.5, 2.5, 5, and 25 μM in DMSO; final DMSO concentration = 0.35%) with human liver microsomes (0.25 mg/mL for CYP1A and CYP3A4, 0.5 mg/mL for CYP2C19 and CYP2D6, 1 mg/mL for CYP2C9) and NADPH (1 mM) in the presence of the probe substrate ethoxyresorufin (0.5 μM) for 5 min (CYP1A), tolbutamide (120 μM) for 60 min (CYP2C9), mephenytoin (25 μM) for 60 min (CYP2C19), dextromethorphan (5 μM) for 30 min (CYP2D6), and midazolam (2.5 μM) for 5 min (CYP3A4) at 37 °C. The selective inhibitors α-naphthoflavone, sulphaphenazole, tranylcypromine, quinidine, and ketoconazole were used as positive controls for CYP1A, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 inhibitors, respectively. For CYP1A, the reactions were terminated by the addition of methanol, and the formation of the metabolite, resorufin, was monitored by fluorescence (excitation wavelength = 535 nm, and emission wavelength = 595 nm). For the CYP2C9, CYP2C19, CYP2D6, and CYP3A4 incubations, the reactions were terminated by the addition of methanol containing an internal standard. The samples were centrifuged, and the supernatants were combined, for the simultaneous analysis of 4-hydroxytolbutamide, 4-hydroxymephenytoin, dextrorphan, 1-hydroxymidazolam, and the internal standard by LC-MS/MS. Formic acid in deionized water (final concentration = 0.1%) was added to the final sample prior to analysis. A decrease in the formation of the metabolites compared to vehicle control was used to calculate an IC<sub>50</sub> value (test compound concentration which produces 50% inhibition).</div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i142" class="anchor-spacer"></div><h3 class="article-section__title" id="_i142"> Caco-2 Bidirectional Permeability Assay</h3><div class="NLM_p last">Compound <b>21c</b> at 5 μM in Hank’s balanced salt solution (HBSS), final DMSO concentration less than 1%, was placed in 21–28 day confluent monolayer cells in Transwell assay plates. Both apical and basolateral sides were maintained at pH 7.4. When dosed on the apical side, the permeability in the A→B direction was assessed and when dosed on the basolateral side, the B→A direction was assessed. Both apical and basolateral sides were sampled at 2 h. The concentration of <b>21c</b> was determined by LC/MS using a 4-point calibration curve. Atenolol (<i>P</i><sub>app</sub> <0.5 × 10<sup>–6</sup> cm/s), propranolol (15 < <i>P</i><sub>app</sub> < 25 × 10<sup>–6</sup> cm/s), Lucifer Yellow (<i>P</i><sub>app</sub> > 0.4 × 10<sup>–6</sup> cm/s), and digoxin (efflux ratio >3) were used in the quality control of the monolayer batch. The integrity of the monolayer was determined by measuring the pre-experiment TEER (between 450 and 650 Ωcm<sup>2</sup>) and using Lucifer Yellow (% efflux ≤0.5). The efflux ratio was defined as the ratio of <i>P</i><sub>app,B→A</sub> to <i>P</i><sub>app,A→B</sub>.</div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i143" class="anchor-spacer"></div><h3 class="article-section__title" id="_i143"> In Vitro Plasma Protein Binding</h3><div class="NLM_p last">Equilibrium dialysis was performed in Micro-Equilibrium Dialyzer (Harvard Apparatus) with a chamber volume of 500 μL (each compartment with a volume of 250 μL). The semipermeable membrane used was rinsed with Milli-Q-water and soaked for 10 min in PBS. Compound <b>21c</b> was added to plasma (from mouse, dog and humans) to obtain a final concentration of 1000 ng/mL. The spiked plasma was vortexed, and 250 μL was aliquoted into one chamber of the dialyzer cell. The other chamber was filled with 250 μL of PBS buffer. The assembled cell was placed into a water-bath at 37 °C, and dialysis was performed for 4 h. Following dialysis, 50 μL of PBS dialyzed samples containing free <b>21c</b> was transferred into 2 mL Eppendorf tubes in triplicate for extraction. Samples were extracted with 1500 μL of MTBE (methyl tertiary-butyl ether) for 30 min using a mixer at motor speed setting 60 with pulsing. After 30 min, the sample tubes were centrifuged at 4 °C for 10 min at 13,000 rpm in a microcentrifuge. The supernatant (1400 μL) was transferred into fresh 2 mL Eppendorf tubes and dried in SpeedVac at 43 °C for 35 min. The dried samples were reconstituted with 100 μL of methanol/Milli-Q-H<sub>2</sub>O (60:40) and analyzed by LC/MS/MS.</div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i144" class="anchor-spacer"></div><h3 class="article-section__title" id="_i144"> Pharmacokinetics</h3><div class="NLM_p last">Male BALB/c mice (aged ∼8 weeks and weighing 20–23 g), male Beagle dogs (∼ 6 to7 months of age, weighing 9–11 kg), and male Wistar rats (aged 6–8 weeks, weighing 270 to 325 g) were used in this study. All of the animal studies were performed as per approved internal protocols for animal care and use. The oral doses for mice, dogs, and rats were 30, 3, and 10 mg/kg, respectively. The doses were administered, by gavage, as suspensions (0.5 % methylcellulose and 0.1%tween 80) to mice and rats, and as gelatin capsules (12 Torpac) to dogs. Following oral dosing, serial blood samples were collected (retroorbital plexus in mice, jugular vein in dogs, and superior vena cava in rats) at different time points (0 to 24 h) in tubes containing K<sub>3</sub>EDTA as anticoagulant, and centrifuged, the plasma was separated and stored at −70 °C until analysis. Plasma samples were processed and analyzed by LC/MS/MS. Pharmacokinetic parameters were estimated by noncompartmental methods using WinNonlin (ver 5.2, Pharsight, CA)</div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i145" class="anchor-spacer"></div><h3 class="article-section__title" id="_i145"> PAMPA (Parallel Artificial Membrane Permeability Assay)</h3><div class="NLM_p last">This assay measures the permeability of compounds in a high throughput format. The assay was performed in a 96 well format (Millipore MultiScreen 96 well acceptor plate, Teflon tray, Millipore MultiScreen 0.4 μm PCTE membrane clear base plate, 96 well, surface area = 0.24 cm<sup>2</sup>, porosity ∼20%). The final concentration of the compounds in the assay was 1 μM. The artificial membrane in the donor plate was prepared by mixing 5% hexadecane in hexane. The donor plate contained 0.15 mL of 5% DMSO in PBS, and the compound (1 μM) and the acceptor plate had 0.3 mL of 5% DMSO in PBS. The assembled plates were placed in a Ziploc bag with wet C-fold towels to prevent evaporation and incubated for 5 h at room temperature. Following incubation, the donor and acceptor solutions were analyzed by LC/MS/MS, and the apparent permeability coefficient (<i>P</i><sub>app</sub>) was estimated.</div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i146" class="anchor-spacer"></div><h3 class="article-section__title" id="_i146"> High Throughput solubility Assay</h3><div class="NLM_p last">This assay measures the solubility of a compound in PBS in high throughput mode. The assay was done using 96-well semitransparent PP microplates with V-shaped bottoms (Greiner Bio-one) and 96-well UV transparent microplates (Greiner Bio-One). Compound solutions (250 μM) were prepared in 10 mM phosphate buffer (pH 7.0) containing 20% DMSO in a total volume of 0.2 mL. Plates were placed on a shaker set at 600 rpm for 1.5 h, following which the plates were allowed to stand for 2 h at room temperature. The plates were centrifuged at 1500<i>g</i> for 15 min. The supernatants were transferred to a UV transparent microplate and analyzed by UV-spectrophotometry at the appropriate absorption maxima. The concentration of the compound in the supernatant was quantified using a calibration curve. For calculated solubilities of 250 ± 30 μM, solubilities are reported as >250 μM (>150 μg/mL).</div></div><div id="sec6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i147" class="anchor-spacer"></div><h3 class="article-section__title" id="_i147"> Computational</h3><div class="NLM_p">The molecules were built using Maestro 8.0.308 or converted to 3D structures from the 2D structure using LigPrep version 2.1.207.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Basic amines were protonated as in the aqueous solution at physiological pH. The conformational space was searched using the Monte Carlo (MCMM) method as implemented in MacroModel version 9.5.207.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> All heavy atoms and hydrogens on heteroatoms were included in the test for duplicate conformations. All rotatable single bonds were included in the conformational search, and all aliphatic rings were ring-opened, and quaternary atoms were allowed to invert. Each search was continued until the global energy minima were found at least 3 times. The energy minimizations were carried out using the truncated Newton conjugate gradient algorithm (TNCG) and the OPLS-AA force field as implemented in MacroModel.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Default parameters were used. The conformational searches were done for aqueous solution using the generalized Born/solvent accessible surface (GB/SA) continuum solvation model.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><div class="NLM_p last">The JAK1 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EYG">3EYG</a>),<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> JAK2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2B7A">2B7A</a>),<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> JAK3 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YVJ">1YVJ</a>),<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> CDK2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1AQ1">1AQ1</a>),<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> and FLT3 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>)<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> X-ray structures were downloaded from the protein data bank (PDB).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> The protein structures were prepared using the protein preparation wizard in Maestro with standard settings. Grids were generated using Glide, version 4.5.208, following the standard procedure recommended by Schrödinger.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The conformational ensembles were docked flexibly using Glide with standard settings in both standard and extra precision mode. Only poses with low energy conformations and good hydrogen bond geometries were considered. Physical properties were calculated using QikProp, version 3.0.207, with standard settings.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i149"><a href="/doi/suppl/10.1021/jm200326p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71483" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71483" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Explanation for CDK2 potency of <b>17h</b>, Western blots showing intracellular target inhibition by <b>21c</b>, and structures of the RCM catalysts employed. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm200326p/suppl_file/jm200326p_si_001.pdf">jm200326p_si_001.pdf (181.25 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm200326p" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03033" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03033" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony D. William</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f1909f85999e9f88ae86989d9d98909cb18293989edf929e9c"><span class="__cf_email__" data-cfemail="2948475d41464750765e404545404844695a4b4046074a4644">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angeline C.-H. Lee</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stéphanie Blanchard</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anders Poulsen</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ee Ling Teo</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harish Nagaraj</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Evelyn Tan</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dizhong Chen</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Meredith Williams</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric T. Sun</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kee Chuan Goh</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wai Chung Ong</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Siok Kun Goh</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Hart</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ramesh Jayaraman</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mohammed Khalid Pasha</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kantharaj Ethirajulu</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeanette M. Wood</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian W. Dymock</span> - <span class="hlFld-Affiliation affiliation">S*BIO Pte. Ltd., 1 Science Park Road, #05-09, The Capricorn, Singapore Science Park II, Singapore 117528</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i148">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66627" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66627" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Changyong Hu, Bee Kheng Ng, and Yong Cheng Tan for the generation of screening data, Venkatesh Reddy for PK sample analysis, Zahid Bonday and Miah Kiat for protein preparation work, Sam Ramanujulu Murugappan for NMR related work, and Dr. Simon Campbell for helpful discussions.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i150" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i150"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i151" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i151"> Abbreviations Used</h2><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">fms-like receptor tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">RTKs</td><td class="NLM_def"><p class="first last">receptor tyrosine kinases</p></td></tr><tr><td class="NLM_term">MF</td><td class="NLM_def"><p class="first last">myelofibrosis</p></td></tr><tr><td class="NLM_term">MPN</td><td class="NLM_def"><p class="first last">myeloproliferative neoplasms</p></td></tr><tr><td class="NLM_term">PV</td><td class="NLM_def"><p class="first last">polycythemia vera</p></td></tr><tr><td class="NLM_term">ET</td><td class="NLM_def"><p class="first last">essential thrombocythemia</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducers and activators of transcription</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">RCM</td><td class="NLM_def"><p class="first last">ring closing metathesis</p></td></tr><tr><td class="NLM_term">SOCS-1 gene</td><td class="NLM_def"><p class="first last">suppressor of cytokine signaling</p></td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">nonreceptor tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">aborption, distribution, metabolism, and elimination</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i152">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72382" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72382" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 57 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Yamaoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saharinen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, V. E. T.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">The Janus kinases (Jaks)</span> <span class="citation_source-journal">Genome Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">253.1</span><span class="NLM_x">–</span> <span class="NLM_lpage">253.6</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=253.1-253.6&author=K.+Yamaokaauthor=P.+Saharinenauthor=M.+Pesuauthor=V.+E.+T.+Holtauthor=O.+Silvennoinenauthor=J.+J.+O%E2%80%99Shea&title=The+Janus+kinases+%28Jaks%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DHolt%26aufirst%3DV.%2BE.%2BT.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Janus%2520kinases%2520%2528Jaks%2529%26jtitle%3DGenome%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D253.1%26epage%3D253.6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Rane, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Janus kinases: components of multiple signaling pathways</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5662</span><span class="NLM_x">–</span> <span class="NLM_lpage">5679</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5662-5679&author=S.+G.+Raneauthor=E.+P.+Reddy&title=Janus+kinases%3A+components+of+multiple+signaling+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DJanus%2520kinases%253A%2520components%2520of%2520multiple%2520signaling%2520pathways%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5662%26epage%3D5679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Levine, R. L.</span><span> </span><span class="NLM_article-title">Mechanisms of mutations in myeloproliferative neoplasms</span> <span class="citation_source-journal">Best Pract. Res. Clin. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2Fj.beha.2009.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=19959098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFagsbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=489-494&author=R.+L.+Levine&title=Mechanisms+of+mutations+in+myeloproliferative+neoplasms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of mutations in myeloproliferative neoplasms</span></div><div class="casAuthors">Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Haematology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">489-494</span>CODEN:
                <span class="NLM_cas:coden">BPRCA5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, a series of studies have provided genetic insight into the pathogenesis of myeloproliferative neoplasms (MPNs).  It is now known that JAK2V617F mutations are present in 90% of patients with polycythemia vera (PV), 60% of patients with essential thrombocytosis (ET) and 50% of patients with myelofibrosis (MF).  Despite the high prevalence of JAK2V617F mutations in these three myeloid malignancies, several questions remain.  For example, how does one mutation contribute to the pathogenesis of three clin. distinct diseases, and how do some patients develop these diseases in the absence of a JAK2V617F mutation Single nucleotide polymorphisms at various loci and somatic mutations, such as those in MPLW515L/K, TET2 and in exon 12 of JAK2, may also contribute to the pathogenesis of these MPNs.  There are likely addnl. germline and somatic genetic factors important to the MPN phenotype.  Addnl. studies of large MPN and control cohorts with new techniques will help identify these factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYBRiT16nHFLVg90H21EOLACvtfcHk0liNodfmwVYSWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFagsbzJ&md5=5d3977a29c4a78be41201ca3a952c75c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.beha.2009.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.beha.2009.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMechanisms%2520of%2520mutations%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Haematol.%26date%3D2009%26volume%3D22%26spage%3D489%26epage%3D494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadleigh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wlodarsaka, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelsperger, J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercher, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenberghe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2Fj.ccr.2005.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=15837627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFSku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=387-397&author=R.+L.+Levineauthor=M.+Wadleighauthor=J.+Coolsauthor=B.+L.+Ebertauthor=G.+Wernigauthor=B.+J.+P.+Huntlyauthor=T.+J.+Boggonauthor=I.+Wlodarsakaauthor=J.+J.+Clarkauthor=S.+Mooreauthor=J+Adelspergerauthor=S.+Kooauthor=J.+C.+Leeauthor=S.+Gabrielauthor=T.+Mercherauthor=A.+D%E2%80%99Andreaauthor=S.+Frohlingauthor=K.+Dohnerauthor=P.+Marynenauthor=P.+Vandenbergheauthor=R.+A.+Mesaauthor=A.+Tefferiauthor=J.+D.+Griffinauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=M.+Meyersonauthor=T.+R.+Golubauthor=S.+J.+Leeauthor=D.+G.+Gilliland&title=Activating+mutation+in+the+tyrosine+kinase+JAK2+in+polycythemia+vera%2C+essential+thrombocythemia%2C+and+myeloid+metaplasia+with+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</span></div><div class="casAuthors">Levine, Ross L.; Wadleigh, Martha; Cools, Jan; Ebert, Benjamin L.; Wernig, Gerlinde; Huntly, Brian J. P.; Boggon, Titus J.; Wlodarska, Iwona; Clark, Jennifer J.; Moore, Sandra; Adelsperger, Jennifer; Koo, Sumin; Lee, Jeffrey C.; Gabriel, Stacey; Mercher, Thomas; D'Andrea, Alan; Froehling, Stefan; Doehner, Konstanze; Marynen, Peter; Vandenberghe, Peter; Mesa, Ruben A.; Tefferi, Ayalew; Griffin, James D.; Eck, Michael J.; Sellers, William R.; Meyerson, Matthew; Golub, Todd R.; Lee, Stephanie J.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">387-397</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors.  An internet-based protocol was used to collect clin. information and biol. specimens from patients with these diseases.  High-throughput DNA re-sequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations.  Mol. and cytogenetic analyses demonstrated that homozygous mutations were due to duplication of the mutant allele.  JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16 of 46 MMM patients, but was not obsd. in 269 normal individuals.  In vitro anal. demonstrated that JAK2V617F is a constitutively active tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJNzUFm3Q3bVg90H21EOLACvtfcHk0liXdZeqp5CmAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFSku7o%253D&md5=2a3e893867b114e8749cd6f5e55990b7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DWadleigh%26aufirst%3DM.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DHuntly%26aufirst%3DB.%2BJ.%2BP.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DWlodarsaka%26aufirst%3DI.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DAdelsperger%26aufirst%3DJ%26aulast%3DKoo%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DMercher%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DActivating%2520mutation%2520in%2520the%2520tyrosine%2520kinase%2520JAK2%2520in%2520polycythemia%2520vera%252C%2520essential%2520thrombocythemia%252C%2520and%2520myeloid%2520metaplasia%2520with%2520myelofibrosis%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D387%26epage%3D397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Baxter, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">East, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourouclas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassiliou, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bench, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erber, W. N.</span><span> </span><span class="NLM_article-title">Green, A. R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1054</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=1054-1061&author=E.+J.+Baxterauthor=L.+M.+Scottauthor=P.+J.+Campbellauthor=C.+Eastauthor=N.+Fourouclasauthor=S.+Swantonauthor=G.+S.+Vassiliouauthor=A.+J.+Benchauthor=E.+M.+Boydauthor=N.+Curtinauthor=M.+A.+Scottauthor=W.+N.+Erber&title=Green%2C+A.+R.+Acquired+mutation+of+the+tyrosine+kinase+JAK2+in+human+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DE.%2BJ.%26aulast%3DScott%26aufirst%3DL.%2BM.%26aulast%3DCampbell%26aufirst%3DP.%2BJ.%26aulast%3DEast%26aufirst%3DC.%26aulast%3DFourouclas%26aufirst%3DN.%26aulast%3DSwanton%26aufirst%3DS.%26aulast%3DVassiliou%26aufirst%3DG.%2BS.%26aulast%3DBench%26aufirst%3DA.%2BJ.%26aulast%3DBoyd%26aufirst%3DE.%2BM.%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DM.%2BA.%26aulast%3DErber%26aufirst%3DW.%2BN.%26atitle%3DGreen%252C%2520A.%2520R.%2520Acquired%2520mutation%2520of%2520the%2520tyrosine%2520kinase%2520JAK2%2520in%2520human%2520myeloproliferative%2520disorders%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D1054%26epage%3D1061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">James, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Couédic, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staerk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delhommeau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacout, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garçon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raslova, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennacaur-Griscelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villeval, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constantinescu, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadevall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainchenker, W.</span><span> </span><span class="NLM_article-title">A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">1144</span><span class="NLM_x">–</span> <span class="NLM_lpage">1148</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=1144-1148&author=C.+Jamesauthor=V.+Ugoauthor=J.+P.+Le+Cou%C3%A9dicauthor=J.+Staerkauthor=F.+Delhommeauauthor=C.+Lacoutauthor=L.+Gar%C3%A7onauthor=H.+Raslovaauthor=R.+Bergerauthor=A.+Bennacaur-Griscelliauthor=J.+L.+Villevalauthor=S.+N.+Constantinescuauthor=N.+Casadevallauthor=W.+Vainchenker&title=A+unique+clonal+JAK2+mutation+leading+to+constitutive+signaling+causes+polycythemia+vera"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DC.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DLe%2BCou%25C3%25A9dic%26aufirst%3DJ.%2BP.%26aulast%3DStaerk%26aufirst%3DJ.%26aulast%3DDelhommeau%26aufirst%3DF.%26aulast%3DLacout%26aufirst%3DC.%26aulast%3DGar%25C3%25A7on%26aufirst%3DL.%26aulast%3DRaslova%26aufirst%3DH.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBennacaur-Griscelli%26aufirst%3DA.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DVainchenker%26aufirst%3DW.%26atitle%3DA%2520unique%2520clonal%2520JAK2%2520mutation%2520leading%2520to%2520constitutive%2520signaling%2520causes%2520polycythemia%2520vera%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D1144%26epage%3D1148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title"><i>JAK</i> and <i>MPL</i> mutations in myeloid malignancies</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">388</span><span class="NLM_x">–</span> <span class="NLM_lpage">397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1080%2F10428190801895360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=18297515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXit1CmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=388-397&author=A.+Tefferi&title=JAK+and+MPL+mutations+in+myeloid+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">JAK and MPL mutations in myeloid malignancies</span></div><div class="casAuthors">Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">388-397</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The Janus family of non-receptor tyrosine kinases (JAK1, JAK2, JAK3 and tyrosine kinase 2) transduces signals downstream of type I and II cytokine receptors via signal transducers and activators of transcription (STATs).  JAK3 is important in lymphoid and JAK2 in myeloid cell proliferation and differentiation.  The thrombopoietin receptor MPL is one of several JAK2 cognate receptors and is essential for myelopoiesis in general and megakaryopoiesis in particular.  Germline loss-of-function (LOF) JAK3 and MPL mutations cause severe combined immunodeficiency and congenital amegakaryocytic thrombocytopenia, resp.  Germline gain-of-function (GOF) MPL mutation (MPLS505N) causes familial thrombocytosis.  Somatic JAK3 (e.g. JAK3A572V, JAK3V722I, JAK3P132T) and fusion JAK2 (e.g. ETV6-JAK2, PCM1-JAK2, BCR-JAK2) mutations have resp. been described in acute megakaryocytic leukemia and acute leukemia/chronic myeloid malignancies.  However, current attention is focused on JAK2 (e.g. JAK2V617F, JAK2 exon 12 mutations) and MPL (e.g. MPLW515L/K/S, MPLS505N) mutations assocd. with myeloproliferative neoplasms (MPNs).  A JAK2 mutation, primarily JAK2V617F, is invariably assocd. with polycythemia vera (PV).  The latter mutation also occurs in the majority of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF).  MPL mutational frequency in MPNs is substantially less (<10%).  In general, despite a certain degree of genotype - phenotype correlations, the prognostic relevance of harbouring one of these mutations, or their allele burden when present, remains dubious.  Regardless, based on the logical assumption that amplified JAK-STAT signalling is central to the pathogenesis of PV, ET and PMF, several anti-JAK2 tyrosine kinase inhibitors have been developed and are currently being tested in humans with these disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqS8-lmJ2SY7Vg90H21EOLACvtfcHk0ljRH83t1TXEEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXit1CmtL8%253D&md5=fd37abba8a06abca87afae8bd478dfb0</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1080%2F10428190801895360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190801895360%26sid%3Dliteratum%253Aachs%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DJAK%2520and%2520MPL%2520mutations%2520in%2520myeloid%2520malignancies%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2008%26volume%3D49%26spage%3D388%26epage%3D397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Gangat, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caramazza, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaidya, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begna, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwager, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passamonti, F.</span><span> </span><span class="NLM_article-title">DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2010&pages=2446&author=N.+Gangatauthor=D.+Caramazzaauthor=R.+Vaidyaauthor=G.+Georgeauthor=K.+Begnaauthor=S.+Schwagerauthor=D.+Van+Dykeauthor=C.+Hansonauthor=W.+Wuauthor=A.+Pardananiauthor=F.+Cervantesauthor=F.+Passamonti&title=DIPSS+plus%3A+A+refined+dynamic+international+prognostic+scoring+system+for+primary+myelofibrosis+that+incorporates+prognostic+information+from+karyotype%2C+platelet+count%2C+and+transfusion+status"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangat%26aufirst%3DN.%26aulast%3DCaramazza%26aufirst%3DD.%26aulast%3DVaidya%26aufirst%3DR.%26aulast%3DGeorge%26aufirst%3DG.%26aulast%3DBegna%26aufirst%3DK.%26aulast%3DSchwager%26aufirst%3DS.%26aulast%3DVan%2BDyke%26aufirst%3DD.%26aulast%3DHanson%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DPassamonti%26aufirst%3DF.%26atitle%3DDIPSS%2520plus%253A%2520A%2520refined%2520dynamic%2520international%2520prognostic%2520scoring%2520system%2520for%2520primary%2520myelofibrosis%2520that%2520incorporates%2520prognostic%2520information%2520from%2520karyotype%252C%2520platelet%2520count%252C%2520and%2520transfusion%2520status%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D32%26spage%3D2446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Purandare, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorenzi, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span> </span><span class="NLM_article-title">Janus kinase 2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasms (MPN)</span> <span class="citation_source-journal">Ann. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2FS0065-7743%2810%2945013-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=210-227&author=A.+V.+Purandareauthor=M.+V.+Lorenziauthor=L.+J.+Lombardo&title=Janus+kinase+2+%28JAK2%29+inhibitors+for+the+treatment+of+myeloproliferative+neoplasms+%28MPN%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2810%2945013-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252810%252945013-7%26sid%3Dliteratum%253Aachs%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26atitle%3DJanus%2520kinase%25202%2520%2528JAK2%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%2520%2528MPN%2529%26jtitle%3DAnn.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D210%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes-Franco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson-Viitanen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis <i>N</i></span> <span class="citation_source-journal">Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis+N"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0ljRH83t1TXEEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%2520N%26jtitle%3DEngl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">Therapeutic potential of JAK2 inhibitors</span> <span class="citation_source-journal">Hematol. Am. Soc. Hematol. Educ. Prog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span><span class="NLM_x">–</span> <span class="NLM_lpage">642</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1182%2Fasheducation-2009.1.636" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=20008249" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=636-642&author=S.+Verstovsek&title=Therapeutic+potential+of+JAK2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1182%2Fasheducation-2009.1.636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fasheducation-2009.1.636%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DTherapeutic%2520potential%2520of%2520JAK2%2520inhibitors%26jtitle%3DHematol.%2520Am.%2520Soc.%2520Hematol.%2520Educ.%2520Prog.%26date%3D2009%26spage%3D636%26epage%3D642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Santos, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">JAK2 inhibitors: What’s the true therapeutic potential?</span> <span class="citation_source-journal">Blood Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2Fj.blre.2010.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=21095048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitFKjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=53-63&author=F.+P.+Santosauthor=S.+Verstovsek&title=JAK2+inhibitors%3A+What%E2%80%99s+the+true+therapeutic+potential%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2 inhibitors: What's the true therapeutic potential?</span></div><div class="casAuthors">Santos, Fabio P. S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">53-63</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Physicians treating patients with the classic Philadelphia-neg. myeloproliferative neoplasms (Ph-neg. MPNs) (polycythemia vera [PV], essential thrombocythemia [ET] and primary myelofibrosis [PMF]) traditionally had few therapeutic drugs available.  Spurred by the discovery of activating mutation of the JAK2 tyrosine kinase (JAK2 V617F mutation) in patients with Ph-neg. MPNs several years ago, several JAK2 inhibitors were synthesized and are currently undergoing clin. trials in patients with PMF, PV and ET.  Initial results from these studies have shown that these drugs can markedly reduce spleen size and alleviate constitutional symptoms, increase wt. and improve exercise capacity in MF patients, thus improve quality of their life, which is significant clin. benefit.  In ET and PV JAK2 inhibitor therapy may efficiently control blood cell count, as well as improve splenomegaly and control disease related symptoms.  JAK2 inhibitors are a novel class of agents with promising results for treating patients with MF, PV and ET.  In this article we will review the current evidence regarding the role of JAK2 mutations in the pathogenesis of Ph-neg. MPNs and summarize results from the most recent clin. trials with JAK2 inhibitors in these disorders.  JAK2 inhibitors are a novel class of agents with promising results for treating patients with MF, PV and ET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZb8q4WeXPbVg90H21EOLACvtfcHk0li_LHZgz5JgGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitFKjsbw%253D&md5=5e99d696b87a7523af5d1fb7c540f386</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2010.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2010.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DF.%2BP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DJAK2%2520inhibitors%253A%2520What%25E2%2580%2599s%2520the%2520true%2520therapeutic%2520potential%253F%26jtitle%3DBlood%2520Rev.%26date%3D2011%26volume%3D25%26spage%3D53%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Verstovsek, S.; Odenike, O.; Scott, B.; Estrov, Z.; Cortes, J.; Thomas, D. A.; Wood, J.; Ethirajulu, K.; Lowe, A.; Zhu, H. J.; Kantarjian, H.; Deeg, H. J.</span><span> </span><span class="NLM_article-title">Phase I dose escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis</span>.  <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span>, Abstr.  <span class="NLM_fpage">3905</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=3905&author=S.+Verstovsek&author=O.+Odenike&author=B.+Scott&author=Z.+Estrov&author=J.+Cortes&author=D.+A.+Thomas&author=J.+Wood&author=K.+Ethirajulu&author=A.+Lowe&author=H.+J.+Zhu&author=H.+Kantarjian&author=H.+J.+Deeg&title=Phase+I+dose+escalation+trial+of+SB1518%2C+a+novel+JAK2%2FFLT3+inhibitor%2C+in+acute+and+chronic+myeloid+diseases%2C+including+primary+or+post-essential+thrombocythemia%2Fpolycythemia+vera+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPhase%2520I%2520dose%2520escalation%2520trial%2520of%2520SB1518%252C%2520a%2520novel%2520JAK2%252FFLT3%2520inhibitor%252C%2520in%2520acute%2520and%2520chronic%2520myeloid%2520diseases%252C%2520including%2520primary%2520or%2520post-essential%2520thrombocythemia%252Fpolycythemia%2520vera%2520myelofibrosis%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D3905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Verstovsek, S.; Deeg, H. J.; Odenike, O.; Zhu, H. J.; Kantarjian, H.; Estrov, Z.; Scott, B.; Cortes, J.; Thomas, D. A.</span><span> </span><span class="NLM_article-title">Phase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis</span>.  <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span>, Abstr.  <span class="NLM_fpage">3082</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=3082&author=S.+Verstovsek&author=H.+J.+Deeg&author=O.+Odenike&author=H.+J.+Zhu&author=H.+Kantarjian&author=Z.+Estrov&author=B.+Scott&author=J.+Cortes&author=D.+A.+Thomas&title=Phase+1%2F2+study+of+SB1518%2C+a+novel+JAK2%2FFLT3+inhibitor%2C+in+the+treatment+of+primary+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPhase%25201%252F2%2520study%2520of%2520SB1518%252C%2520a%2520novel%2520JAK2%252FFLT3%2520inhibitor%252C%2520in%2520the%2520treatment%2520of%2520primary%2520myelofibrosis%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D3082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Blanchard, S.; Lee, A. C.-H.; Nagaraj, H. K.-M.; Poulsen, A.; Sun, E. T.; Tan, E. Y.-L.; William, A. D.</span><span> </span><span class="NLM_article-title">Oxygen linked pyrimidine derivavtives</span>. WO 2007/058627 A,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+Blanchard&author=A.+C.-H.+Lee&author=H.+K.-M.+Nagaraj&author=A.+Poulsen&author=E.+T.+Sun&author=E.+Y.-L.+Tan&author=A.+D.+William&title=Oxygen+linked+pyrimidine+derivavtives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlanchard%26aufirst%3DS.%26atitle%3DOxygen%2520linked%2520pyrimidine%2520derivavtives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Weniger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melzner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menz, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wegener, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucur, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattfeldt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, T. F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moller, P.</span><span> </span><span class="NLM_article-title">Mutations of the tumor suppressor gene <i>SOCS-1</i> in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2679</span><span class="NLM_x">–</span> <span class="NLM_lpage">2684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=2679-2684&author=M.+A.+Wenigerauthor=I.+Melznerauthor=C.+K.+Menzauthor=S.+Wegenerauthor=A.+J.+Bucurauthor=K.+Dorschauthor=T.+Mattfeldtauthor=T.+F.+E.+Barthauthor=P.+Moller&title=Mutations+of+the+tumor+suppressor+gene+SOCS-1+in+classical+Hodgkin+lymphoma+are+frequent+and+associated+with+nuclear+phospho-STAT5+accumulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeniger%26aufirst%3DM.%2BA.%26aulast%3DMelzner%26aufirst%3DI.%26aulast%3DMenz%26aufirst%3DC.%2BK.%26aulast%3DWegener%26aufirst%3DS.%26aulast%3DBucur%26aufirst%3DA.%2BJ.%26aulast%3DDorsch%26aufirst%3DK.%26aulast%3DMattfeldt%26aufirst%3DT.%26aulast%3DBarth%26aufirst%3DT.%2BF.%2BE.%26aulast%3DMoller%26aufirst%3DP.%26atitle%3DMutations%2520of%2520the%2520tumor%2520suppressor%2520gene%2520SOCS-1%2520in%2520classical%2520Hodgkin%2520lymphoma%2520are%2520frequent%2520and%2520associated%2520with%2520nuclear%2520phospho-STAT5%2520accumulation%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D2679%26epage%3D2684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Navarro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pons, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Codony, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montserrat, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monzo, M.</span><span> </span><span class="NLM_article-title">Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">2945</span><span class="NLM_x">–</span> <span class="NLM_lpage">2951</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2945-2951&author=A.+Navarroauthor=T.+Diazauthor=A.+Martinezauthor=A.+Gayaauthor=A.+Ponsauthor=B.+Gelauthor=C.+Codonyauthor=G.+Ferrerauthor=C.+Martinezauthor=E.+Montserratauthor=M.+Monzo&title=Regulation+of+JAK2+by+miR-135a%3A+prognostic+impact+in+classic+Hodgkin+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DT.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DGaya%26aufirst%3DA.%26aulast%3DPons%26aufirst%3DA.%26aulast%3DGel%26aufirst%3DB.%26aulast%3DCodony%26aufirst%3DC.%26aulast%3DFerrer%26aufirst%3DG.%26aulast%3DMartinez%26aufirst%3DC.%26aulast%3DMontserrat%26aufirst%3DE.%26aulast%3DMonzo%26aufirst%3DM.%26atitle%3DRegulation%2520of%2520JAK2%2520by%2520miR-135a%253A%2520prognostic%2520impact%2520in%2520classic%2520Hodgkin%2520lymphoma%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2945%26epage%3D2951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Raia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schilling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böhm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowarsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sticht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saile, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Möller, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gretz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, W.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klingmüller, U.</span><span> </span><span class="NLM_article-title">Dynamic mathematical modeling of IL13-induced signaling in hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=693-704&author=V.+Raiaauthor=M.+Schillingauthor=M.+B%C3%B6hmauthor=B.+Hahnauthor=A.+Kowarschauthor=A.+Raueauthor=C.+Stichtauthor=S.+Bohlauthor=M.+Saileauthor=P.+M%C3%B6llerauthor=N.+Gretzauthor=J.+Timmerauthor=F.+Theisauthor=W.-D.+Lehmannauthor=P.+Lichterauthor=U.+Klingm%C3%BCller&title=Dynamic+mathematical+modeling+of+IL13-induced+signaling+in+hodgkin+and+primary+mediastinal+B-cell+lymphoma+allows+prediction+of+therapeutic+targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaia%26aufirst%3DV.%26aulast%3DSchilling%26aufirst%3DM.%26aulast%3DB%25C3%25B6hm%26aufirst%3DM.%26aulast%3DHahn%26aufirst%3DB.%26aulast%3DKowarsch%26aufirst%3DA.%26aulast%3DRaue%26aufirst%3DA.%26aulast%3DSticht%26aufirst%3DC.%26aulast%3DBohl%26aufirst%3DS.%26aulast%3DSaile%26aufirst%3DM.%26aulast%3DM%25C3%25B6ller%26aufirst%3DP.%26aulast%3DGretz%26aufirst%3DN.%26aulast%3DTimmer%26aufirst%3DJ.%26aulast%3DTheis%26aufirst%3DF.%26aulast%3DLehmann%26aufirst%3DW.-D.%26aulast%3DLichter%26aufirst%3DP.%26aulast%3DKlingm%25C3%25BCller%26aufirst%3DU.%26atitle%3DDynamic%2520mathematical%2520modeling%2520of%2520IL13-induced%2520signaling%2520in%2520hodgkin%2520and%2520primary%2520mediastinal%2520B-cell%2520lymphoma%2520allows%2520prediction%2520of%2520therapeutic%2520targets%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D693%26epage%3D704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Hart, S.; Goh, K. C.; Novotny-Diermayr, V.; Hu, C. Y.; Hentze, H.; Tan, Y. C.; Madan, B.; Amalini, C.; Loh, Y. K.; Ong, L. C.; William, A.; Lee, A.; Poulsen, A.; Jayaraman, R.; Ethirajulu, K.; Dymock, B.; Wood, J.</span><span> </span><span class="NLM_article-title">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span>. Leukemia<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">, </span>not supplied. </span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Hart&author=K.+C.+Goh&author=V.+Novotny-Diermayr&author=C.+Y.+Hu&author=H.+Hentze&author=Y.+C.+Tan&author=B.+Madan&author=C.+Amalini&author=Y.+K.+Loh&author=L.+C.+Ong&author=A.+William&author=A.+Lee&author=A.+Poulsen&author=R.+Jayaraman&author=K.+Ethirajulu&author=B.+Dymock&author=J.+Wood&title=SB1518%2C+a+novel+macrocyclic+pyrimidine-based+JAK2+inhibitor+for+the+treatment+of+myeloid+and+lymphoid+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26atitle%3DSB1518%252C%2520a%2520novel%2520macrocyclic%2520pyrimidine-based%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloid%2520and%2520lymphoid%2520malignancies%26jtitle%3DLeukemia%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favata, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi., J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">5298</span><span class="NLM_x">–</span> <span class="NLM_lpage">307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shi.author=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0ljFY04M3TOWhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi.%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Mesa, R. A.</span><span> </span><span class="NLM_article-title">Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis</span> <span class="citation_source-journal">IDrugs.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=20506062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1yltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=394-403&author=R.+A.+Mesa&title=Ruxolitinib%2C+a+selective+JAK1+and+JAK2+inhibitor+for+the+treatment+of+myeloproliferative+neoplasms+and+psoriasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis</span></div><div class="casAuthors">Mesa, Ruben A.</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-403</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, being developed by Incyte Corp and Novartis AG.  Ruxolitinib was initially developed to target the constitutive activation of the JAK-STAT pathway in patients with myeloproliferative neoplasms (MPNs).  Meaningful redns. in spleen size and constitutional symptoms have been noted in patients with myelofibrosis (both primary and post-essential thrombocythemia/polycythemia vera).  Data from a phase I/II clin. trial led to ongoing registration trials in the US and Europe.  Toxicity (primarily decreased erythropoiesis and thrombocytopoiesis) has been managed by close control of dosing.  The inhibition of inflammatory cytokine signaling through JAK1 inhibition has led to intriguing results in patients with rheumatoid arthritis and psoriasis (using a topical cream formulation).  Ruxolitinib is a well tolerated, first-in-class JAK2 inhibitor with various potential clin. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5yUMfeRYwE7Vg90H21EOLACvtfcHk0lgJjLU9c0BIiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1yltr0%253D&md5=9f89b13c71527c112b797375c93ccbff</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26atitle%3DRuxolitinib%252C%2520a%2520selective%2520JAK1%2520and%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%2520and%2520psoriasis%26jtitle%3DIDrugs.%26date%3D2010%26volume%3D13%26spage%3D394%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Nosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Deursen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripp, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierfelder., W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witthuhn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMickle, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosveld, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">Defective lymphoid development in mice lacking Jak3</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">800</span><span class="NLM_x">–</span> <span class="NLM_lpage">802</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=800-802&author=T.+Nosakaauthor=J.+M.+van+Deursenauthor=R.+A.+Trippauthor=W.+E.+Thierfelder.author=B.+A.+Witthuhnauthor=A.+P.+McMickleauthor=P.+C.+Dohertyauthor=G.+C.+Grosveldauthor=J.+N.+Ihle&title=Defective+lymphoid+development+in+mice+lacking+Jak3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNosaka%26aufirst%3DT.%26aulast%3Dvan%2BDeursen%26aufirst%3DJ.%2BM.%26aulast%3DTripp%26aufirst%3DR.%2BA.%26aulast%3DThierfelder.%26aufirst%3DW.%2BE.%26aulast%3DWitthuhn%26aufirst%3DB.%2BA.%26aulast%3DMcMickle%26aufirst%3DA.%2BP.%26aulast%3DDoherty%26aufirst%3DP.%2BC.%26aulast%3DGrosveld%26aufirst%3DG.%2BC.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DDefective%2520lymphoid%2520development%2520in%2520mice%2520lacking%2520Jak3%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D800%26epage%3D802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors</span> <span class="citation_source-journal">Best Prac. Res. Clin. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2FS1521-6926%2803%2900063-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=12935959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVCgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=409-417&author=D.+G.+Gilliland&title=FLT3-activating+mutations+in+acute+promyelocytic+leukaemia%3A+a+rationale+for+risk-adapted+therapy+with+FLT3+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors</span></div><div class="casAuthors">Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Haematology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-417</span>CODEN:
                <span class="NLM_cas:coden">BPRCA5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Our understanding of the genetic basis of acute myeloid leukemias has been enhanced through cloning of recurring chromosomal translocation breakpoints.  However, the remarkable observation, more than a decade ago, that all-trans retinoic acid (ATRA) induced remission in patients with t(15;17) acute promyelocytic leukemia (APL) was a driving force in the subsequent cloning and characterization of the PML-RARα fusion that is causally implicated in the pathogenesis of this disease.  Major improvements in treatment and outcome of APL patients have been made since that time by incorporating ATRA in conventional chemotherapy but 30% of APL patients still succumb to complications of their disease or their therapy.  Recent information that the hematopoietic receptor tyrosine kinase FLT3 is mutated in about 30% of APL patients suggests strategies for further improving treatment and outcome in this subset of APL patients using small-mol. inhibitors of FLT3.  The role of FLT3 mutations in APL and other AML is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo4Lxfsmnh9rVg90H21EOLACvtfcHk0lgJjLU9c0BIiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVCgu7s%253D&md5=f7b4d39e56a475225ab3fb7cb09e082b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS1521-6926%2803%2900063-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1521-6926%252803%252900063-X%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DFLT3-activating%2520mutations%2520in%2520acute%2520promyelocytic%2520leukaemia%253A%2520a%2520rationale%2520for%2520risk-adapted%2520therapy%2520with%2520FLT3%2520inhibitors%26jtitle%3DBest%2520Prac.%2520Res.%2520Clin.%2520Haematol.%26date%3D2003%26volume%3D16%26spage%3D409%26epage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Naoe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span> </span><span class="NLM_article-title">Oncogenic protein kinases: normal and oncogenic FLT3</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2932</span><span class="NLM_x">–</span> <span class="NLM_lpage">2938</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1007%2Fs00018-004-4274-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=15583855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXot1agtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2004&pages=2932-2938&author=T.+Naoeauthor=H.+Kiyoi&title=Oncogenic+protein+kinases%3A+normal+and+oncogenic+FLT3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Normal and oncogenic FLT3</span></div><div class="casAuthors">Naoe, T.; Kiyoi, H.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2932-2938</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  FLT3, a member of the class III receptor tyrosine kinases (RTKs), is preferentially expressed on the cell surface of hematopoietic progenitors, and the ligand of FLT3 (FL) is expressed as a membrane-bound or sol. form by bone marrow stroma cells.  It has been disclosed that FL-FLT3 interaction plays an important role in the maintenance, proliferation and differentiation of hematopoiesis.  FLT3 is also expressed in a high proportion of acute myeloid leukemia (AML) and B-lineage acute lymphoblastic leukemia cells.  Activating mutations of FLT3 are the most frequent genetic lesions in AML, and AML patients with FLT3 mutations have a worse prognosis than those with normal FLT3.  Exploring the mechanism by which FLT3 mutations cause autoactivation and uncontrolled signaling might lead to a better understanding of how FLT3 becomes oncogenic and provide insights for the development of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojXMnqCiA_ZrVg90H21EOLACvtfcHk0lhPURcKqexjyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXot1agtg%253D%253D&md5=902c59f9824b5e4d44cbe9372b1e1f35</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs00018-004-4274-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-004-4274-x%26sid%3Dliteratum%253Aachs%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DOncogenic%2520protein%2520kinases%253A%2520normal%2520and%2520oncogenic%2520FLT3%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2004%26volume%3D61%26spage%3D2932%26epage%3D2938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Kottaridis, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linch, D. C.</span><span> </span><span class="NLM_article-title">Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">913</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1080%2F1042819031000067503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=12854887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1yqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=905-913&author=P.+D.+Kottaridisauthor=R.+E.+Galeauthor=D.+C.+Linch&title=Prognostic+implications+of+the+presence+of+FLT3+mutations+in+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic Implications of the Presence of FLT3 Mutations in Patients with Acute Myeloid Leukemia</span></div><div class="casAuthors">Kottaridis, Panagiotis D.; Gale, Rosemary E.; Linch, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">905-913</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Several studies have shown that mutations in the FLT3 gene are common events in AML, with approx. one third of adult patients harboring either an internal tandem duplication in the juxtramembrane domain or a D835 mutation in the kinase domain.  The majority of studies in pediatric and adult AML have shown that FLT3 mutations are powerful prognostic factors predicting for increased relapse risk and adverse overall survival.  Some reports have suggested that loss of the wild type allele might be assocd. with an even worse prognosis.  Changes in the pattern of FLT3 mutations between disease presentation and relapse restrict their value as a marker of minimal residual disease, and have significant implications for therapy.  The optimum treatment for patients with FLT3 mutations remains unknown and large prospective studies are warranted to evaluate the efficacy of various treatment modalities such as bone marrow transplantation and targeted therapy with tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQTwjPfq-GmbVg90H21EOLACvtfcHk0lhPURcKqexjyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1yqsLY%253D&md5=a8e8475402ecf5d5600a0e4ed7a5fdb3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1080%2F1042819031000067503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1042819031000067503%26sid%3Dliteratum%253Aachs%26aulast%3DKottaridis%26aufirst%3DP.%2BD.%26aulast%3DGale%26aufirst%3DR.%2BE.%26aulast%3DLinch%26aufirst%3DD.%2BC.%26atitle%3DPrognostic%2520implications%2520of%2520the%2520presence%2520of%2520FLT3%2520mutations%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2003%26volume%3D44%26spage%3D905%26epage%3D913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Reilly, J. T.</span><span> </span><span class="NLM_article-title">FLT3 and its role in the pathogenesis of acute myeloid leukaemia</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1080%2F1042819021000040233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=12691136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVCkurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=1-7&author=J.+T.+Reilly&title=FLT3+and+its+role+in+the+pathogenesis+of+acute+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 and its Role in the Pathogenesis of Acute Myeloid Leukaemia</span></div><div class="casAuthors">Reilly, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  FLT3, a tyrosine kinase receptor class III (RTK), and its ligand (FL) are important for normal hematopoiesis and the development of the immune system.  Recently, internal tandem duplications (FLT3 ITDs) in exons 14 and/or 15 that lead to constitutive receptor activation, have been described in 20-25% of adults with acute myeloid leukemia (AML).  The FLT ITD mutations, which are thought to disrupt a repressor sequence in the juxtamembrane region, confer a poor prognosis in AML, esp. in patients under the age of 60 yr.  Furthermore, FLT3 "activating loop" mutations involving exon 20 have been reported in 7 of AML cases, making FLT3 the most commonly mutated gene in AML.  FLT3, therefore, is a potentially important mol. target for AML therapy and already phase I clin. trials have been initiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-7XEr7cYqRrVg90H21EOLACvtfcHk0lhPURcKqexjyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVCkurw%253D&md5=4cd59dcba4c00464b5a06bf1cc7196cf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1080%2F1042819021000040233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1042819021000040233%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DJ.%2BT.%26atitle%3DFLT3%2520and%2520its%2520role%2520in%2520the%2520pathogenesis%2520of%2520acute%2520myeloid%2520leukaemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2003%26volume%3D44%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Role of FLT3 in leukemia</span> <span class="citation_source-journal">Curr. Opin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">274</span><span class="NLM_x">–</span> <span class="NLM_lpage">281</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1097%2F00062752-200207000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=12042700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A280%3ADC%252BD38zgtFSgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=274-281&author=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Role+of+FLT3+in+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Role of FLT3 in leukemia</span></div><div class="casAuthors">Gilliland D Gary; Griffin James D</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in hematology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">274-81</span>
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    </div><div class="casAbstract">FLT3 is the most frequently mutated gene in cases of acute myelogenous leukemia (AML).  About 30 to 35% of patients have either internal tandem duplications (ITDs) in the juxtamembrane domain or mutations in the activating loop of FLT3.  FLT3 mutations occur in a broad spectrum of FAB subtypes in adult and pediatric AML and are particularly common in acute promyelocytic leukemia (APL).  FLT3 mutations confer a poor prognosis in most retrospective studies.  The consequence of either FLT3-ITD or activating loop mutations, which occur predominantly at position D835, is constitutive activation of the tyrosine kinase; FLT3 mutants confer factor-independent growth to Ba/F3 and 32D cells and activate similar transduction pathways as the native receptor in response to ligand, including the STAT, RAS/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3; kinase (PI3K)/AKT pathways.  Injection of FLT3-ITD transformed cells, such as Ba/F3 or 32D, into syngeneic recipient mice results in a leukemia-like syndrome, and expression in primary murine bone marrow cells in a retroviral transduction assay results in a myeloproliferative disorder.  Mutations that abrogate FLT3 kinase activity result in loss of transforming properties in these assays.  Further, FLT3-selective inhibitors impair transformation of primary AML cells that harbor these mutations, and also inhibit FLT3 transformed hematopoietic cell lines, and leukemias induced by activated FLT3 mutants in murine models.  Collectively, these data indicate that FLT3 may be a viable therapeutic target for treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFpKjX-b8FPb0AGQpJZWpJfW6udTcc2eaIqRTmBr-63bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zgtFSgsQ%253D%253D&md5=5a3742936355291f8a13f6f7eaf35cbf</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1097%2F00062752-200207000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00062752-200207000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DRole%2520of%2520FLT3%2520in%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2002%26volume%3D9%26spage%3D274%26epage%3D281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Younes, A.; Fanale, M. A.; McLaughlin, P.; Copeland, A.; Zhu, J.; Faria, S. C.</span><span> </span><span class="NLM_article-title">Phase 1 study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: Evidence of clinical and biological activity in multiple lymphoma subtypes</span>.  <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span>, Abstr.  <span class="NLM_fpage">2830</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=2830&author=A.+Younes&author=M.+A.+Fanale&author=P.+McLaughlin&author=A.+Copeland&author=J.+Zhu&author=S.+C.+Faria&title=Phase+1+study+of+a+novel+oral+JAK-2+inhibitor+SB1518+in+patients+with+relapsed+lymphoma%3A+Evidence+of+clinical+and+biological+activity+in+multiple+lymphoma+subtypes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26atitle%3DPhase%25201%2520study%2520of%2520a%2520novel%2520oral%2520JAK-2%2520inhibitor%2520SB1518%2520in%2520patients%2520with%2520relapsed%2520lymphoma%253A%2520Evidence%2520of%2520clinical%2520and%2520biological%2520activity%2520in%2520multiple%2520lymphoma%2520subtypes%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D2830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Kiss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sayeski, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keserũ, G. M.</span><span> </span><span class="NLM_article-title">Recent developments on JAK2 inhibitors: a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">495</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1517%2F13543771003639436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=20205617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslalsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=471-495&author=R.+Kissauthor=P.+P.+Sayeskiauthor=G.+M.+Keser%C5%A9&title=Recent+developments+on+JAK2+inhibitors%3A+a+patent+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments on JAK2 inhibitors: a patent review</span></div><div class="casAuthors">Kiss, Robert; Sayeski, Peter P.; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-495</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: JAK2 is one of the most promising targets against neoplastic growth.  A somatic mutation (V617F) resulting in enhanced JAK2 kinase activity can be frequently found in patients with serious myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia and primary myelofibrosis.  Preclin. results strongly support that JAK2 inhibitors could be effectively used in these indications.  Pharmaceutical companies and academic groups have developed a no. of potent JAK2 inhibitors during the last decade.  Tolerability and effectiveness of the most promising compds. are currently being investigated in clin. trials.  Areas covered in this review: In this paper, we aim to give a comprehensive review of the currently available patent literature of JAK2 inhibitors.  What the reader will gain: We tried to collect the published core structures possessing JAK2 inhibitory potency including compds. developed by academic and industrial research groups.  We review the currently available patent literature as well as the key papers contg. addnl. information about the described JAK2 inhibitors.  Clin. status data were collected by searching the Prous Integrity and Pharmaprojects databases.  Take home message: The significant no. of JAK2 inhibitors published and numerous clin. trials involving these compds. suggest that some of them might be approved in the next few years and can serve as novel drugs for the treatment of JAK2-dependent pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJQgQopptoVrVg90H21EOLACvtfcHk0lhh-V2C3MRBvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslalsrY%253D&md5=2531795d8c66c3b7173a0c1a3b2738e1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1517%2F13543771003639436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543771003639436%26sid%3Dliteratum%253Aachs%26aulast%3DKiss%26aufirst%3DR.%26aulast%3DSayeski%26aufirst%3DP.%2BP.%26aulast%3DKeser%25C5%25A9%26aufirst%3DG.%2BM.%26atitle%3DRecent%2520developments%2520on%2520JAK2%2520inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D471%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Grubbs, R. H.</span> <span class="citation_source-book">Handbook of Metathesis</span>; <span class="NLM_publisher-name">Wiley- VCH</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span><span class="NLM_x">; </span>Vols.  <span class="NLM_volume">1–3</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1002%2F9783527619481" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=R.+H.+Grubbs&title=Handbook+of+Metathesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2F9783527619481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527619481%26sid%3Dliteratum%253Aachs%26aulast%3DGrubbs%26aufirst%3DR.%2BH.%26btitle%3DHandbook%2520of%2520Metathesis%26pub%3DWiley-%2520VCH%26date%3D2003%26volume%3D1%25E2%2580%25933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Quincheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manfred, H.</span><span> </span><span class="NLM_article-title">Ring closure methods in the synthesis of macrocyclic natural products</span> <span class="citation_source-journal">Top. Curr. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=1992&pages=107-176&author=M.+Quinchengauthor=H.+Manfred&title=Ring+closure+methods+in+the+synthesis+of+macrocyclic+natural+products"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuincheng%26aufirst%3DM.%26aulast%3DManfred%26aufirst%3DH.%26atitle%3DRing%2520closure%2520methods%2520in%2520the%2520synthesis%2520of%2520macrocyclic%2520natural%2520products%26jtitle%3DTop.%2520Curr.%2520Chem.%26date%3D1992%26volume%3D161%26spage%3D107%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Deiters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. F.</span><span> </span><span class="NLM_article-title">Synthesis of oxygen- and nitrogen-containing heterocycles by ring-closing metathesis</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2199</span><span class="NLM_x">–</span> <span class="NLM_lpage">2238</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr0200872" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVSltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=2199-2238&author=A.+Deitersauthor=S.+F.+Martin&title=Synthesis+of+oxygen-+and+nitrogen-containing+heterocycles+by+ring-closing+metathesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of oxygen- and nitrogen-containing heterocycles by ring-closing metathesis</span></div><div class="casAuthors">Deiters, Alexander; Martin, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2199-2238</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the synthesis of oxygen- and nitrogen-contg. heterocycles by ring-closing metathesis (RCM).  Applications of olefin and alkyne RCM, enyne RCM, and tandem processes in which these reactions are combined with ring-opening metathesis (ROM) to construct O- and N-heterocycles are presented with a particular emphasis on natural product synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxORod8gOrIrVg90H21EOLACvtfcHk0liBWxQBg32VjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVSltb0%253D&md5=93d648a549ce629a402b4849c15c577c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fcr0200872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0200872%26sid%3Dliteratum%253Aachs%26aulast%3DDeiters%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DSynthesis%2520of%2520oxygen-%2520and%2520nitrogen-containing%2520heterocycles%2520by%2520ring-closing%2520metathesis%26jtitle%3DChem.%2520Rev.%26date%3D2004%26volume%3D104%26spage%3D2199%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1356</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1002%2Fanie.200390347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=1356-1360&author=Y.+S.+Tsantrizosauthor=G.+Bolgerauthor=P.+Bonneauauthor=D.+R.+Cameronauthor=N.+Goudreauauthor=G.+Kukoljauthor=S.+R.+LaPlanteauthor=M.+Llin%C3%A0s-Brunetauthor=H.+Narauthor=D.+Lamarre&title=Macrocyclic+inhibitors+of+the+NS3+protease+as+potential+therapeutic+agents+of+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span></div><div class="casAuthors">Tsantrizos, Youla S.; Bolger, Gordon; Bonneau, Pierre; Cameron, Dale R.; Goudreau, Nathalie; Kukolj, George; LaPlante, Steven R.; Llinas-Brunet, Montse; Nar, Herbert; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1356-1360</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel class of selective inhibitors of the hepatitis C virus NS3 protease, an enzyme which is essential for viral replication in vivo, was developed.  The inhibitors are based on the structure-activity relationship between a substrate-based peptidomimetic ligand and the HCV NS3 serine protease.  The designed HCV inhibitor and its satd. analogs are the first inhibitors of the NS3 protease which inhibit HCV RNA replication in the cell-based replicon assay.  In addn., they are orally absorbed and stable to metabolic breakdown.  Thus, these compds. show many of the desirable properties of a druglike archetype and could lead t a clin. useful antiviral agent for the treatment of hepatitis C viral infections in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCij3shP5tmLVg90H21EOLACvtfcHk0liBWxQBg32VjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D&md5=e0a3c98ee0096bfc3d058bf0b92b81c3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fanie.200390347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200390347%26sid%3Dliteratum%253Aachs%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DMacrocyclic%2520inhibitors%2520of%2520the%2520NS3%2520protease%2520as%2520potential%2520therapeutic%2520agents%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D1356%26epage%3D1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Graziani, E. I.</span><span> </span><span class="NLM_article-title">Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs</span> <span class="citation_source-journal">Nat. Prod. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">602</span><span class="NLM_x">–</span> <span class="NLM_lpage">609</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1039%2Fb804602f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=19387497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvValsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=602-609&author=E.+I.+Graziani&title=Recent+advances+in+the+chemistry%2C+biosynthesis+and+pharmacology+of+rapamycin+analogs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs</span></div><div class="casAuthors">Graziani, Edmund I.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">602-609</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  In the period 1998 to 2003, a no. of reviews have appeared evaluating the potential of rapamycin and other immunophilin ligands as therapies for cancer, organ transplantation, restenosis prevention, autoimmune disorders, and neurodegenerative diseases.  This review aims to evaluate advances in the field since that time, specifically detailing progress in: (i) the role of rapamycin in inhibiting its principal cellular target, the mammalian target of rapamycin (mTOR) in both of its protein complexes, (ii) understanding the role of specific genes in the mechanism of rapamycin biosynthesis, (iii) the prodn. of novel analogs of rapamycin via precursor-directed biosynthesis, (iv) the enzymol. of the pipecolate incorporating enzyme (RapL) in vitro, and (v) the pharmacol. and mechanistic chem. biol. of rapamycin analog mediated neuroprotection and neuroregeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4t3kBQAAJ67Vg90H21EOLACvtfcHk0ljwlo0xk6fEkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvValsrY%253D&md5=5df618a99547a56784d74bac6cbfdaf0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fb804602f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb804602f%26sid%3Dliteratum%253Aachs%26aulast%3DGraziani%26aufirst%3DE.%2BI.%26atitle%3DRecent%2520advances%2520in%2520the%2520chemistry%252C%2520biosynthesis%2520and%2520pharmacology%2520of%2520rapamycin%2520analogs%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2009%26volume%3D26%26spage%3D602%26epage%3D609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Driggers, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terret, N. K.</span><span> </span><span class="NLM_article-title">The exploration of macrocycles for drug discovery—an underexploited structural class</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">608</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=608-624&author=E.+M.+Driggersauthor=S.+P.+Haleauthor=J.+Leeauthor=N.+K.+Terret&title=The+exploration+of+macrocycles+for+drug+discovery%E2%80%94an+underexploited+structural+class"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDriggers%26aufirst%3DE.%2BM.%26aulast%3DHale%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTerret%26aufirst%3DN.%2BK.%26atitle%3DThe%2520exploration%2520of%2520macrocycles%2520for%2520drug%2520discovery%25E2%2580%2594an%2520underexploited%2520structural%2520class%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D608%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Joshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maikap, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Titirmare, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurjar, M. K.</span><span> </span><span class="NLM_article-title">An improved synthesis of etravirine</span> <span class="citation_source-journal">Org. Proc. Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span></span><div class="citationLinks">[<a href="/doi/10.1021/op9003289" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=657-660&author=S.+Joshiauthor=G.+C.+Maikapauthor=S.+Titirmareauthor=A.+Chaudhariauthor=M.+K.+Gurjar&title=An+improved+synthesis+of+etravirine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fop9003289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop9003289%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DMaikap%26aufirst%3DG.%2BC.%26aulast%3DTitirmare%26aufirst%3DS.%26aulast%3DChaudhari%26aufirst%3DA.%26aulast%3DGurjar%26aufirst%3DM.%2BK.%26atitle%3DAn%2520improved%2520synthesis%2520of%2520etravirine%26jtitle%3DOrg.%2520Proc.%2520Res.%2520Dev.%26date%3D2010%26volume%3D14%26spage%3D657%26epage%3D660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Schmidt, B.</span><span> </span><span class="NLM_article-title">Ruthenium-catalyzed cyclizations: more than just olefin metathesis!</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">4996</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=4996-4999&author=B.+Schmidt&title=Ruthenium-catalyzed+cyclizations%3A+more+than+just+olefin+metathesis%21"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DB.%26atitle%3DRuthenium-catalyzed%2520cyclizations%253A%2520more%2520than%2520just%2520olefin%2520metathesis%2521%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D4996%26epage%3D4999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, S.-L.</span><span> </span><span class="NLM_article-title">Asymmetric construction of polycyclic indoles through olefin cross- metathesis/intramolecular Friedel–Crafts alkylation under sequential catalysis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7428</span><span class="NLM_x">–</span> <span class="NLM_lpage">7431</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=7428-7431&author=Q.+Caiauthor=Z.-A.+Zhaoauthor=S.-L.+You&title=Asymmetric+construction+of+polycyclic+indoles+through+olefin+cross-+metathesis%2Fintramolecular+Friedel%E2%80%93Crafts+alkylation+under+sequential+catalysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DZ.-A.%26aulast%3DYou%26aufirst%3DS.-L.%26atitle%3DAsymmetric%2520construction%2520of%2520polycyclic%2520indoles%2520through%2520olefin%2520cross-%2520metathesis%252Fintramolecular%2520Friedel%25E2%2580%2593Crafts%2520alkylation%2520under%2520sequential%2520catalysis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D7428%26epage%3D7431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Suzuki, A.</span><span> </span><span class="NLM_article-title">Synthetic studies via the cross-coupling reaction of organoboron derivatives with organic halides</span> <span class="citation_source-journal">Pure Appl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1991&pages=419-422&author=A.+Suzuki&title=Synthetic+studies+via+the+cross-coupling+reaction+of+organoboron+derivatives+with+organic+halides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DSynthetic%2520studies%2520via%2520the%2520cross-coupling%2520reaction%2520of%2520organoboron%2520derivatives%2520with%2520organic%2520halides%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D1991%26volume%3D63%26spage%3D419%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Miyaura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, A.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed cross-coupling reactions of organoboron compounds</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">2457</span><span class="NLM_x">–</span> <span class="NLM_lpage">2483</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-catalyzed+cross-coupling+reactions+of+organoboron+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0ljl9Wuph6W13g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-catalyzed%2520cross-coupling%2520reactions%2520of%2520organoboron%2520compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26spage%3D2457%26epage%3D2483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Rao, P. S-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senthilkumar, S. P.</span><span> </span><span class="NLM_article-title">A convenient procedure for the synthesis of allyl and benzyl ethers from alcohols and phenols</span> <span class="citation_source-journal">Proc. Indian Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1007%2FBF02704069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmslSjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2001&pages=191-196&author=P.+S-H.+Raoauthor=S.+P.+Senthilkumar&title=A+convenient+procedure+for+the+synthesis+of+allyl+and+benzyl+ethers+from+alcohols+and+phenols"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient procedure for the synthesis of allyl and benzyl ethers from alcohols and phenols</span></div><div class="casAuthors">Rao, H. Surya Prakash; Senthilkumar, S. P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings - Indian Academy of Sciences, Chemical Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-196</span>CODEN:
                <span class="NLM_cas:coden">PIAADM</span>;
        ISSN:<span class="NLM_cas:issn">0253-4134</span>.
    
            (<span class="NLM_cas:orgname">Indian Academy of Sciences</span>)
        </div><div class="casAbstract">Allyl and benzyl ethers of alcs. can be prepd. conveniently and in high yield with allyl and benzyl bromide in the presence of solid potassium hydroxide without use of any solvent.  Phenols can be converted to allyl ethers but are inert to benzylation under above conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2t9aaL_hdt7Vg90H21EOLACvtfcHk0ljl9Wuph6W13g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmslSjs7s%253D&md5=6ffb92097143c2371b533e6cfd27de8d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2FBF02704069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02704069%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DP.%2BS-H.%26aulast%3DSenthilkumar%26aufirst%3DS.%2BP.%26atitle%3DA%2520convenient%2520procedure%2520for%2520the%2520synthesis%2520of%2520allyl%2520and%2520benzyl%2520ethers%2520from%2520alcohols%2520and%2520phenols%26jtitle%3DProc.%2520Indian%2520Acad.%2520Sci.%26date%3D2001%26volume%3D113%26spage%3D191%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Koehling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eilbracht, P.</span><span> </span><span class="NLM_article-title">Tandem hydroformylation/Fischer indole synthesis: a novel and convenient approach to indoles from olefins</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3213</span><span class="NLM_x">–</span> <span class="NLM_lpage">3216</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=3213-3216&author=P.+Koehlingauthor=A.+M.+Schmidtauthor=P.+Eilbracht&title=Tandem+hydroformylation%2FFischer+indole+synthesis%3A+a+novel+and+convenient+approach+to+indoles+from+olefins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoehling%26aufirst%3DP.%26aulast%3DSchmidt%26aufirst%3DA.%2BM.%26aulast%3DEilbracht%26aufirst%3DP.%26atitle%3DTandem%2520hydroformylation%252FFischer%2520indole%2520synthesis%253A%2520a%2520novel%2520and%2520convenient%2520approach%2520to%2520indoles%2520from%2520olefins%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D3213%26epage%3D3216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Ramadas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasan, N.</span><span> </span><span class="NLM_article-title">Iron-ammonium chloride: a convenient and inexpensive reductant</span> <span class="citation_source-journal">Synth. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3189</span><span class="NLM_x">–</span> <span class="NLM_lpage">3195</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1080%2F00397919208021132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1ykt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1992&pages=3189-3195&author=K.+Ramadasauthor=N.+Srinivasan&title=Iron-ammonium+chloride%3A+a+convenient+and+inexpensive+reductant"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Iron-ammonium chloride - a convenient and inexpensive reductant</span></div><div class="casAuthors">Ramadas, Krishnamurthy; Srinivasan, Natarajan</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3189-95</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    </div><div class="casAbstract">The redn. of nitro arom. compds., I (R1 = H, NH2, Me, Cl, R2 = H, NH2, NO2, R3 = H, CH2CN, CH2CO2H, Me, OH, NHAc, Br, Cl, NH2, R4 = NO2), contg. other susceptible groups is reinvestigated to provide a viable economic route from the point of view of quant. transformation, reduced reaction times, and simple work up using iron powder and ammonium chloride soln. in neutral medium.  Thus, using Fe/NH4Cl on I gave I (R4 = NH2) in 67-90% yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD_QX8c0Gcx7Vg90H21EOLACvtfcHk0ljJJCiF4MeHCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1ykt7k%253D&md5=7b3830ad2efaf09a30cbff04b89eb32a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F00397919208021132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919208021132%26sid%3Dliteratum%253Aachs%26aulast%3DRamadas%26aufirst%3DK.%26aulast%3DSrinivasan%26aufirst%3DN.%26atitle%3DIron-ammonium%2520chloride%253A%2520a%2520convenient%2520and%2520inexpensive%2520reductant%26jtitle%3DSynth.%2520Commun.%26date%3D1992%26volume%3D22%26spage%3D3189%26epage%3D3195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Hardcastle, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlands, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laughton, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trent, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neidle, S.</span><span> </span><span class="NLM_article-title">Rationally designed analogs of tamoxifen with improved calmodulin antagonism</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00002a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=241-248&author=I.+R.+Hardcastleauthor=M.+G.+Rowlandsauthor=J.+Houghtonauthor=I.+B.+Parrauthor=G.+A.+Potterauthor=M.+Jarmanauthor=K.+J.+Edwardsauthor=C.+A.+Laughtonauthor=J.+O.+Trentauthor=S.+Neidle&title=Rationally+designed+analogs+of+tamoxifen+with+improved+calmodulin+antagonism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm00002a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00002a005%26sid%3Dliteratum%253Aachs%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DRowlands%26aufirst%3DM.%2BG.%26aulast%3DHoughton%26aufirst%3DJ.%26aulast%3DParr%26aufirst%3DI.%2BB.%26aulast%3DPotter%26aufirst%3DG.%2BA.%26aulast%3DJarman%26aufirst%3DM.%26aulast%3DEdwards%26aufirst%3DK.%2BJ.%26aulast%3DLaughton%26aufirst%3DC.%2BA.%26aulast%3DTrent%26aufirst%3DJ.%2BO.%26aulast%3DNeidle%26aufirst%3DS.%26atitle%3DRationally%2520designed%2520analogs%2520of%2520tamoxifen%2520with%2520improved%2520calmodulin%2520antagonism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D241%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Dodge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocksdale, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahey, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. D.</span><span> </span><span class="NLM_article-title">Regioselectivity in the alkaline thiolate deprotection of aryl methyl ethers</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">741</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00108a046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1995&pages=739-741&author=J.+A.+Dodgeauthor=M.+G.+Stocksdaleauthor=K.+J.+Faheyauthor=C.+D.+Jones&title=Regioselectivity+in+the+alkaline+thiolate+deprotection+of+aryl+methyl+ethers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjo00108a046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00108a046%26sid%3Dliteratum%253Aachs%26aulast%3DDodge%26aufirst%3DJ.%2BA.%26aulast%3DStocksdale%26aufirst%3DM.%2BG.%26aulast%3DFahey%26aufirst%3DK.%2BJ.%26aulast%3DJones%26aufirst%3DC.%2BD.%26atitle%3DRegioselectivity%2520in%2520the%2520alkaline%2520thiolate%2520deprotection%2520of%2520aryl%2520methyl%2520ethers%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1995%26volume%3D60%26spage%3D739%26epage%3D741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Niu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumey, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagirath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subrath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eid, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, D.</span><span> </span><span class="NLM_article-title">First generation 5-vinyl-3-pyridinecarbonitrile PKCθ inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5829</span><span class="NLM_x">–</span> <span class="NLM_lpage">5832</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5829-5832&author=C.+Niuauthor=D.+H.+Boschelliauthor=L.+N.+Tumeyauthor=N.+Bhagirathauthor=J.+Subrathauthor=J.+Shimauthor=Y.+Wangauthor=B.+Wuauthor=C.+Eidauthor=J.+Leeauthor=X.+Yangauthor=A.+Brennanauthor=D.+Chaudhary&title=First+generation+5-vinyl-3-pyridinecarbonitrile+PKC%CE%B8+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DTumey%26aufirst%3DL.%2BN.%26aulast%3DBhagirath%26aufirst%3DN.%26aulast%3DSubrath%26aufirst%3DJ.%26aulast%3DShim%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DEid%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBrennan%26aufirst%3DA.%26aulast%3DChaudhary%26aufirst%3DD.%26atitle%3DFirst%2520generation%25205-vinyl-3-pyridinecarbonitrile%2520PKC%25CE%25B8%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5829%26epage%3D5832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasho, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1441</span><span class="NLM_x">–</span> <span class="NLM_lpage">1445</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1441-1445&author=A.+Pardananiauthor=T.+Lashoauthor=G.+Smithauthor=C.+J.+Burnsauthor=E+Fantinoauthor=A.+Tefferi&title=CYT387%2C+a+selective+JAK1%2FJAK2+inhibitor%3A+in+vitro+assessment+of+kinase+selectivity+and+preclinical+studies+using+cell+lines+and+primary+cells+from+polycythemia+vera+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DLasho%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DFantino%26aufirst%3DE%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DCYT387%252C%2520a%2520selective%2520JAK1%252FJAK2%2520inhibitor%253A%2520in%2520vitro%2520assessment%2520of%2520kinase%2520selectivity%2520and%2520preclinical%2520studies%2520using%2520cell%2520lines%2520and%2520primary%2520cells%2520from%2520polycythemia%2520vera%2520patients%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D1441%26epage%3D1445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="note"><p class="first last">For latest trials in Myelofibrosis, Advanced Myeloid Malignancies and Advanced Lymphoid Malignancies see <a href="http://clinicaltrials.gov" class="extLink">http://clinicaltrials.gov</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span>Maestro, Ligprep, Macromodel, Glide and QikProp; <span class="NLM_publisher-name">Schrodinger, LLC</span>, <span class="NLM_publisher-loc">New York, NY</span>.<span class="NLM_x"> </span><span class="NLM_year">2011</span>. <a href="http://www.schrodinger.com" class="extLink">http://www.schrodinger.com</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maestro%2C+Ligprep%2C+Macromodel%2C+Glide+and+QikProp%3B+Schrodinger%2C+LLC%2C+New+York%2C+NY.+2011.+http%3A%2F%2Fwww.schrodinger.com"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMaestro%252C%2520Ligprep%252C%2520Macromodel%252C%2520Glide%2520and%2520QikProp%26pub%3DSchrodinger%252C%2520LLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxwell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado-Rives, J.</span><span> </span><span class="NLM_article-title">Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">11225</span><span class="NLM_x">–</span> <span class="NLM_lpage">11236</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja9621760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADyaK28XmtlOitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=11225-11236&author=W.+L.+Jorgensenauthor=D.+S.+Maxwellauthor=J.+Tirado-Rives&title=Development+and+testing+of+the+OPLS+all-atom+force+field+on+conformational+energetics+and+properties+of+organic+liquids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids</span></div><div class="casAuthors">Jorgensen, William L.; Maxwell, David S.; Tirado-Rives, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">11225-11236</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The parametrization and testing of the OPLS all-atom force field for org. mols. and peptides are described.  Parameters for both torsional and nonbonded energetics have been derived, while the bond stretching and angle bending parameters have been adopted mostly from the AMBER all-atom force field.  The torsional parameters were detd. by fitting to rotational energy profiles obtained from ab initio MO calcns. at the RHF/6-31G*//RHF/6-31G* level for more than 50 org. mols. and ions.  The quality of the fits was high with av. errors for conformational energies of less than 0.2 kcal/mol.  The force-field results for mol. structures are also demonstrated to closely match the ab initio predictions.  The nonbonded parameters were developed in conjunction with Monte Carlo statistical mechanics simulations by computing thermodn. and structural properties for 34 pure org. liqs. including alkanes, alkenes, alcs., ethers, acetals, thiols, sulfides, disulfides, aldehydes, ketones, and amides.  Av. errors in comparison with exptl. data are 2% for heats of vaporization and densities.  The Monte Carlo simulations included sampling all internal and intermol. degrees of freedom.  It is found that such non-polar and monofunctional systems do not show significant condensed-phase effects on internal energies in going from the gas phase to the pure liqs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhGotSev_b1LVg90H21EOLACvtfcHk0ljKXu8S_eVUMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtlOitrs%253D&md5=fef2924a69421881390282aa309ae91b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fja9621760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9621760%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DMaxwell%26aufirst%3DD.%2BS.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26atitle%3DDevelopment%2520and%2520testing%2520of%2520the%2520OPLS%2520all-atom%2520force%2520field%2520on%2520conformational%2520energetics%2520and%2520properties%2520of%2520organic%2520liquids%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26spage%3D11225%26epage%3D11236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Hasel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Still, W. C.</span><span> </span><span class="NLM_article-title">A rapid approximation to the solvent accessible surface areas of atoms</span> <span class="citation_source-journal">Tetrahedron Comput. Method</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2F0898-5529%2888%2990015-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1988&pages=103-116&author=W.+Haselauthor=T.+F.+Hendricksonauthor=W.+C.+Still&title=A+rapid+approximation+to+the+solvent+accessible+surface+areas+of+atoms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid approximation to the solvent-accessible surface areas of atoms</span></div><div class="casAuthors">Hasel, Winnfried; Hendrickson, Thomas F.; Still, W. Clark</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Computer Methodology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-16</span>CODEN:
                <span class="NLM_cas:coden">TCMTE6</span>;
        ISSN:<span class="NLM_cas:issn">0898-5529</span>.
    </div><div class="casAbstract">An anal. expression for approx. at. and mol. van der Waals and solvent accessible surface areas is described.  The treatment is based on the probabilistic method of Wodak and Janin (1980) but with modifications which allow it to be applied to the calcn. of at. surface areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEtlzGPkwT_7Vg90H21EOLACvtfcHk0lgi1B-5gv2cYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D&md5=98b3e7fab9432dccb1ff22f726d54fbf</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2F0898-5529%2888%2990015-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0898-5529%252888%252990015-2%26sid%3Dliteratum%253Aachs%26aulast%3DHasel%26aufirst%3DW.%26aulast%3DHendrickson%26aufirst%3DT.%2BF.%26aulast%3DStill%26aufirst%3DW.%2BC.%26atitle%3DA%2520rapid%2520approximation%2520to%2520the%2520solvent%2520accessible%2520surface%2520areas%2520of%2520atoms%26jtitle%3DTetrahedron%2520Comput.%2520Method%26date%3D1988%26volume%3D1%26spage%3D103%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Williams, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn., J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucet, I. S.</span><span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohn.author=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0lgi1B-5gv2cYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn.%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Lucet, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Styles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broughton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treutlein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span> </span><span class="NLM_article-title">The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">176</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=176-183&author=I.+S.+Lucetauthor=E.+Fantinoauthor=M.+Stylesauthor=R.+Bamertauthor=O.+Patelauthor=S.+E.+Broughtonauthor=M.+Walterauthor=C.+J.+Burnsauthor=H.+Treutleinauthor=A.+F.+Wilksauthor=J.+Rossjohn&title=The+structural+basis+of+Janus+kinase+2+inhibition+by+a+potent+and+specific+pan-Janus+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLucet%26aufirst%3DI.%2BS.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DStyles%26aufirst%3DM.%26aulast%3DBamert%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DBroughton%26aufirst%3DS.%2BE.%26aulast%3DWalter%26aufirst%3DM.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DTreutlein%26aufirst%3DH.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DRossjohn%26aufirst%3DJ.%26atitle%3DThe%2520structural%2520basis%2520of%2520Janus%2520kinase%25202%2520inhibition%2520by%2520a%2520potent%2520and%2520specific%2520pan-Janus%2520kinase%2520inhibitor%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D176%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Crystal structure of the JAK3 kinase domain in complex with a staurosporine analog</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">996</span><span class="NLM_x">–</span> <span class="NLM_lpage">1002</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1182%2Fblood-2005-02-0707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=15831699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVSmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=996-1002&author=T.+J.+Boggonauthor=Y.+Liauthor=P.+W.+Manleyauthor=M.+J.+Eck&title=Crystal+structure+of+the+JAK3+kinase+domain+in+complex+with+a+staurosporine+analog"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog</span></div><div class="casAuthors">Boggon, Titus J.; Li, Yiqun; Manley, Paul W.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">996-1002</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Jak (Janus kinase) family nonreceptor tyrosine kinases are central mediators of cytokine signaling.  The Jak kinases exhibit distinct cytokine receptor assocn. profiles and so transduce different signals.  Jak3 expression is limited to the immune system, where it plays a key role in signal transduction from cytokine receptors contg. the common gamma chain, γc.  Patients unable to signal via γc present with severe combined immunodeficiency (SCID).  The finding that Jak3 mutations result in SCID has made it a target for development of lymphocyte-specific immunosuppressants.  Here, we present the crystal structure of the Jak3 kinase domain in complex with staurosporine analog AFN941.  The kinase domain is in the active conformation, with both activation loop tyrosine residues phosphorylated.  The phosphate group on pTyr981 in the activation loop is in part coordinated by an arginine residue in the regulatory C-helix, suggesting a direct mechanism by which the active position of the C-helix is induced by phosphorylation of the activation loop.  Such a direct coupling has not been previously obsd. in tyrosine kinases and may be unique to Jak kinases.  The crystal structure provides a detailed view of the Jak3 active site and will facilitate computational and structure-directed approaches to development of Jak3-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ-bnI3-sVjLVg90H21EOLACvtfcHk0ljRGJJIXrTK3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVSmsr4%253D&md5=12f87a37a495559c6e34dde019578371</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-02-0707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-02-0707%26sid%3Dliteratum%253Aachs%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520JAK3%2520kinase%2520domain%2520in%2520complex%2520with%2520a%2520staurosporine%2520analog%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D996%26epage%3D1002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Lawrie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunnah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span> </span><span class="NLM_article-title">Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">796</span><span class="NLM_x">–</span> <span class="NLM_lpage">801</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=796-801&author=A.+M.+Lawrieauthor=M.+E.+M.+Nobleauthor=P.+Tunnahauthor=N.+R.+Brownauthor=L.+A.+Johnsonauthor=J.+A.+Endicott&title=Protein+kinase+inhibition+by+staurosporine+revealed+in+details+of+the+molecular+interaction+with+CDK2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLawrie%26aufirst%3DA.%2BM.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26aulast%3DTunnah%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DN.%2BR.%26aulast%3DJohnson%26aufirst%3DL.%2BA.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26atitle%3DProtein%2520kinase%2520inhibition%2520by%2520staurosporine%2520revealed%2520in%2520details%2520of%2520the%2520molecular%2520interaction%2520with%2520CDK2%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D1997%26volume%3D4%26spage%3D796%26epage%3D801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Griffith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faerman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, K.</span><span> </span><span class="NLM_article-title">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+structural+basis+for+autoinhibition+of+FLT3+by+the+juxtamembrane+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0lj881AipUENsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520structural%2520basis%2520for%2520autoinhibition%2520of%2520FLT3%2520by%2520the%2520juxtamembrane%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D169%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Berman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindyalov, I. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, P. E.</span><span> </span><span class="NLM_article-title">The Protein Data Bank</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1093%2Fnar%2F28.1.235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=10592235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=235-242&author=H.+M.+Bermanauthor=J.+Westbrookauthor=Z.+Fengauthor=G.+Gillilandauthor=T.+N.+Bhatauthor=H.+Weissigauthor=I.+N.+Shindyalovauthor=P.+E.+Bourne&title=The+Protein+Data+Bank"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Data Bank</span></div><div class="casAuthors">Berman, Helen M.; Westbrook, John; Feng, Zukang; Gilliland, Gary; Bhat, T. N.; Weissig, Helge; Shindyalov, Ilya N.; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Protein Data Bank (PDB; http://www.rcsb.org/pdb/)is the single worldwide archive of structural data of biol. macromols.  This paper describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information, and near-term plans for the future development of the resource.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpStGCxT8QzirVg90H21EOLACvtfcHk0lj881AipUENsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D&md5=227fb393f754be2be375ab727bfd05dc</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F28.1.235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F28.1.235%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DWestbrook%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DShindyalov%26aufirst%3DI.%2BN.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DThe%2520Protein%2520Data%2520Bank%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2000%26volume%3D28%26spage%3D235%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':[],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 96 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jennifer Alisa Amrhein, Stefan Knapp, <span class="NLM_string-name hlFld-ContribAuthor">Thomas Hanke</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7991-8009. <a href="https://doi.org/10.1021/acs.jmedchem.1c00217" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00217</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00217%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BOpportunities%252Band%252BChallenges%252Bfor%252BMacrocyclic%252BKinase%252BInhibitors%26aulast%3DAmrhein%26aufirst%3DJennifer%2BAlisa%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D04022021%26date%3D02062021%26volume%3D64%26issue%3D12%26spage%3D7991%26epage%3D8009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xin-Hui Zhang, Qin-Ma, Hui-Pan Wu, Mussa Yussuf Khamis, Yi-Han Li, Li-Ying Ma, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Min Liu</span>. </span><span class="cited-content_cbyCitation_article-title">A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1362-1391. <a href="https://doi.org/10.1021/acs.jmedchem.0c01782" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01782</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01782%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BReview%252Bof%252BProgress%252Bin%252BHistone%252BDeacetylase%252B6%252BInhibitors%252BResearch%25253A%252BStructural%252BSpecificity%252Band%252BFunctional%252BDiversity%26aulast%3DZhang%26aufirst%3DXin-Hui%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12102020%26date%3D01022021%26volume%3D64%26issue%3D3%26spage%3D1362%26epage%3D1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jonathan A. Spencer, Ian R. Baldwin, Nick Barton, Chun-Wa Chung, Máire A. Convery, Christopher D. Edwards, Craig Jamieson, David N. Mallett, James E. Rowedder, Paul Rowland, Daniel A. Thomas, <span class="NLM_string-name hlFld-ContribAuthor">Charlotte J. Hardy</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Development of a Macrocyclic Series Targeting Phosphoinositide 3-Kinase δ. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (7)
                                     , 1386-1391. <a href="https://doi.org/10.1021/acsmedchemlett.0c00061" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00061%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252BDevelopment%252Bof%252Ba%252BMacrocyclic%252BSeries%252BTargeting%252BPhosphoinositide%252B3-Kinase%252B%2525CE%2525B4%26aulast%3DSpencer%26aufirst%3DJonathan%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04022020%26date%3D03062020%26date%3D18062020%26date%3D03062020%26volume%3D11%26issue%3D7%26spage%3D1386%26epage%3D1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Olga Cruz-López, Carolin Temps, Beatrice Longo, Samuel H. Myers, Francisco Franco-Montalban, <span class="NLM_string-name hlFld-ContribAuthor">Asier Unciti-Broceta</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (25)
                                     , 21620-21626. <a href="https://doi.org/10.1021/acsomega.9b03525" title="DOI URL">https://doi.org/10.1021/acsomega.9b03525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b03525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b03525%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252Ba%252BClick-Assembled%252B18-Atom%252BMacrocycle%252BThat%252BDisplays%252BSelective%252BAXL%252BKinase%252BInhibitory%252BActivity%26aulast%3DCruz-L%25C3%25B3pez%26aufirst%3DOlga%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22102019%26date%3D14112019%26date%3D03122019%26volume%3D4%26issue%3D25%26spage%3D21620%26epage%3D21626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Yang, Mengshi Hu, Wenyan Qi, Zhuang Yang, Minghai Tang, Jun He, Yong Chen, Peng Bai, Xue Yuan, Chufeng Zhang, Kongjun Liu, Yulin Lu, Mingli Xiang, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (22)
                                     , 10305-10320. <a href="https://doi.org/10.1021/acs.jmedchem.9b01348" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01348</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01348%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BOrally%252BEffective%252BDual%252BJanus%252BKinase%252B2%25252FFLT3%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BAcute%252BMyelogenous%252BLeukemia%252Band%252BMyeloproliferative%252BNeoplasms%26aulast%3DYang%26aufirst%3DTao%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15082019%26date%3D08112019%26date%3D31102019%26volume%3D62%26issue%3D22%26spage%3D10305%26epage%3D10320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maxwell D. Cummings, <span class="NLM_string-name hlFld-ContribAuthor">Sivakumar Sekharan</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 6843-6853. <a href="https://doi.org/10.1021/acs.jmedchem.8b01985" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01985</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01985%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BMacrocycle%252BDesign%252Bin%252BSmall-Molecule%252BDrug%252BDiscovery%252Band%252BSimple%252BMetrics%252BTo%252BIdentify%252BOpportunities%252Bfor%252BMacrocyclization%252Bof%252BSmall-Molecule%252BLigands%26aulast%3DCummings%26aufirst%3DMaxwell%2BD.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D18122018%26date%3D22032019%26date%3D12032019%26volume%3D62%26issue%3D15%26spage%3D6843%26epage%3D6853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Heyi Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Zhan Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Nickel/Copper Dual Catalysis for Sequential Nazarov Cyclization/Decarboxylative Aldol Reaction. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (18)
                                     , 5709-5713. <a href="https://doi.org/10.1021/acs.orglett.8b02426" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b02426</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b02426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b02426%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DNickel%25252FCopper%252BDual%252BCatalysis%252Bfor%252BSequential%252BNazarov%252BCyclization%25252FDecarboxylative%252BAldol%252BReaction%26aulast%3DZhang%26aufirst%3DHeyi%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D30072018%26date%3D30082018%26volume%3D20%26issue%3D18%26spage%3D5709%26epage%3D5713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yahui Huang, Guoqiang Dong, Huanqiu Li, Na Liu, Wannian Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Chunquan Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 6056-6074. <a href="https://doi.org/10.1021/acs.jmedchem.8b00393" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00393</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BJanus%252BKinase%252B2%252B%252528JAK2%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BDual%252BInhibitors%252Bas%252Ba%252BNovel%252BStrategy%252Bfor%252Bthe%252BCombinational%252BTreatment%252Bof%252BLeukemia%252Band%252BInvasive%252BFungal%252BInfections%26aulast%3DHuang%26aufirst%3DYahui%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D10032018%26date%3D14072018%26date%3D25062018%26volume%3D61%26issue%3D14%26spage%3D6056%26epage%3D6074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lianbin  Yao</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Eng Chong  Tan</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Prachi  Singh</span>, <span class="hlFld-ContribAuthor ">Minh-Dao  Duong-Thi</span>, <span class="hlFld-ContribAuthor ">Jeannie X. T.  Lee</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Jeffrey J. Y.  Yen</span>, <span class="hlFld-ContribAuthor ">Sten  Ohlson</span>, and <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (20)
                                     , 8336-8357. <a href="https://doi.org/10.1021/acs.jmedchem.7b00678" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00678</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00678%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BLigand%252BEfficient%252BDual%252BInhibitors%252Bof%252BJanus%252BKinase%252B%252528JAK%252529%252Band%252BHistone%252BDeacetylase%252B%252528HDAC%252529%252BBased%252Bon%252BRuxolitinib%252Band%252BVorinostat%26aulast%3DYao%26aufirst%3DLianbin%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11052017%26date%3D10102017%26date%3D26102017%26date%3D27092017%26volume%3D60%26issue%3D20%26spage%3D8336%26epage%3D8357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eugene Guorong  Yang</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Eng Chong  Tan</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Jeffrey J. Y.  Yen</span>, and <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>  . </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (18)
                                     , 8233-8262. <a href="https://doi.org/10.1021/acs.jmedchem.6b00157" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00157</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BJanus%252BKinase%252B2%252B%252528JAK2%252529%252Band%252BHistone%252BDeacetlyase%252B%252528HDAC%252529%252BBispecific%252BInhibitors%252BBased%252Bon%252BPacritinib%252Band%252BEvidence%252Bof%252BDual%252BPathway%252BInhibition%252Bin%252BHematological%252BCell%252BLines%26aulast%3DYang%26aufirst%3DEugene%2BGuorong%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03022016%26date%3D08092016%26date%3D22092016%26date%3D19082016%26volume%3D59%26issue%3D18%26spage%3D8233%26epage%3D8262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Salaheddin A. I.  Sharif</span>, <span class="hlFld-ContribAuthor ">Ewen D. D.  Calder</span>, <span class="hlFld-ContribAuthor ">Fábio G.  Delolo</span>, and <span class="hlFld-ContribAuthor ">Andrew  Sutherland</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of 5-Amino-2,5-dihydro-1H-benzo[b]azepines Using a One-Pot Multibond Forming Process. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (15)
                                     , 6697-6706. <a href="https://doi.org/10.1021/acs.joc.6b01357" title="DOI URL">https://doi.org/10.1021/acs.joc.6b01357</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b01357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b01357%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252B5-Amino-2%25252C5-dihydro-1H-benzo%25255Bb%25255Dazepines%252BUsing%252Ba%252BOne-Pot%252BMultibond%252BForming%252BProcess%26aulast%3DSharif%26aufirst%3DSalaheddin%2BA.%2BI.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D04062016%26date%3D21072016%26date%3D05082016%26date%3D14072016%26volume%3D81%26issue%3D15%26spage%3D6697%26epage%3D6706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sébastien L.  Degorce</span>, <span class="hlFld-ContribAuthor ">Scott  Boyd</span>, <span class="hlFld-ContribAuthor ">Jon O.  Curwen</span>, <span class="hlFld-ContribAuthor ">Richard  Ducray</span>, <span class="hlFld-ContribAuthor ">Christopher T.  Halsall</span>, <span class="hlFld-ContribAuthor ">Clifford D.  Jones</span>, <span class="hlFld-ContribAuthor ">Franck  Lach</span>, <span class="hlFld-ContribAuthor ">Eva M.  Lenz</span>, <span class="hlFld-ContribAuthor ">Martin  Pass</span>, <span class="hlFld-ContribAuthor ">Sarah  Pass</span>, and <span class="hlFld-ContribAuthor ">Catherine  Trigwell</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (10)
                                     , 4859-4866. <a href="https://doi.org/10.1021/acs.jmedchem.6b00203" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00203</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00203%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%25252C%252BSelective%25252C%252BOrally%252BBioavailable%25252C%252Band%252BEfficacious%252BNovel%252B2-%252528Pyrazol-4-ylamino%252529-pyrimidine%252BInhibitor%252Bof%252Bthe%252BInsulin-like%252BGrowth%252BFactor-1%252BReceptor%252B%252528IGF-1R%252529%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D07022016%26date%3D22042016%26date%3D26052016%26date%3D14042016%26volume%3D59%26issue%3D10%26spage%3D4859%26epage%3D4866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anees  Ahmad</span> and <span class="hlFld-ContribAuthor ">Luiz F.  Silva, Jr.</span>  . </span><span class="cited-content_cbyCitation_article-title">Metal-Free Asymmetric Synthesis of Indanes through Chiral Hypervalent Iodine(III)-Mediated Ring Contraction. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (5)
                                     , 2174-2181. <a href="https://doi.org/10.1021/acs.joc.5b02803" title="DOI URL">https://doi.org/10.1021/acs.joc.5b02803</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.5b02803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.5b02803%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DMetal-Free%252BAsymmetric%252BSynthesis%252Bof%252BIndanes%252Bthrough%252BChiral%252BHypervalent%252BIodine%252528III%252529-Mediated%252BRing%252BContraction%26aulast%3DAhmad%26aufirst%3DAnees%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D17122015%26date%3D19022016%26date%3D04032016%26date%3D11022016%26volume%3D81%26issue%3D5%26spage%3D2174%26epage%3D2181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dávid  Bajusz</span>, <span class="hlFld-ContribAuthor ">György G.  Ferenczy</span>, and <span class="hlFld-ContribAuthor ">György M.  Keserű</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (1)
                                     , 234-247. <a href="https://doi.org/10.1021/acs.jcim.5b00634" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00634%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDiscovery%252Bof%252BSubtype%252BSelective%252BJanus%252BKinase%252B%252528JAK%252529%252BInhibitors%252Bby%252BStructure-Based%252BVirtual%252BScreening%26aulast%3DBajusz%26aufirst%3DD%25C3%25A1vid%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D18102015%26date%3D31122015%26date%3D25012016%26date%3D18122015%26volume%3D56%26issue%3D1%26spage%3D234%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott E.  Allen</span>, <span class="hlFld-ContribAuthor ">Nikolay V.  Dokholyan</span>, and <span class="hlFld-ContribAuthor ">Albert A.  Bowers</span>  . </span><span class="cited-content_cbyCitation_article-title">Dynamic Docking of Conformationally Constrained Macrocycles: Methods and Applications. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2016,</strong> <em>11 </em>
                                    (1)
                                     , 10-24. <a href="https://doi.org/10.1021/acschembio.5b00663" title="DOI URL">https://doi.org/10.1021/acschembio.5b00663</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.5b00663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.5b00663%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDynamic%252BDocking%252Bof%252BConformationally%252BConstrained%252BMacrocycles%25253A%252BMethods%252Band%252BApplications%26aulast%3DAllen%26aufirst%3DScott%2BE.%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D19082015%26date%3D17112015%26date%3D04122015%26date%3D15012016%26date%3D17112015%26volume%3D11%26issue%3D1%26spage%3D10%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Honghe  Wan</span>, <span class="hlFld-ContribAuthor ">Gretchen M.  Schroeder</span>, <span class="hlFld-ContribAuthor ">Amy C.  Hart</span>, <span class="hlFld-ContribAuthor ">Jennifer  Inghrim</span>, <span class="hlFld-ContribAuthor ">James  Grebinski</span>, <span class="hlFld-ContribAuthor ">John S.  Tokarski</span>, <span class="hlFld-ContribAuthor ">Matthew V.  Lorenzi</span>, <span class="hlFld-ContribAuthor ">Dan  You</span>, <span class="hlFld-ContribAuthor ">Theresa  Mcdevitt</span>, <span class="hlFld-ContribAuthor ">Becky  Penhallow</span>, <span class="hlFld-ContribAuthor ">Ragini  Vuppugalla</span>, <span class="hlFld-ContribAuthor ">Yueping  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Gu</span>, <span class="hlFld-ContribAuthor ">Ramaswamy  Iyer</span>, <span class="hlFld-ContribAuthor ">Louis J.  Lombardo</span>, <span class="hlFld-ContribAuthor ">George L.  Trainor</span>, <span class="hlFld-ContribAuthor ">Stefan  Ruepp</span>, <span class="hlFld-ContribAuthor ">Jonathan  Lippy</span>, <span class="hlFld-ContribAuthor ">Yuval  Blat</span>, <span class="hlFld-ContribAuthor ">John S.  Sack</span>, <span class="hlFld-ContribAuthor ">Javed A.  Khan</span>, <span class="hlFld-ContribAuthor ">Kevin  Stefanski</span>, <span class="hlFld-ContribAuthor ">Bogdan  Sleczka</span>, <span class="hlFld-ContribAuthor ">Arvind  Mathur</span>, <span class="hlFld-ContribAuthor ">Jung-Hui  Sun</span>, <span class="hlFld-ContribAuthor ">Michael K.  Wong</span>, <span class="hlFld-ContribAuthor ">Dauh-Rurng  Wu</span>, <span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Anuradha  Gupta</span>, <span class="hlFld-ContribAuthor ">P. N.  Arunachalam</span>, <span class="hlFld-ContribAuthor ">Bala  Pragalathan</span>, <span class="hlFld-ContribAuthor ">Sankara  Narayanan</span>, <span class="hlFld-ContribAuthor ">Nanjundaswamy  K.C.</span>, <span class="hlFld-ContribAuthor ">Prakasam  Kuppusamy</span>, and <span class="hlFld-ContribAuthor ">Ashok V.  Purandare</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (8)
                                     , 850-855. <a href="https://doi.org/10.1021/acsmedchemlett.5b00226" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00226</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00226%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BHighly%252BSelective%252BJAK2%252BInhibitor%25252C%252BBMS-911543%25252C%252Bfor%252Bthe%252BTreatment%252Bof%252BMyeloproliferative%252BNeoplasms%26aulast%3DWan%26aufirst%3DHonghe%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D09062015%26date%3D12072015%26date%3D14072015%26date%3D13082015%26date%3D12072015%26volume%3D6%26issue%3D8%26spage%3D850%26epage%3D855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabrizio  Giordanetto</span> and <span class="hlFld-ContribAuthor ">Jan  Kihlberg</span>  . </span><span class="cited-content_cbyCitation_article-title">Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (2)
                                     , 278-295. <a href="https://doi.org/10.1021/jm400887j" title="DOI URL">https://doi.org/10.1021/jm400887j</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400887j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400887j%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMacrocyclic%252BDrugs%252Band%252BClinical%252BCandidates%25253A%252BWhat%252BCan%252BMedicinal%252BChemists%252BLearn%252Bfrom%252BTheir%252BProperties%25253F%26aulast%3DGiordanetto%26aufirst%3DFabrizio%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D14062013%26date%3D17092013%26date%3D23012014%26date%3D28082013%26volume%3D57%26issue%3D2%26spage%3D278%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Christopher A.  Hurley</span>, <span class="hlFld-ContribAuthor ">Stuart I.  Ward</span>, <span class="hlFld-ContribAuthor ">Philippe  Bergeron</span>, <span class="hlFld-ContribAuthor ">Kathy  Barrett</span>, <span class="hlFld-ContribAuthor ">Mercedesz  Balazs</span>, <span class="hlFld-ContribAuthor ">Wade S.  Blair</span>, <span class="hlFld-ContribAuthor ">Richard  Bull</span>, <span class="hlFld-ContribAuthor ">Paroma  Chakravarty</span>, <span class="hlFld-ContribAuthor ">Christine  Chang</span>, <span class="hlFld-ContribAuthor ">Peter  Crackett</span>, <span class="hlFld-ContribAuthor ">Gauri  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Jason  DeVoss</span>, <span class="hlFld-ContribAuthor ">Peter S.  Dragovich</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Charles  Ellwood</span>, <span class="hlFld-ContribAuthor ">Simon  Gaines</span>, <span class="hlFld-ContribAuthor ">Nico  Ghilardi</span>, <span class="hlFld-ContribAuthor ">Paul  Gibbons</span>, <span class="hlFld-ContribAuthor ">Stefan  Gradl</span>, <span class="hlFld-ContribAuthor ">Peter  Gribling</span>, <span class="hlFld-ContribAuthor ">Chris  Hamman</span>, <span class="hlFld-ContribAuthor ">Eric  Harstad</span>, <span class="hlFld-ContribAuthor ">Peter  Hewitt</span>, <span class="hlFld-ContribAuthor ">Adam  Johnson</span>, <span class="hlFld-ContribAuthor ">Tony  Johnson</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Michael F. T.  Koehler</span>, <span class="hlFld-ContribAuthor ">Pawan  Bir Kohli</span>, <span class="hlFld-ContribAuthor ">Sharada  Labadie</span>, <span class="hlFld-ContribAuthor ">Wyne P.  Lee</span>, <span class="hlFld-ContribAuthor ">Jiangpeng  Liao</span>, <span class="hlFld-ContribAuthor ">Marya  Liimatta</span>, <span class="hlFld-ContribAuthor ">Rohan  Mendonca</span>, <span class="hlFld-ContribAuthor ">Raman  Narukulla</span>, <span class="hlFld-ContribAuthor ">Rebecca  Pulk</span>, <span class="hlFld-ContribAuthor ">Austin  Reeve</span>, <span class="hlFld-ContribAuthor ">Scott  Savage</span>, <span class="hlFld-ContribAuthor ">Steven  Shia</span>, <span class="hlFld-ContribAuthor ">Micah  Steffek</span>, <span class="hlFld-ContribAuthor ">Savita  Ubhayakar</span>, <span class="hlFld-ContribAuthor ">Anne  van Abbema</span>, <span class="hlFld-ContribAuthor ">Ignacio  Aliagas</span>, <span class="hlFld-ContribAuthor ">Barbara  Avitabile-Woo</span>, <span class="hlFld-ContribAuthor ">Yisong  Xiao</span>, <span class="hlFld-ContribAuthor ">Jing  Yang</span>, and <span class="hlFld-ContribAuthor ">Janusz J.  Kulagowski</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (11)
                                     , 4764-4785. <a href="https://doi.org/10.1021/jm4004895" title="DOI URL">https://doi.org/10.1021/jm4004895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4004895%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BC-2%252BHydroxyethyl%252BImidazopyrrolopyridines%252Bas%252BPotent%252BJAK1%252BInhibitors%252Bwith%252BFavorable%252BPhysicochemical%252BProperties%252Band%252BHigh%252BSelectivity%252Bover%252BJAK2%26aulast%3DZak%26aufirst%3DMark%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D04042013%26date%3D31052013%26date%3D13062013%26date%3D09052013%26volume%3D56%26issue%3D11%26spage%3D4764%26epage%3D4785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Rohan  Mendonca</span>, <span class="hlFld-ContribAuthor ">Mercedesz  Balazs</span>, <span class="hlFld-ContribAuthor ">Kathy  Barrett</span>, <span class="hlFld-ContribAuthor ">Philippe  Bergeron</span>, <span class="hlFld-ContribAuthor ">Wade S.  Blair</span>, <span class="hlFld-ContribAuthor ">Christine  Chang</span>, <span class="hlFld-ContribAuthor ">Gauri  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Jason  DeVoss</span>, <span class="hlFld-ContribAuthor ">Peter S.  Dragovich</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Nico  Ghilardi</span>, <span class="hlFld-ContribAuthor ">Paul  Gibbons</span>, <span class="hlFld-ContribAuthor ">Stefan  Gradl</span>, <span class="hlFld-ContribAuthor ">Chris  Hamman</span>, <span class="hlFld-ContribAuthor ">Emily J.  Hanan</span>, <span class="hlFld-ContribAuthor ">Eric  Harstad</span>, <span class="hlFld-ContribAuthor ">Peter R.  Hewitt</span>, <span class="hlFld-ContribAuthor ">Christopher A.  Hurley</span>, <span class="hlFld-ContribAuthor ">Tian  Jin</span>, <span class="hlFld-ContribAuthor ">Adam  Johnson</span>, <span class="hlFld-ContribAuthor ">Tony  Johnson</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Michael F. T.  Koehler</span>, <span class="hlFld-ContribAuthor ">Pawan  Bir Kohli</span>, <span class="hlFld-ContribAuthor ">Janusz J.  Kulagowski</span>, <span class="hlFld-ContribAuthor ">Sharada  Labadie</span>, <span class="hlFld-ContribAuthor ">Jiangpeng  Liao</span>, <span class="hlFld-ContribAuthor ">Marya  Liimatta</span>, <span class="hlFld-ContribAuthor ">Zhonghua  Lin</span>, <span class="hlFld-ContribAuthor ">Patrick J.  Lupardus</span>, <span class="hlFld-ContribAuthor ">Robert J.  Maxey</span>, <span class="hlFld-ContribAuthor ">Jeremy M.  Murray</span>, <span class="hlFld-ContribAuthor ">Rebecca  Pulk</span>, <span class="hlFld-ContribAuthor ">Madeleine  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Scott  Savage</span>, <span class="hlFld-ContribAuthor ">Steven  Shia</span>, <span class="hlFld-ContribAuthor ">Micah  Steffek</span>, <span class="hlFld-ContribAuthor ">Savita  Ubhayakar</span>, <span class="hlFld-ContribAuthor ">Mark  Ultsch</span>, <span class="hlFld-ContribAuthor ">Anne  van Abbema</span>, <span class="hlFld-ContribAuthor ">Stuart I.  Ward</span>, <span class="hlFld-ContribAuthor ">Ling  Xiao</span>, and <span class="hlFld-ContribAuthor ">Yisong  Xiao</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (13)
                                     , 6176-6193. <a href="https://doi.org/10.1021/jm300628c" title="DOI URL">https://doi.org/10.1021/jm300628c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm300628c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm300628c%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252BC-2%252BMethyl%252BImidazopyrrolopyridines%252Bas%252BPotent%252Band%252BOrally%252BBioavailable%252BJAK1%252BInhibitors%252Bwith%252BSelectivity%252Bover%252BJAK2%26aulast%3DZak%26aufirst%3DMark%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D05052012%26date%3D28062012%26date%3D12072012%26date%3D14062012%26volume%3D55%26issue%3D13%26spage%3D6176%26epage%3D6193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin J.  Dugan</span>, <span class="hlFld-ContribAuthor ">Diane E.  Gingrich</span>, <span class="hlFld-ContribAuthor ">Eugen F.  Mesaros</span>, <span class="hlFld-ContribAuthor ">Karen L.  Milkiewicz</span>, <span class="hlFld-ContribAuthor ">Matthew A.  Curry</span>, <span class="hlFld-ContribAuthor ">Allison L.  Zulli</span>, <span class="hlFld-ContribAuthor ">Pawel  Dobrzanski</span>, <span class="hlFld-ContribAuthor ">Cynthia  Serdikoff</span>, <span class="hlFld-ContribAuthor ">Mahfuza  Jan</span>, <span class="hlFld-ContribAuthor ">Thelma S.  Angeles</span>, <span class="hlFld-ContribAuthor ">Mark S.  Albom</span>, <span class="hlFld-ContribAuthor ">Jennifer L.  Mason</span>, <span class="hlFld-ContribAuthor ">Lisa D.  Aimone</span>, <span class="hlFld-ContribAuthor ">Sheryl L.  Meyer</span>, <span class="hlFld-ContribAuthor ">Zeqi  Huang</span>, <span class="hlFld-ContribAuthor ">Kevin J.  Wells-Knecht</span>, <span class="hlFld-ContribAuthor ">Mark A.  Ator</span>, <span class="hlFld-ContribAuthor ">Bruce A.  Ruggeri</span>, and <span class="hlFld-ContribAuthor ">Bruce D.  Dorsey</span>  . </span><span class="cited-content_cbyCitation_article-title">A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (11)
                                     , 5243-5254. <a href="https://doi.org/10.1021/jm300248q" title="DOI URL">https://doi.org/10.1021/jm300248q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm300248q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm300248q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BSelective%25252C%252BOrally%252BBioavailable%252B1%25252C2%25252C4-Triazolo%25255B1%25252C5-a%25255Dpyridine-Based%252BInhibitor%252Bof%252BJanus%252BKinase%252B2%252Bfor%252BUse%252Bin%252BAnticancer%252BTherapy%25253A%252BDiscovery%252Bof%252BCEP-33779%26aulast%3DDugan%26aufirst%3DBenjamin%2BJ.%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D23022012%26date%3D18052012%26date%3D14062012%26date%3D10052012%26volume%3D55%26issue%3D11%26spage%3D5243%26epage%3D5254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony D.  William</span>, <span class="hlFld-ContribAuthor ">Angeline C.-H.  Lee</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Kee Chuan  Goh</span>, <span class="hlFld-ContribAuthor ">Babita  Madan</span>, <span class="hlFld-ContribAuthor ">Stefan  Hart</span>, <span class="hlFld-ContribAuthor ">Evelyn  Tan</span>, <span class="hlFld-ContribAuthor ">Haishan  Wang</span>, <span class="hlFld-ContribAuthor ">Harish  Nagaraj</span>, <span class="hlFld-ContribAuthor ">Dizhong  Chen</span>, <span class="hlFld-ContribAuthor ">Chai Ping  Lee</span>, <span class="hlFld-ContribAuthor ">Eric T.  Sun</span>, <span class="hlFld-ContribAuthor ">Ramesh  Jayaraman</span>, <span class="hlFld-ContribAuthor ">Mohammad Khalid  Pasha</span>, <span class="hlFld-ContribAuthor ">Kantharaj  Ethirajulu</span>, <span class="hlFld-ContribAuthor ">Jeanette M.  Wood</span>, and <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (6)
                                     , 2623-2640. <a href="https://doi.org/10.1021/jm201454n" title="DOI URL">https://doi.org/10.1021/jm201454n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201454n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201454n%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthe%252BMacrocycle%252B%2525289E%252529-15-%2525282-%252528Pyrrolidin-1-yl%252529ethoxy%252529-7%25252C12%25252C25-trioxa-19%25252C21%25252C24-triaza-tetracyclo%25255B18.3.1.1%2525282%25252C5%252529.1%25252814%25252C18%252529%25255Dhexacosa-1%25252824%252529%25252C2%25252C4%25252C9%25252C14%25252826%252529%25252C15%25252C17%25252C20%25252C22-nonaene%252B%252528SB1578%252529%25252C%252Ba%252BPotent%252BInhibitor%252Bof%252BJanus%252BKinase%252B2%25252FFms-LikeTyrosine%252BKinase-3%252B%252528JAK2%25252FFLT3%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DWilliam%26aufirst%3DAnthony%2BD.%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D27102011%26date%3D06032012%26date%3D22032012%26date%3D17022012%26volume%3D55%26issue%3D6%26spage%3D2623%26epage%3D2640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony D.  William</span>, <span class="hlFld-ContribAuthor ">Angeline C.-H.  Lee</span>, <span class="hlFld-ContribAuthor ">Kee Chuan  Goh</span>, <span class="hlFld-ContribAuthor ">Stéphanie  Blanchard</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Ee Ling  Teo</span>, <span class="hlFld-ContribAuthor ">Harish  Nagaraj</span>, <span class="hlFld-ContribAuthor ">Chai Ping  Lee</span>, <span class="hlFld-ContribAuthor ">Haishan  Wang</span>, <span class="hlFld-ContribAuthor ">Meredith  Williams</span>, <span class="hlFld-ContribAuthor ">Eric T.  Sun</span>, <span class="hlFld-ContribAuthor ">Changyong  Hu</span>, <span class="hlFld-ContribAuthor ">Ramesh  Jayaraman</span>, <span class="hlFld-ContribAuthor ">Mohammed Khalid  Pasha</span>, <span class="hlFld-ContribAuthor ">Kantharaj  Ethirajulu</span>, <span class="hlFld-ContribAuthor ">Jeanette M.  Wood</span>, and <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (1)
                                     , 169-196. <a href="https://doi.org/10.1021/jm201112g" title="DOI URL">https://doi.org/10.1021/jm201112g</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201112g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201112g%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BKinase%252BSpectrum%252BSelective%252BMacrocycle%252B%25252816E%252529-14-Methyl-20-oxa-5%25252C7%25252C14%25252C26-tetraazatetracyclo%25255B19.3.1.1%2525282%25252C6%252529.1%2525288%25252C12%252529%25255Dheptacosa-1%25252825%252529%25252C2%25252826%252529%25252C3%25252C5%25252C8%25252827%252529%25252C9%25252C11%25252C16%25252C21%25252C23-decaene%252B%252528SB1317%25252FTG02%252529%25252C%252Ba%252BPotent%252BInhibitor%252Bof%252BCyclin%252BDependent%252BKinases%252B%252528CDKs%252529%25252C%252BJanus%252BKinase%252B2%252B%252528JAK2%252529%25252C%252Band%252BFms-like%252BTyrosine%252BKinase-3%252B%252528FLT3%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BCancer%26aulast%3DWilliam%26aufirst%3DAnthony%2BD.%26date%3D2012%26date%3D2011%26date%3D2011%26date%3D18082011%26date%3D29122011%26date%3D12012012%26date%3D08122011%26volume%3D55%26issue%3D1%26spage%3D169%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Henry J.  Breslin</span>, <span class="hlFld-ContribAuthor ">Brandon M.  Lane</span>, <span class="hlFld-ContribAuthor ">Gregory R.  Ott</span>, <span class="hlFld-ContribAuthor ">Arup K.  Ghose</span>, <span class="hlFld-ContribAuthor ">Thelma S.  Angeles</span>, <span class="hlFld-ContribAuthor ">Mark S.  Albom</span>, <span class="hlFld-ContribAuthor ">Mangeng  Cheng</span>, <span class="hlFld-ContribAuthor ">Weihua  Wan</span>, <span class="hlFld-ContribAuthor ">R. Curtis  Haltiwanger</span>, <span class="hlFld-ContribAuthor ">Kevin J.  Wells-Knecht</span>, and <span class="hlFld-ContribAuthor ">Bruce D.  Dorsey</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Anaplastic Lymphoma Kinase (ALK) Inhibitory Activity for a Novel Series of 2,4,8,22-Tetraazatetracyclo[14.3.1.13,7.19,13]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene Macrocycles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (1)
                                     , 449-464. <a href="https://doi.org/10.1021/jm201333e" title="DOI URL">https://doi.org/10.1021/jm201333e</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201333e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201333e%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%252BInhibitory%252BActivity%252Bfor%252Ba%252BNovel%252BSeries%252Bof%252B2%25252C4%25252C8%25252C22-Tetraazatetracyclo%25255B14.3.1.13%25252C7.19%25252C13%25255Ddocosa-1%25252820%252529%25252C3%25252822%252529%25252C4%25252C6%25252C9%25252821%252529%25252C10%25252C12%25252C16%25252C18-nonaene%252BMacrocycles%26aulast%3DBreslin%26aufirst%3DHenry%2BJ.%26date%3D2012%26date%3D2011%26date%3D2011%26date%3D06102011%26date%3D15122011%26date%3D12012012%26volume%3D55%26issue%3D1%26spage%3D449%26epage%3D464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kajal  Sharma</span>, <span class="hlFld-ContribAuthor ">Shalki  Choudhary</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">Portraying molecular modulation and therapeutic aspects of psoriasis: Retrospection and current status. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1243 </em>, 130770. <a href="https://doi.org/10.1016/j.molstruc.2021.130770" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130770</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130770%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DPortraying%252Bmolecular%252Bmodulation%252Band%252Btherapeutic%252Baspects%252Bof%252Bpsoriasis%25253A%252BRetrospection%252Band%252Bcurrent%252Bstatus%26aulast%3DSharma%26aufirst%3DKajal%26date%3D2021%26volume%3D1243%26spage%3D130770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Hai  Wang</span>, <span class="hlFld-ContribAuthor ">Lian  Qin</span>, <span class="hlFld-ContribAuthor ">Jie  Ren</span>, <span class="hlFld-ContribAuthor ">Qiushuang  Sun</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Yi  Zhong</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>, <span class="hlFld-ContribAuthor ">Zhixia  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113394. <a href="https://doi.org/10.1016/j.ejmech.2021.113394" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113394%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bimidazopyrrolopyridines%252Bderivatives%252Bas%252Bnovel%252Band%252Bselective%252Binhibitors%252Bof%252BJAK2%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2021%26volume%3D218%26spage%3D113394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiali  Zhu</span>, <span class="hlFld-ContribAuthor ">Tao  Yang</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Zhuang  Yang</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Haoyu  Ye</span>, <span class="hlFld-ContribAuthor ">Yu  Tang</span>, <span class="hlFld-ContribAuthor ">Zhixuan  Cheng</span>, <span class="hlFld-ContribAuthor ">Ping  Lin</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Studies on the anti-psoriasis effects and its mechanism of a dual JAK2/FLT3 inhibitor flonoltinib maleate. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2021,</strong> <em>137 </em>, 111373. <a href="https://doi.org/10.1016/j.biopha.2021.111373" title="DOI URL">https://doi.org/10.1016/j.biopha.2021.111373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2021.111373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2021.111373%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DStudies%252Bon%252Bthe%252Banti-psoriasis%252Beffects%252Band%252Bits%252Bmechanism%252Bof%252Ba%252Bdual%252BJAK2%25252FFLT3%252Binhibitor%252Bflonoltinib%252Bmaleate%26aulast%3DZhu%26aufirst%3DJiali%26date%3D2021%26volume%3D137%26spage%3D111373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana  Dolšak</span>, <span class="hlFld-ContribAuthor ">Kristjan  Mrgole</span>, <span class="hlFld-ContribAuthor ">Matej  Sova</span>. </span><span class="cited-content_cbyCitation_article-title">Microwave-Assisted Regioselective Suzuki Coupling of 2,4-Dichloropyrimidines with Aryl and Heteroaryl Boronic Acids. </span><span class="cited-content_cbyCitation_journal-name">Catalysts</span><span> <strong>2021,</strong> <em>11 </em>
                                    (4)
                                     , 439. <a href="https://doi.org/10.3390/catal11040439" title="DOI URL">https://doi.org/10.3390/catal11040439</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/catal11040439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcatal11040439%26sid%3Dliteratum%253Aachs%26jtitle%3DCatalysts%26atitle%3DMicrowave-Assisted%252BRegioselective%252BSuzuki%252BCoupling%252Bof%252B2%25252C4-Dichloropyrimidines%252Bwith%252BAryl%252Band%252BHeteroaryl%252BBoronic%252BAcids%26aulast%3DDol%25C5%25A1ak%26aufirst%3DAna%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D4%26spage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karima  Alim</span>, <span class="hlFld-ContribAuthor ">Arnaud  Bruyère</span>, <span class="hlFld-ContribAuthor ">Alain  Lescoat</span>, <span class="hlFld-ContribAuthor ">Elodie  Jouan</span>, <span class="hlFld-ContribAuthor ">Valérie  Lecureur</span>, <span class="hlFld-ContribAuthor ">Marc  Le Vée</span>, <span class="hlFld-ContribAuthor ">Olivier  Fardel</span>. </span><span class="cited-content_cbyCitation_article-title">Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Metabolism & Toxicology</span><span> <strong>2021,</strong> <em>17 </em>
                                    (3)
                                     , 259-271. <a href="https://doi.org/10.1080/17425255.2021.1862084" title="DOI URL">https://doi.org/10.1080/17425255.2021.1862084</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425255.2021.1862084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425255.2021.1862084%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Metabolism%2520%2526%2520Toxicology%26atitle%3DInteractions%252Bof%252Bjanus%252Bkinase%252Binhibitors%252Bwith%252Bdrug%252Btransporters%252Band%252Bconsequences%252Bfor%252Bpharmacokinetics%252Band%252Btoxicity%26aulast%3DAlim%26aufirst%3DKarima%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D3%26spage%3D259%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xavier  Thomas</span>, <span class="hlFld-ContribAuthor ">Mohamed  Elhamri</span>, <span class="hlFld-ContribAuthor ">Maël  Heiblig</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging pharmacotherapies for elderly acute myeloid leukemia patients. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Hematology</span><span> <strong>2020,</strong> <em>13 </em>
                                    (6)
                                     , 619-643. <a href="https://doi.org/10.1080/17474086.2020.1758058" title="DOI URL">https://doi.org/10.1080/17474086.2020.1758058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17474086.2020.1758058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17474086.2020.1758058%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Hematology%26atitle%3DEmerging%252Bpharmacotherapies%252Bfor%252Belderly%252Bacute%252Bmyeloid%252Bleukemia%252Bpatients%26aulast%3DThomas%26aufirst%3DXavier%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D6%26spage%3D619%26epage%3D643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lexian  Tong</span>, <span class="hlFld-ContribAuthor ">Xuemei  Li</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in FLT3 inhibitors for acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 961-981. <a href="https://doi.org/10.4155/fmc-2019-0365" title="DOI URL">https://doi.org/10.4155/fmc-2019-0365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0365%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252BFLT3%252Binhibitors%252Bfor%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DTong%26aufirst%3DLexian%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D961%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jae Yoon  Jeon</span>, <span class="hlFld-ContribAuthor ">Qiuhong  Zhao</span>, <span class="hlFld-ContribAuthor ">Daelynn R.  Buelow</span>, <span class="hlFld-ContribAuthor ">Mitch  Phelps</span>, <span class="hlFld-ContribAuthor ">Alison R.  Walker</span>, <span class="hlFld-ContribAuthor ">Alice S.  Mims</span>, <span class="hlFld-ContribAuthor ">Sumithira  Vasu</span>, <span class="hlFld-ContribAuthor ">Gregory  Behbehani</span>, <span class="hlFld-ContribAuthor ">James  Blachly</span>, <span class="hlFld-ContribAuthor ">William  Blum</span>, <span class="hlFld-ContribAuthor ">Rebecca B.  Klisovic</span>, <span class="hlFld-ContribAuthor ">John C.  Byrd</span>, <span class="hlFld-ContribAuthor ">Ramiro  Garzon</span>, <span class="hlFld-ContribAuthor ">Sharyn D.  Baker</span>, <span class="hlFld-ContribAuthor ">Bhavana  Bhatnagar</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2020,</strong> <em>38 </em>
                                    (2)
                                     , 340-349. <a href="https://doi.org/10.1007/s10637-019-00786-4" title="DOI URL">https://doi.org/10.1007/s10637-019-00786-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-019-00786-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-019-00786-4%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DPreclinical%252Bactivity%252Band%252Ba%252Bpilot%252Bphase%252BI%252Bstudy%252Bof%252Bpacritinib%25252C%252Ban%252Boral%252BJAK2%25252FFLT3%252Binhibitor%25252C%252Band%252Bchemotherapy%252Bin%252BFLT3-ITD-positive%252BAML%26aulast%3DJeon%26aufirst%3DJae%2BYoon%26date%3D2020%26date%3D2019%26volume%3D38%26issue%3D2%26spage%3D340%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyu  Ma</span>, <span class="hlFld-ContribAuthor ">Yanyan  Diao</span>, <span class="hlFld-ContribAuthor ">Huan  Ge</span>, <span class="hlFld-ContribAuthor ">Fangling  Xu</span>, <span class="hlFld-ContribAuthor ">Lili  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Honglin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (8)
                                     , 127048. <a href="https://doi.org/10.1016/j.bmcl.2020.127048" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127048%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252Boptimization%252Bof%252B2-aminopyridine%252Bderivatives%252Bas%252Bnovel%252Band%252Bselective%252BJAK2%252Binhibitors%26aulast%3DMa%26aufirst%3DXiangyu%26date%3D2020%26volume%3D30%26issue%3D8%26spage%3D127048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Xinying  Cheng</span>, <span class="hlFld-ContribAuthor ">Qiuyu  Chen</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112155. <a href="https://doi.org/10.1016/j.ejmech.2020.112155" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112155%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DJanus%252Bkinases%252B%252528JAKs%252529%25253A%252BThe%252Befficient%252Btherapeutic%252Btargets%252Bfor%252Bautoimmune%252Bdiseases%252Band%252Bmyeloproliferative%252Bdisorders%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2020%26volume%3D192%26spage%3D112155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stanislav S.  Shcherbakov</span>, <span class="hlFld-ContribAuthor ">Artyom Yu.  Magometov</span>, <span class="hlFld-ContribAuthor ">Viktoriia Yu.  Shcherbakova</span>, <span class="hlFld-ContribAuthor ">Alexander V.  Aksenov</span>, <span class="hlFld-ContribAuthor ">Dmitriy A.  Domenyuk</span>, <span class="hlFld-ContribAuthor ">Vladimir A.  Zelensky</span>, <span class="hlFld-ContribAuthor ">Michael  Rubin</span>. </span><span class="cited-content_cbyCitation_article-title">Electrophilic alkylation of arenes with 5-bromopyrimidine en route to 4-aryl-5-alkynylpyrimidines. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (17)
                                     , 10315-10321. <a href="https://doi.org/10.1039/D0RA01335H" title="DOI URL">https://doi.org/10.1039/D0RA01335H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA01335H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA01335H%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DElectrophilic%252Balkylation%252Bof%252Barenes%252Bwith%252B5-bromopyrimidine%252Ben%252Broute%252Bto%252B4-aryl-5-alkynylpyrimidines%26aulast%3DShcherbakov%26aufirst%3DStanislav%2BS.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D17%26spage%3D10315%26epage%3D10321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sangeetha  Venugopal</span>, <span class="hlFld-ContribAuthor ">Michal  Bar-Natan</span>, <span class="hlFld-ContribAuthor ">John O.  Mascarenhas</span>. </span><span class="cited-content_cbyCitation_article-title">JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Blood Reviews</span><span> <strong>2020,</strong> <em>40 </em>, 100634. <a href="https://doi.org/10.1016/j.blre.2019.100634" title="DOI URL">https://doi.org/10.1016/j.blre.2019.100634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.blre.2019.100634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.blre.2019.100634%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%2520Reviews%26atitle%3DJAKs%252Bto%252BSTATs%25253A%252BA%252Btantalizing%252Btherapeutic%252Btarget%252Bin%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DVenugopal%26aufirst%3DSangeetha%26date%3D2020%26volume%3D40%26spage%3D100634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingxiu  Li</span>, <span class="hlFld-ContribAuthor ">Tianyu  Ye</span>, <span class="hlFld-ContribAuthor ">Le  Xu</span>, <span class="hlFld-ContribAuthor ">Yuhong  Dong</span>, <span class="hlFld-ContribAuthor ">Yong  Luo</span>, <span class="hlFld-ContribAuthor ">Chu  Wang</span>, <span class="hlFld-ContribAuthor ">Yufei  Han</span>, <span class="hlFld-ContribAuthor ">Ke  Chen</span>, <span class="hlFld-ContribAuthor ">Mingze  Qin</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>181 </em>, 111590. <a href="https://doi.org/10.1016/j.ejmech.2019.111590" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111590</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111590%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-piperazinyl-2-aminopyrimidine%252Bderivatives%252Bas%252Bdual%252Binhibitors%252Bof%252BJAK2%252Band%252BFLT3%26aulast%3DLi%26aufirst%3DYingxiu%26date%3D2019%26volume%3D181%26spage%3D111590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harbinder  Singh</span>, <span class="hlFld-ContribAuthor ">Nihar  Kinarivala</span>, <span class="hlFld-ContribAuthor ">Sahil  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (7)
                                     , 842-874. <a href="https://doi.org/10.2174/1871520619666190118120708" title="DOI URL">https://doi.org/10.2174/1871520619666190118120708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520619666190118120708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520619666190118120708%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DMulti-Targeting%252BAnticancer%252BAgents%25253A%252BRational%252BApproaches%25252C%252BSynthetic%252BRoutes%252Band%252BStructure%252BActivity%252BRelationship%26aulast%3DSingh%26aufirst%3DHarbinder%26date%3D2019%26volume%3D19%26issue%3D7%26spage%3D842%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reem Fawaz  Abutayeh</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2019,</strong> <em>88 </em>, 128-151. <a href="https://doi.org/10.1016/j.jmgm.2019.01.011" title="DOI URL">https://doi.org/10.1016/j.jmgm.2019.01.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2019.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2019.01.011%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DDiscovery%252Bof%252Bnovel%252BFlt3%252Binhibitory%252Bchemotypes%252Bthrough%252Bextensive%252Bligand-based%252Band%252Bnew%252Bstructure-based%252Bpharmacophore%252Bmodelling%252Bmethods%26aulast%3DAbutayeh%26aufirst%3DReem%2BFawaz%26date%3D2019%26volume%3D88%26spage%3D128%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mona M.  Hosseini</span>, <span class="hlFld-ContribAuthor ">Stephen E.  Kurtz</span>, <span class="hlFld-ContribAuthor ">Sherif  Abdelhamed</span>, <span class="hlFld-ContribAuthor ">Shawn  Mahmood</span>, <span class="hlFld-ContribAuthor ">Monika A.  Davare</span>, <span class="hlFld-ContribAuthor ">Andy  Kaempf</span>, <span class="hlFld-ContribAuthor ">Johannes  Elferich</span>, <span class="hlFld-ContribAuthor ">Jason E.  McDermott</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>, <span class="hlFld-ContribAuthor ">Samuel H.  Payne</span>, <span class="hlFld-ContribAuthor ">Ujwal  Shinde</span>, <span class="hlFld-ContribAuthor ">Karin D.  Rodland</span>, <span class="hlFld-ContribAuthor ">Motomi  Mori</span>, <span class="hlFld-ContribAuthor ">Brian J.  Druker</span>, <span class="hlFld-ContribAuthor ">Jack W.  Singer</span>, <span class="hlFld-ContribAuthor ">Anupriya  Agarwal</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. </span><span class="cited-content_cbyCitation_journal-name">Leukemia</span><span> <strong>2018,</strong> <em>32 </em>
                                    (11)
                                     , 2374-2387. <a href="https://doi.org/10.1038/s41375-018-0112-2" title="DOI URL">https://doi.org/10.1038/s41375-018-0112-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41375-018-0112-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41375-018-0112-2%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%26atitle%3DInhibition%252Bof%252Binterleukin-1%252Breceptor-associated%252Bkinase-1%252Bis%252Ba%252Btherapeutic%252Bstrategy%252Bfor%252Bacute%252Bmyeloid%252Bleukemia%252Bsubtypes%26aulast%3DHosseini%26aufirst%3DMona%2BM.%26date%3D2018%26date%3D2018%26volume%3D32%26issue%3D11%26spage%3D2374%26epage%3D2387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Catalytic Metathesis Reactions: Nobel Prize Catalysis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 259-290. <a href="https://doi.org/10.1002/9783527807253.ch7" title="DOI URL">https://doi.org/10.1002/9783527807253.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527807253.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527807253.ch7%26sid%3Dliteratum%253Aachs%26atitle%3DCatalytic%252BMetathesis%252BReactions%25253A%252BNobel%252BPrize%252BCatalysis%26date%3D2018%26date%3D2018%26spage%3D259%26epage%3D290%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DActive%252BPharmaceutical%252BIngredients%252Bin%252BSynthesis%26aulast%3DBurke%26aufirst%3DAnthony%2BJ%26date%3D2018%26volume%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-yi  Chu-Farseeva</span>, <span class="hlFld-ContribAuthor ">Nurulhuda  Mustafa</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Eng Chong  Tan</span>, <span class="hlFld-ContribAuthor ">Jeffrey J.Y.  Yen</span>, <span class="hlFld-ContribAuthor ">Wee Joo  Chng</span>, <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 593-619. <a href="https://doi.org/10.1016/j.ejmech.2018.09.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bpotent%252Bdual%252Binhibitors%252Bof%252BJAK2%252Band%252BHDAC%252Bbased%252Bon%252Bfusing%252Bthe%252Bpharmacophores%252Bof%252BXL019%252Band%252Bvorinostat%26aulast%3DChu-Farseeva%26aufirst%3DYu-yi%26date%3D2018%26volume%3D158%26spage%3D593%26epage%3D619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jack W.  Singer</span>, <span class="hlFld-ContribAuthor ">Angela  Fleischman</span>, <span class="hlFld-ContribAuthor ">Suliman  Al-Fayoumi</span>, <span class="hlFld-ContribAuthor ">John O.  Mascarenhas</span>, <span class="hlFld-ContribAuthor ">Qiang  Yu</span>, <span class="hlFld-ContribAuthor ">Anupriya  Agarwal</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (70)
                                     , 33416-33439. <a href="https://doi.org/10.18632/oncotarget.26058" title="DOI URL">https://doi.org/10.18632/oncotarget.26058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.26058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.26058%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DInhibition%252Bof%252Binterleukin-1%252Breceptor-associated%252Bkinase%252B1%252B%252528IRAK1%252529%252Bas%252Ba%252Btherapeutic%252Bstrategy%26aulast%3DSinger%26aufirst%3DJack%2BW.%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D70%26spage%3D33416%26epage%3D33439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Douglas  Tremblay</span>, <span class="hlFld-ContribAuthor ">John  Mascarenhas</span>. </span><span class="cited-content_cbyCitation_article-title">Pacritinib to treat myelofibrosis patients with thrombocytopenia. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Hematology</span><span> <strong>2018,</strong> <em>11 </em>
                                    (9)
                                     , 707-714. <a href="https://doi.org/10.1080/17474086.2018.1500456" title="DOI URL">https://doi.org/10.1080/17474086.2018.1500456</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17474086.2018.1500456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17474086.2018.1500456%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Hematology%26atitle%3DPacritinib%252Bto%252Btreat%252Bmyelofibrosis%252Bpatients%252Bwith%252Bthrombocytopenia%26aulast%3DTremblay%26aufirst%3DDouglas%26date%3D2018%26date%3D2018%26volume%3D11%26issue%3D9%26spage%3D707%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lianbin  Yao</span>, <span class="hlFld-ContribAuthor ">Pondy Murugappan  Ramanujulu</span>, <span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Sten  Ohlson</span>, <span class="hlFld-ContribAuthor ">Brian W.  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (15)
                                     , 2636-2640. <a href="https://doi.org/10.1016/j.bmcl.2018.06.037" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.06.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.06.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.06.037%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMerging%252Bof%252Bruxolitinib%252Band%252Bvorinostat%252Bleads%252Bto%252Bhighly%252Bpotent%252Binhibitors%252Bof%252BJAK2%252Band%252Bhistone%252Bdeacetylase%252B6%252B%252528HDAC6%252529%26aulast%3DYao%26aufirst%3DLianbin%26date%3D2018%26volume%3D28%26issue%3D15%26spage%3D2636%26epage%3D2640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eduardo  Hernández-Vázquez</span>, <span class="hlFld-ContribAuthor ">Alejandra  Chávez-Riveros</span>, <span class="hlFld-ContribAuthor ">Adriana  Romo-Pérez</span>, <span class="hlFld-ContribAuthor ">María Teresa  Ramírez-Apán</span>, <span class="hlFld-ContribAuthor ">Alma D.  Chávez-Blanco</span>, <span class="hlFld-ContribAuthor ">Rocío  Morales-Bárcenas</span>, <span class="hlFld-ContribAuthor ">Alfonso  Dueñas-González</span>, <span class="hlFld-ContribAuthor ">Luis D.  Miranda</span>. </span><span class="cited-content_cbyCitation_article-title">Cytotoxic Activity and Structure-Activity Relationship of Triazole-Containing Bis(Aryl Ether) Macrocycles. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (12)
                                     , 1193-1209. <a href="https://doi.org/10.1002/cmdc.201800075" title="DOI URL">https://doi.org/10.1002/cmdc.201800075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800075%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DCytotoxic%252BActivity%252Band%252BStructure-Activity%252BRelationship%252Bof%252BTriazole-Containing%252BBis%252528Aryl%252BEther%252529%252BMacrocycles%26aulast%3DHern%25C3%25A1ndez-V%25C3%25A1zquez%26aufirst%3DEduardo%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D12%26spage%3D1193%26epage%3D1209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adolfo Enrique  Diaz</span>, <span class="hlFld-ContribAuthor ">Ruben A  Mesa</span>. </span><span class="cited-content_cbyCitation_article-title">Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2018,</strong> <em>14 </em>
                                    (9)
                                     , 797-807. <a href="https://doi.org/10.2217/fon-2017-0494" title="DOI URL">https://doi.org/10.2217/fon-2017-0494</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2017-0494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2017-0494%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DPacritinib%252Band%252Bits%252Buse%252Bin%252Bthe%252Btreatment%252Bof%252Bpatients%252Bwith%252Bmyelofibrosis%252Bwho%252Bhave%252Bthrombocytopenia%26aulast%3DDiaz%26aufirst%3DAdolfo%2BEnrique%26date%3D2018%26volume%3D14%26issue%3D9%26spage%3D797%26epage%3D807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>, <span class="hlFld-ContribAuthor ">Jiankang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 449-463. <a href="https://doi.org/10.1016/j.ejmech.2017.11.049" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.049%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploiting%252Bpolypharmacology%252Bfor%252Bimproving%252Btherapeutic%252Boutcome%252Bof%252Bkinase%252Binhibitors%252B%252528KIs%252529%25253A%252BAn%252Bupdate%252Bof%252Brecent%252Bmedicinal%252Bchemistry%252Befforts%26aulast%3DMa%26aufirst%3DXiaodong%26date%3D2018%26volume%3D143%26spage%3D449%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ludger A.  Wessjohann</span>, <span class="hlFld-ContribAuthor ">Ricardo A. W. Neves  Filho</span>, <span class="hlFld-ContribAuthor ">Alfredo R.  Puentes</span>, <span class="hlFld-ContribAuthor ">Micjel Chávez  Morejón</span>. </span><span class="cited-content_cbyCitation_article-title">Macrocycles from Multicomponent Reactions. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 339-376. <a href="https://doi.org/10.1002/9781119092599.ch14" title="DOI URL">https://doi.org/10.1002/9781119092599.ch14</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119092599.ch14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119092599.ch14%26sid%3Dliteratum%253Aachs%26atitle%3DMacrocycles%252Bfrom%252BMulticomponent%252BReactions%26aulast%3DWessjohann%26aufirst%3DLudger%2BA.%26date%3D2017%26date%3D2017%26spage%3D339%26epage%3D376%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPractical%252BMedicinal%252BChemistry%252Bwith%252BMacrocycles%26aulast%3DMarsault%26aufirst%3DEric%26date%3D2017%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Stotani</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Giordanetto</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of Macrocycles in Clinical Development and Clinically Used. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 411-499. <a href="https://doi.org/10.1002/9781119092599.ch16" title="DOI URL">https://doi.org/10.1002/9781119092599.ch16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119092599.ch16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119092599.ch16%26sid%3Dliteratum%253Aachs%26atitle%3DOverview%252Bof%252BMacrocycles%252Bin%252BClinical%252BDevelopment%252Band%252BClinically%252BUsed%26aulast%3DStotani%26aufirst%3DSilvia%26date%3D2017%26date%3D2017%26spage%3D411%26epage%3D499%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPractical%252BMedicinal%252BChemistry%252Bwith%252BMacrocycles%26aulast%3DMarsault%26aufirst%3DEric%26date%3D2017%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shinji  Yamazaki</span>, <span class="hlFld-ContribAuthor ">Justine L.  Lam</span>, <span class="hlFld-ContribAuthor ">Ted W.  Johnson</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Pharmacokinetic-Pharmacodynamic Evaluation of an Orally Available Novel Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 519-543. <a href="https://doi.org/10.1002/9781119092599.ch18" title="DOI URL">https://doi.org/10.1002/9781119092599.ch18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119092599.ch18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119092599.ch18%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BPharmacokinetic-Pharmacodynamic%252BEvaluation%252Bof%252Ban%252BOrally%252BAvailable%252BNovel%252BMacrocyclic%252BInhibitor%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252Band%252Bc-Ros%252BOncogene%252B1%26aulast%3DYamazaki%26aufirst%3DShinji%26date%3D2017%26date%3D2017%26spage%3D519%26epage%3D543%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPractical%252BMedicinal%252BChemistry%252Bwith%252BMacrocycles%26aulast%3DMarsault%26aufirst%3DEric%26date%3D2017%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T. Patrick  Montgomery</span>, <span class="hlFld-ContribAuthor ">Tonia S.  Ahmed</span>, <span class="hlFld-ContribAuthor ">Robert H.  Grubbs</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoretentive Olefinmetathese: ein Weg zur kinetischen Selektivität. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2017,</strong> <em>129 </em>
                                    (37)
                                     , 11168-11181. <a href="https://doi.org/10.1002/ange.201704686" title="DOI URL">https://doi.org/10.1002/ange.201704686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201704686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201704686%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DStereoretentive%252BOlefinmetathese%25253A%252Bein%252BWeg%252Bzur%252Bkinetischen%252BSelektivit%2525C3%2525A4t%26aulast%3DMontgomery%26aufirst%3DT.%2BPatrick%26date%3D2017%26date%3D2017%26volume%3D129%26issue%3D37%26spage%3D11168%26epage%3D11181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T. Patrick  Montgomery</span>, <span class="hlFld-ContribAuthor ">Tonia S.  Ahmed</span>, <span class="hlFld-ContribAuthor ">Robert H.  Grubbs</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoretentive Olefin Metathesis: An Avenue to Kinetic Selectivity. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2017,</strong> <em>56 </em>
                                    (37)
                                     , 11024-11036. <a href="https://doi.org/10.1002/anie.201704686" title="DOI URL">https://doi.org/10.1002/anie.201704686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201704686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201704686%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DStereoretentive%252BOlefin%252BMetathesis%25253A%252BAn%252BAvenue%252Bto%252BKinetic%252BSelectivity%26aulast%3DMontgomery%26aufirst%3DT.%2BPatrick%26date%3D2017%26date%3D2017%26volume%3D56%26issue%3D37%26spage%3D11024%26epage%3D11036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akihide  Yoshimi</span>, <span class="hlFld-ContribAuthor ">Maria E.  Balasis</span>, <span class="hlFld-ContribAuthor ">Alexis  Vedder</span>, <span class="hlFld-ContribAuthor ">Kira  Feldman</span>, <span class="hlFld-ContribAuthor ">Yan  Ma</span>, <span class="hlFld-ContribAuthor ">Hailing  Zhang</span>, <span class="hlFld-ContribAuthor ">Stanley Chun-Wei  Lee</span>, <span class="hlFld-ContribAuthor ">Christopher  Letson</span>, <span class="hlFld-ContribAuthor ">Sandrine  Niyongere</span>, <span class="hlFld-ContribAuthor ">Sydney X.  Lu</span>, <span class="hlFld-ContribAuthor ">Markus  Ball</span>, <span class="hlFld-ContribAuthor ">Justin  Taylor</span>, <span class="hlFld-ContribAuthor ">Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Yulong  Zhao</span>, <span class="hlFld-ContribAuthor ">Salma  Youssef</span>, <span class="hlFld-ContribAuthor ">Young Rock  Chung</span>, <span class="hlFld-ContribAuthor ">Xiao Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Benjamin H.  Durham</span>, <span class="hlFld-ContribAuthor ">Wendy  Yang</span>, <span class="hlFld-ContribAuthor ">Alan F.  List</span>, <span class="hlFld-ContribAuthor ">Mignon L.  Loh</span>, <span class="hlFld-ContribAuthor ">Virginia  Klimek</span>, <span class="hlFld-ContribAuthor ">Michael F.  Berger</span>, <span class="hlFld-ContribAuthor ">Elliot  Stieglitz</span>, <span class="hlFld-ContribAuthor ">Eric  Padron</span>, <span class="hlFld-ContribAuthor ">Omar  Abdel-Wahab</span>. </span><span class="cited-content_cbyCitation_article-title">Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2017,</strong> <em>130 </em>
                                    (4)
                                     , 397-407. <a href="https://doi.org/10.1182/blood-2017-01-763219" title="DOI URL">https://doi.org/10.1182/blood-2017-01-763219</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood-2017-01-763219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood-2017-01-763219%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DRobust%252Bpatient-derived%252Bxenografts%252Bof%252BMDS%25252FMPN%252Boverlap%252Bsyndromes%252Bcapture%252Bthe%252Bunique%252Bcharacteristics%252Bof%252BCMML%252Band%252BJMML%26aulast%3DYoshimi%26aufirst%3DAkihide%26date%3D2017%26volume%3D130%26issue%3D4%26spage%3D397%26epage%3D407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao  Shen</span>, <span class="hlFld-ContribAuthor ">Thach T.  Nguyen</span>, <span class="hlFld-ContribAuthor ">Ming Joo  Koh</span>, <span class="hlFld-ContribAuthor ">Dongmin  Xu</span>, <span class="hlFld-ContribAuthor ">Alexander W. H.  Speed</span>, <span class="hlFld-ContribAuthor ">Richard R.  Schrock</span>, <span class="hlFld-ContribAuthor ">Amir H.  Hoveyda</span>. </span><span class="cited-content_cbyCitation_article-title">Kinetically E-selective macrocyclic ring-closing metathesis. </span><span class="cited-content_cbyCitation_journal-name">Nature</span><span> <strong>2017,</strong> <em>541 </em>
                                    (7637)
                                     , 380-385. <a href="https://doi.org/10.1038/nature20800" title="DOI URL">https://doi.org/10.1038/nature20800</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nature20800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnature20800%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%26atitle%3DKinetically%252BE-selective%252Bmacrocyclic%252Bring-closing%252Bmetathesis%26aulast%3DShen%26aufirst%3DXiao%26date%3D2017%26date%3D2017%26volume%3D541%26issue%3D7637%26spage%3D380%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting-Ting  Yao</span>, <span class="hlFld-ContribAuthor ">Jiang-Feng  Xie</span>, <span class="hlFld-ContribAuthor ">Xing-Guo  Liu</span>, <span class="hlFld-ContribAuthor ">Jing-Li  Cheng</span>, <span class="hlFld-ContribAuthor ">Cheng-Yuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Jin-Hao  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiao-Wu  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Integration of pharmacophore mapping and molecular docking in sequential virtual screening: towards the discovery of novel JAK2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2017,</strong> <em>7 </em>
                                    (17)
                                     , 10353-10360. <a href="https://doi.org/10.1039/C6RA24959K" title="DOI URL">https://doi.org/10.1039/C6RA24959K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA24959K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA24959K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DIntegration%252Bof%252Bpharmacophore%252Bmapping%252Band%252Bmolecular%252Bdocking%252Bin%252Bsequential%252Bvirtual%252Bscreening%25253A%252Btowards%252Bthe%252Bdiscovery%252Bof%252Bnovel%252BJAK2%252Binhibitors%26aulast%3DYao%26aufirst%3DTing-Ting%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D17%26spage%3D10353%26epage%3D10360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Srdan  Verstovsek</span>, <span class="hlFld-ContribAuthor ">Olatoyosi  Odenike</span>, <span class="hlFld-ContribAuthor ">Jack W.  Singer</span>, <span class="hlFld-ContribAuthor ">Tanya  Granston</span>, <span class="hlFld-ContribAuthor ">Suliman  Al-Fayoumi</span>, <span class="hlFld-ContribAuthor ">H. Joachim  Deeg</span>. </span><span class="cited-content_cbyCitation_article-title">Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2016,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-016-0367-x" title="DOI URL">https://doi.org/10.1186/s13045-016-0367-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-016-0367-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-016-0367-x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DPhase%252B1%25252F2%252Bstudy%252Bof%252Bpacritinib%25252C%252Ba%252Bnext%252Bgeneration%252BJAK2%25252FFLT3%252Binhibitor%25252C%252Bin%252Bmyelofibrosis%252Bor%252Bother%252Bmyeloid%252Bmalignancies%26aulast%3DVerstovsek%26aufirst%3DSrdan%26date%3D2016%26date%3D2016%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tania  Jain</span>, <span class="hlFld-ContribAuthor ">Ruben  Mesa</span>. </span><span class="cited-content_cbyCitation_article-title">The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Anticancer Therapy</span><span> <strong>2016,</strong> <em>16 </em>
                                    (11)
                                     , 1101-1108. <a href="https://doi.org/10.1080/14737140.2016.1233061" title="DOI URL">https://doi.org/10.1080/14737140.2016.1233061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14737140.2016.1233061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14737140.2016.1233061%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Anticancer%2520Therapy%26atitle%3DThe%252Bdevelopment%25252C%252Bsafety%252Band%252Befficacy%252Bof%252Bpacritinib%252Bfor%252Bthe%252Btreatment%252Bof%252Bmyelofibrosis%26aulast%3DJain%26aufirst%3DTania%26date%3D2016%26date%3D2016%26volume%3D16%26issue%3D11%26spage%3D1101%26epage%3D1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Myke R.  Green</span>, <span class="hlFld-ContribAuthor ">Michael D.  Newton</span>, <span class="hlFld-ContribAuthor ">Karen M.  Fancher</span>. </span><span class="cited-content_cbyCitation_article-title">Off-Target Effects of BCR-ABL and JAK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Clinical Oncology</span><span> <strong>2016,</strong> <em>39 </em>
                                    (1)
                                     , 76-84. <a href="https://doi.org/10.1097/COC.0000000000000023" title="DOI URL">https://doi.org/10.1097/COC.0000000000000023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/COC.0000000000000023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FCOC.0000000000000023%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Clinical%2520Oncology%26atitle%3DOff-Target%252BEffects%252Bof%252BBCR-ABL%252Band%252BJAK2%252BInhibitors%26aulast%3DGreen%26aufirst%3DMyke%2BR.%26date%3D2016%26volume%3D39%26issue%3D1%26spage%3D76%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">G.W.  Reuther</span>. </span><span class="cited-content_cbyCitation_article-title">Myeloproliferative Neoplasms. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 437-484. <a href="https://doi.org/10.1016/bs.pmbts.2016.09.004" title="DOI URL">https://doi.org/10.1016/bs.pmbts.2016.09.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.pmbts.2016.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.pmbts.2016.09.004%26sid%3Dliteratum%253Aachs%26atitle%3DMyeloproliferative%252BNeoplasms%26aulast%3DReuther%26aufirst%3DG.W.%26date%3D2016%26spage%3D437%26epage%3D484%26pub%3DElsevier%26atitle%3DMolecular%252Band%252BCellular%252BChanges%252Bin%252Bthe%252BCancer%252BCell%26date%3D2016%26volume%3D144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rosalba  Camicia</span>, <span class="hlFld-ContribAuthor ">Hans C.  Winkler</span>, <span class="hlFld-ContribAuthor ">Paul O.  Hassa</span>. </span><span class="cited-content_cbyCitation_article-title">Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2015,</strong> <em>14 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-015-0474-2" title="DOI URL">https://doi.org/10.1186/s12943-015-0474-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-015-0474-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-015-0474-2%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DNovel%252Bdrug%252Btargets%252Bfor%252Bpersonalized%252Bprecision%252Bmedicine%252Bin%252Brelapsed%25252Frefractory%252Bdiffuse%252Blarge%252BB-cell%252Blymphoma%25253A%252Ba%252Bcomprehensive%252Breview%26aulast%3DCamicia%26aufirst%3DRosalba%26date%3D2015%26date%3D2015%26volume%3D14%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Srdan  Verstovsek</span>, <span class="hlFld-ContribAuthor ">Rami S  Komrokji</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive review of pacritinib in myelofibrosis. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2015,</strong> <em>11 </em>
                                    (20)
                                     , 2819-2830. <a href="https://doi.org/10.2217/fon.15.200" title="DOI URL">https://doi.org/10.2217/fon.15.200</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon.15.200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon.15.200%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DA%252Bcomprehensive%252Breview%252Bof%252Bpacritinib%252Bin%252Bmyelofibrosis%26aulast%3DVerstovsek%26aufirst%3DSrdan%26date%3D2015%26volume%3D11%26issue%3D20%26spage%3D2819%26epage%3D2830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Concepción  Sánchez-Martínez</span>, <span class="hlFld-ContribAuthor ">Lawrence M.  Gelbert</span>, <span class="hlFld-ContribAuthor ">María José  Lallena</span>, <span class="hlFld-ContribAuthor ">Alfonso  de Dios</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (17)
                                     , 3420-3435. <a href="https://doi.org/10.1016/j.bmcl.2015.05.100" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.05.100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.05.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.05.100%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCyclin%252Bdependent%252Bkinase%252B%252528CDK%252529%252Binhibitors%252Bas%252Banticancer%252Bdrugs%26aulast%3DS%25C3%25A1nchez-Mart%25C3%25ADnez%26aufirst%3DConcepci%25C3%25B3n%26date%3D2015%26volume%3D25%26issue%3D17%26spage%3D3420%26epage%3D3435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana B.  Duenas-Perez</span>, <span class="hlFld-ContribAuthor ">Adam J.  Mead</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical potential of pacritinib in the treatment of myelofibrosis. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Hematology</span><span> <strong>2015,</strong> <em>6 </em>
                                    (4)
                                     , 186-201. <a href="https://doi.org/10.1177/2040620715586527" title="DOI URL">https://doi.org/10.1177/2040620715586527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2040620715586527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2040620715586527%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Hematology%26atitle%3DClinical%252Bpotential%252Bof%252Bpacritinib%252Bin%252Bthe%252Btreatment%252Bof%252Bmyelofibrosis%26aulast%3DDuenas-Perez%26aufirst%3DAna%2BB.%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D4%26spage%3D186%26epage%3D201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony D.  Pomicter</span>, <span class="hlFld-ContribAuthor ">Anna M.  Eiring</span>, <span class="hlFld-ContribAuthor ">Anna V.  Senina</span>, <span class="hlFld-ContribAuthor ">Matthew S.  Zabriskie</span>, <span class="hlFld-ContribAuthor ">James E.  Marvin</span>, <span class="hlFld-ContribAuthor ">Josef T.  Prchal</span>, <span class="hlFld-ContribAuthor ">Thomas  O'Hare</span>, <span class="hlFld-ContribAuthor ">Michael W.  Deininger</span>. </span><span class="cited-content_cbyCitation_article-title">Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. </span><span class="cited-content_cbyCitation_journal-name">Experimental Hematology</span><span> <strong>2015,</strong> <em>43 </em>
                                    (7)
                                     , 537-545.e11. <a href="https://doi.org/10.1016/j.exphem.2015.03.006" title="DOI URL">https://doi.org/10.1016/j.exphem.2015.03.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.exphem.2015.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.exphem.2015.03.006%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520Hematology%26atitle%3DLimited%252Befficacy%252Bof%252BBMS-911543%252Bin%252Ba%252Bmurine%252Bmodel%252Bof%252BJanus%252Bkinase%252B2%252BV617F%252Bmyeloproliferative%252Bneoplasm%26aulast%3DPomicter%26aufirst%3DAnthony%2BD.%26date%3D2015%26volume%3D43%26issue%3D7%26spage%3D537%26epage%3D545.e11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng-Qing  Ning</span>, <span class="hlFld-ContribAuthor ">Cheng  Lu</span>, <span class="hlFld-ContribAuthor ">Liang  Hu</span>, <span class="hlFld-ContribAuthor ">Yan-Jing  Bi</span>, <span class="hlFld-ContribAuthor ">Lei  Yao</span>, <span class="hlFld-ContribAuthor ">Yu-Jun  He</span>, <span class="hlFld-ContribAuthor ">Li-Fei  Liu</span>, <span class="hlFld-ContribAuthor ">Xiao-Yu  Liu</span>, <span class="hlFld-ContribAuthor ">Nie-Fang  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Macrocyclic compounds as anti-cancer agents: Design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>95 </em>, 104-115. <a href="https://doi.org/10.1016/j.ejmech.2015.03.034" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.03.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.03.034%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMacrocyclic%252Bcompounds%252Bas%252Banti-cancer%252Bagents%25253A%252BDesign%252Band%252Bsynthesis%252Bof%252Bmulti-acting%252Binhibitors%252Bagainst%252BHDAC%25252C%252BFLT3%252Band%252BJAK2%26aulast%3DNing%26aufirst%3DCheng-Qing%26date%3D2015%26volume%3D95%26spage%3D104%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan  Göring</span>, <span class="hlFld-ContribAuthor ">Dennis  Bensinger</span>, <span class="hlFld-ContribAuthor ">Eva C.  Naumann</span>, <span class="hlFld-ContribAuthor ">Boris  Schmidt</span>. </span><span class="cited-content_cbyCitation_article-title">Computer-Guided Design, Synthesis, and Biological Evaluation of Quinoxalinebisarylureas as FLT3 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2015,</strong> <em>10 </em>
                                    (3)
                                     , 511-522. <a href="https://doi.org/10.1002/cmdc.201402477" title="DOI URL">https://doi.org/10.1002/cmdc.201402477</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201402477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201402477%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DComputer-Guided%252BDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BQuinoxalinebisarylureas%252Bas%252BFLT3%252BInhibitors%26aulast%3DG%25C3%25B6ring%26aufirst%3DStefan%26date%3D2015%26date%3D2015%26volume%3D10%26issue%3D3%26spage%3D511%26epage%3D522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael O.  Frederick</span>, <span class="hlFld-ContribAuthor ">Douglas P.  Kjell</span>. </span><span class="cited-content_cbyCitation_article-title">A synthesis of abemaciclib utilizing a Leuckart–Wallach reaction. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2015,</strong> <em>56 </em>
                                    (7)
                                     , 949-951. <a href="https://doi.org/10.1016/j.tetlet.2014.12.082" title="DOI URL">https://doi.org/10.1016/j.tetlet.2014.12.082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2014.12.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2014.12.082%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DA%252Bsynthesis%252Bof%252Babemaciclib%252Butilizing%252Ba%252BLeuckart%2525E2%252580%252593Wallach%252Breaction%26aulast%3DFrederick%26aufirst%3DMichael%2BO.%26date%3D2015%26volume%3D56%26issue%3D7%26spage%3D949%26epage%3D951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin  Xu</span>, <span class="hlFld-ContribAuthor ">Esther H.Q.  Ong</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Hill</span>, <span class="hlFld-ContribAuthor ">Anqi  Chen</span>, <span class="hlFld-ContribAuthor ">Christina L.L.  Chai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (23)
                                     , 6625-6637. <a href="https://doi.org/10.1016/j.bmc.2014.10.006" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.10.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.10.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BFLT3%252Bcovalent%252Binhibitors%252Bwith%252Ba%252Bresorcylic%252Bacid%252Bcore%26aulast%3DXu%26aufirst%3DJin%26date%3D2014%26volume%3D22%26issue%3D23%26spage%3D6625%26epage%3D6637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gaëlle  Mariaule</span>, <span class="hlFld-ContribAuthor ">Philippe  Belmont</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2014,</strong> <em>19 </em>
                                    (9)
                                     , 14366-14382. <a href="https://doi.org/10.3390/molecules190914366" title="DOI URL">https://doi.org/10.3390/molecules190914366</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules190914366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules190914366%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DCyclin-Dependent%252BKinase%252BInhibitors%252Bas%252BMarketed%252BAnticancer%252BDrugs%25253A%252BWhere%252BAre%252BWe%252BNow%25253F%252BA%252BShort%252BSurvey%26aulast%3DMariaule%26aufirst%3DGa%25C3%25ABlle%26date%3D2014%26date%3D2014%26volume%3D19%26issue%3D9%26spage%3D14366%26epage%3D14382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian W  Dymock</span>, <span class="hlFld-ContribAuthor ">Eugene Guorong  Yang</span>, <span class="hlFld-ContribAuthor ">Yuyi  Chu-Farseeva</span>, <span class="hlFld-ContribAuthor ">Lianbin  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Selective JAK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2014,</strong> <em>6 </em>
                                    (12)
                                     , 1439-1471. <a href="https://doi.org/10.4155/fmc.14.92" title="DOI URL">https://doi.org/10.4155/fmc.14.92</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.14.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.14.92%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DSelective%252BJAK%252Binhibitors%26aulast%3DDymock%26aufirst%3DBrian%2BW%26date%3D2014%26volume%3D6%26issue%3D12%26spage%3D1439%26epage%3D1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bruna Velosa  Ferreira</span>, <span class="hlFld-ContribAuthor ">Claire  Harrison</span>. </span><span class="cited-content_cbyCitation_article-title">How many JAK inhibitors in myelofibrosis?. </span><span class="cited-content_cbyCitation_journal-name">Best Practice & Research Clinical Haematology</span><span> <strong>2014,</strong> <em>27 </em>
                                    (2)
                                     , 187-195. <a href="https://doi.org/10.1016/j.beha.2014.07.010" title="DOI URL">https://doi.org/10.1016/j.beha.2014.07.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.beha.2014.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.beha.2014.07.010%26sid%3Dliteratum%253Aachs%26jtitle%3DBest%2520Practice%2520%2526%2520Research%2520Clinical%2520Haematology%26atitle%3DHow%252Bmany%252BJAK%252Binhibitors%252Bin%252Bmyelofibrosis%25253F%26aulast%3DFerreira%26aufirst%3DBruna%2BVelosa%26date%3D2014%26volume%3D27%26issue%3D2%26spage%3D187%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vu H  Duong</span>, <span class="hlFld-ContribAuthor ">Rami S  Komrokji</span>. </span><span class="cited-content_cbyCitation_article-title">The role of pacritinib in the management of myelofibrosis. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Hematology</span><span> <strong>2014,</strong> <em>7 </em>
                                    (3)
                                     , 325-332. <a href="https://doi.org/10.1586/17474086.2014.905200" title="DOI URL">https://doi.org/10.1586/17474086.2014.905200</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1586/17474086.2014.905200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1586%2F17474086.2014.905200%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Hematology%26atitle%3DThe%252Brole%252Bof%252Bpacritinib%252Bin%252Bthe%252Bmanagement%252Bof%252Bmyelofibrosis%26aulast%3DDuong%26aufirst%3DVu%2BH%26date%3D2014%26date%3D2014%26volume%3D7%26issue%3D3%26spage%3D325%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claire N  Harrison</span>, <span class="hlFld-ContribAuthor ">Michael  Bennett</span>. </span><span class="cited-content_cbyCitation_article-title">Orphan drugs for myelofibrosis. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Orphan Drugs</span><span> <strong>2014,</strong> <em>2 </em>
                                    (4)
                                     , 391-405. <a href="https://doi.org/10.1517/21678707.2014.888346" title="DOI URL">https://doi.org/10.1517/21678707.2014.888346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/21678707.2014.888346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F21678707.2014.888346%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Orphan%2520Drugs%26atitle%3DOrphan%252Bdrugs%252Bfor%252Bmyelofibrosis%26aulast%3DHarrison%26aufirst%3DClaire%2BN%26date%3D2014%26date%3D2014%26volume%3D2%26issue%3D4%26spage%3D391%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dmitriy M.  Volochnyuk</span>, <span class="hlFld-ContribAuthor ">Oleksandr O.  Grygorenko</span>, <span class="hlFld-ContribAuthor ">Alina O.  Gorlova</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine Containing Diazines. Synthesis and Properties. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 291-575. <a href="https://doi.org/10.1007/978-3-319-04435-4_6" title="DOI URL">https://doi.org/10.1007/978-3-319-04435-4_6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-04435-4_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-04435-4_6%26sid%3Dliteratum%253Aachs%26atitle%3DFluorine%252BContaining%252BDiazines.%252BSynthesis%252Band%252BProperties%26aulast%3DVolochnyuk%26aufirst%3DDmitriy%2BM.%26date%3D2014%26date%3D2014%26spage%3D291%26epage%3D575%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DFluorine%252Bin%252BHeterocyclic%252BChemistry%252BVolume%252B2%26aulast%3DNenajdenko%26aufirst%3DValentine%26date%3D2014%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">K.  Foote</span>, <span class="hlFld-ContribAuthor ">J.  Kettle</span>, <span class="hlFld-ContribAuthor ">B.  Aquila</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.11033-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.11033-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.11033-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.11033-9%26sid%3Dliteratum%253Aachs%26atitle%3DKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.%26date%3D2014%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2014%26volume%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gregory T.  Notte</span>. </span><span class="cited-content_cbyCitation_article-title">New Chemical Entities Entering Phase III Trials in 2013. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 417-436. <a href="https://doi.org/10.1016/B978-0-12-800167-7.00026-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-800167-7.00026-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-800167-7.00026-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-800167-7.00026-2%26sid%3Dliteratum%253Aachs%26atitle%3DNew%252BChemical%252BEntities%252BEntering%252BPhase%252BIII%252BTrials%252Bin%252B2013%26aulast%3DNotte%26aufirst%3DGregory%2BT.%26date%3D2014%26spage%3D417%26epage%3D436%26pub%3DElsevier%26date%3D2014%26volume%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kh. Dhanachandra  Singh</span>, <span class="hlFld-ContribAuthor ">Queen  Naveena</span>, <span class="hlFld-ContribAuthor ">Muthusamy  Karthikeyan</span>. </span><span class="cited-content_cbyCitation_article-title">Jak2 inhibitor – a jackpot for pharmaceutical industries: a comprehensive computational method in the discovery of new potent Jak2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Mol. BioSyst.</span><span> <strong>2014,</strong> <em>10 </em>
                                    (8)
                                     , 2146-2159. <a href="https://doi.org/10.1039/C4MB00071D" title="DOI URL">https://doi.org/10.1039/C4MB00071D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4MB00071D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4MB00071D%26sid%3Dliteratum%253Aachs%26jtitle%3DMol.%2520BioSyst.%26atitle%3DJak2%252Binhibitor%252B%2525E2%252580%252593%252Ba%252Bjackpot%252Bfor%252Bpharmaceutical%252Bindustries%25253A%252Ba%252Bcomprehensive%252Bcomputational%252Bmethod%252Bin%252Bthe%252Bdiscovery%252Bof%252Bnew%252Bpotent%252BJak2%252Binhibitors%26aulast%3DSingh%26aufirst%3DKh.%2BDhanachandra%26date%3D2014%26date%3D2014%26volume%3D10%26issue%3D8%26spage%3D2146%26epage%3D2159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Enrico  Derenzini</span>, <span class="hlFld-ContribAuthor ">Anas  Younes</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2013,</strong> <em>22 </em>
                                    (6)
                                     , 775-785. <a href="https://doi.org/10.1517/13543784.2013.775244" title="DOI URL">https://doi.org/10.1517/13543784.2013.775244</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543784.2013.775244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543784.2013.775244%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DTargeting%252Bthe%252BJAK-STAT%252Bpathway%252Bin%252Blymphoma%25253A%252Ba%252Bfocus%252Bon%252Bpacritinib%26aulast%3DDerenzini%26aufirst%3DEnrico%26date%3D2013%26date%3D2013%26volume%3D22%26issue%3D6%26spage%3D775%26epage%3D785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian W  Dymock</span>, <span class="hlFld-ContribAuthor ">Cheng Shang  See</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 – 2012. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2013,</strong> <em>23 </em>
                                    (4)
                                     , 449-501. <a href="https://doi.org/10.1517/13543776.2013.765862" title="DOI URL">https://doi.org/10.1517/13543776.2013.765862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2013.765862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2013.765862%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DInhibitors%252Bof%252BJAK2%252Band%252BJAK3%25253A%252Ban%252Bupdate%252Bon%252Bthe%252Bpatent%252Bliterature%252B2010%252B%2525E2%252580%252593%252B2012%26aulast%3DDymock%26aufirst%3DBrian%2BW%26date%3D2013%26date%3D2013%26volume%3D23%26issue%3D4%26spage%3D449%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher J.  Burns</span>, <span class="hlFld-ContribAuthor ">David  Segal</span>, <span class="hlFld-ContribAuthor ">Andrew F.  Wilks</span>. </span><span class="cited-content_cbyCitation_article-title">The Use of JAK-Specific Inhibitors as Chemical Biology Tools. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 99-113. <a href="https://doi.org/10.1007/978-1-62703-242-1_7" title="DOI URL">https://doi.org/10.1007/978-1-62703-242-1_7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-1-62703-242-1_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-1-62703-242-1_7%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BUse%252Bof%252BJAK-Specific%252BInhibitors%252Bas%252BChemical%252BBiology%252BTools%26aulast%3DBurns%26aufirst%3DChristopher%2BJ.%26date%3D2013%26date%3D2012%26spage%3D99%26epage%3D113%26pub%3DHumana%2520Press%26atitle%3DJAK-STAT%252BSignalling%26aulast%3DNicholson%26aufirst%3DSandra%2BE.%26date%3D2013%26volume%3D967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Anthony  William</span>, <span class="hlFld-ContribAuthor ">Stéphanie  Blanchard</span>, <span class="hlFld-ContribAuthor ">Harish  Nagaraj</span>, <span class="hlFld-ContribAuthor ">Meredith  Williams</span>, <span class="hlFld-ContribAuthor ">Haishan  Wang</span>, <span class="hlFld-ContribAuthor ">Angeline  Lee</span>, <span class="hlFld-ContribAuthor ">Eric  Sun</span>, <span class="hlFld-ContribAuthor ">Ee-Ling  Teo</span>, <span class="hlFld-ContribAuthor ">Evelyn  Tan</span>, <span class="hlFld-ContribAuthor ">Kee Chuan  Goh</span>, <span class="hlFld-ContribAuthor ">Brian  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3). </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2013,</strong> <em>19 </em>
                                    (1)
                                     , 119-130. <a href="https://doi.org/10.1007/s00894-012-1528-7" title="DOI URL">https://doi.org/10.1007/s00894-012-1528-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-012-1528-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-012-1528-7%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DStructure-based%252Bdesign%252Bof%252Bnitrogen-linked%252Bmacrocyclic%252Bkinase%252Binhibitors%252Bleading%252Bto%252Bthe%252Bclinical%252Bcandidate%252BSB1317%25252FTG02%25252C%252Ba%252Bpotent%252Binhibitor%252Bof%252Bcyclin%252Bdependant%252Bkinases%252B%252528CDKs%252529%25252C%252BJanus%252Bkinase%252B2%252B%252528JAK2%252529%25252C%252Band%252BFms-like%252Btyrosine%252Bkinase-3%252B%252528FLT3%252529%26aulast%3DPoulsen%26aufirst%3DAnders%26date%3D2013%26date%3D2012%26volume%3D19%26issue%3D1%26spage%3D119%26epage%3D130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandrine  Vendeville</span>, <span class="hlFld-ContribAuthor ">Maxwell D.  Cummings</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Macrocycles in Small-Molecule Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 371-386. <a href="https://doi.org/10.1016/B978-0-12-417150-3.00023-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-417150-3.00023-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-417150-3.00023-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-417150-3.00023-5%26sid%3Dliteratum%253Aachs%26atitle%3DSynthetic%252BMacrocycles%252Bin%252BSmall-Molecule%252BDrug%252BDiscovery%26aulast%3DVendeville%26aufirst%3DSandrine%26date%3D2013%26spage%3D371%26epage%3D386%26pub%3DElsevier%26date%3D2013%26volume%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christel J.  Menet</span>, <span class="hlFld-ContribAuthor ">Luc Van  Rompaey</span>, <span class="hlFld-ContribAuthor ">Raphaël  Geney</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in the Discovery of Selective JAK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 153-223. <a href="https://doi.org/10.1016/B978-0-444-62652-3.00004-1" title="DOI URL">https://doi.org/10.1016/B978-0-444-62652-3.00004-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-444-62652-3.00004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-444-62652-3.00004-1%26sid%3Dliteratum%253Aachs%26atitle%3DAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BSelective%252BJAK%252BInhibitors%26aulast%3DMenet%26aufirst%3DChristel%2BJ.%26date%3D2013%26spage%3D153%26epage%3D223%26pub%3DElsevier%26date%3D2013%26volume%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad  Furqan</span>, <span class="hlFld-ContribAuthor ">Nikhil  Mukhi</span>, <span class="hlFld-ContribAuthor ">Byung  Lee</span>, <span class="hlFld-ContribAuthor ">Delong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. </span><span class="cited-content_cbyCitation_journal-name">Biomarker Research</span><span> <strong>2013,</strong> <em>1 </em>
                                    (1)
                                     , 5. <a href="https://doi.org/10.1186/2050-7771-1-5" title="DOI URL">https://doi.org/10.1186/2050-7771-1-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/2050-7771-1-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2F2050-7771-1-5%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomarker%2520Research%26atitle%3DDysregulation%252Bof%252BJAK-STAT%252Bpathway%252Bin%252Bhematological%252Bmalignancies%252Band%252BJAK%252Binhibitors%252Bfor%252Bclinical%252Bapplication%26aulast%3DFurqan%26aufirst%3DMuhammad%26date%3D2013%26volume%3D1%26issue%3D1%26spage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy  Forsyth</span>, <span class="hlFld-ContribAuthor ">Patrick C.  Kearney</span>, <span class="hlFld-ContribAuthor ">Byung Gyu  Kim</span>, <span class="hlFld-ContribAuthor ">Henry W.B.  Johnson</span>, <span class="hlFld-ContribAuthor ">Naing  Aay</span>, <span class="hlFld-ContribAuthor ">Arlyn  Arcalas</span>, <span class="hlFld-ContribAuthor ">David S.  Brown</span>, <span class="hlFld-ContribAuthor ">Vicky  Chan</span>, <span class="hlFld-ContribAuthor ">Jeff  Chen</span>, <span class="hlFld-ContribAuthor ">Hongwang  Du</span>, <span class="hlFld-ContribAuthor ">Sergey  Epshteyn</span>, <span class="hlFld-ContribAuthor ">Adam A.  Galan</span>, <span class="hlFld-ContribAuthor ">Tai P.  Huynh</span>, <span class="hlFld-ContribAuthor ">Mohamed A.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Brian  Kane</span>, <span class="hlFld-ContribAuthor ">Elena S.  Koltun</span>, <span class="hlFld-ContribAuthor ">Grace  Mann</span>, <span class="hlFld-ContribAuthor ">Lisa E.  Meyr</span>, <span class="hlFld-ContribAuthor ">Matthew S.  Lee</span>, <span class="hlFld-ContribAuthor ">Gary L.  Lewis</span>, <span class="hlFld-ContribAuthor ">Robin T.  Noguchi</span>, <span class="hlFld-ContribAuthor ">Michael  Pack</span>, <span class="hlFld-ContribAuthor ">Brian H.  Ridgway</span>, <span class="hlFld-ContribAuthor ">Xian  Shi</span>, <span class="hlFld-ContribAuthor ">Craig S.  Takeuchi</span>, <span class="hlFld-ContribAuthor ">Peiwen  Zu</span>, <span class="hlFld-ContribAuthor ">James W.  Leahy</span>, <span class="hlFld-ContribAuthor ">John M.  Nuss</span>, <span class="hlFld-ContribAuthor ">Ron  Aoyama</span>, <span class="hlFld-ContribAuthor ">Stefan  Engst</span>, <span class="hlFld-ContribAuthor ">Steven B.  Gendreau</span>, <span class="hlFld-ContribAuthor ">Robert  Kassees</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Shwu-Hwa  Lin</span>, <span class="hlFld-ContribAuthor ">Jean-Francois  Martini</span>, <span class="hlFld-ContribAuthor ">Thomas  Stout</span>, <span class="hlFld-ContribAuthor ">Philip  Tong</span>, <span class="hlFld-ContribAuthor ">John  Woolfrey</span>, <span class="hlFld-ContribAuthor ">Wentao  Zhang</span>, <span class="hlFld-ContribAuthor ">Peiwen  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2012,</strong> <em>22 </em>
                                    (24)
                                     , 7653-7658. <a href="https://doi.org/10.1016/j.bmcl.2012.10.007" title="DOI URL">https://doi.org/10.1016/j.bmcl.2012.10.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2012.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2012.10.007%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSAR%252Band%252Bin%252Bvivo%252Bevaluation%252Bof%252B4-aryl-2-aminoalkylpyrimidines%252Bas%252Bpotent%252Band%252Bselective%252BJanus%252Bkinase%252B2%252B%252528JAK2%252529%252Binhibitors%26aulast%3DForsyth%26aufirst%3DTimothy%26date%3D2012%26volume%3D22%26issue%3D24%26spage%3D7653%26epage%3D7658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anas  Younes</span>, <span class="hlFld-ContribAuthor ">Jorge  Romaguera</span>, <span class="hlFld-ContribAuthor ">Michelle  Fanale</span>, <span class="hlFld-ContribAuthor ">Peter  McLaughlin</span>, <span class="hlFld-ContribAuthor ">Frederick  Hagemeister</span>, <span class="hlFld-ContribAuthor ">Amanda  Copeland</span>, <span class="hlFld-ContribAuthor ">Sattva  Neelapu</span>, <span class="hlFld-ContribAuthor ">Larry  Kwak</span>, <span class="hlFld-ContribAuthor ">Jatin  Shah</span>, <span class="hlFld-ContribAuthor ">Silvana  de Castro Faria</span>, <span class="hlFld-ContribAuthor ">Stefan  Hart</span>, <span class="hlFld-ContribAuthor ">Jeanette  Wood</span>, <span class="hlFld-ContribAuthor ">Ramesh  Jayaraman</span>, <span class="hlFld-ContribAuthor ">Kantharaj  Ethirajulu</span>, <span class="hlFld-ContribAuthor ">Joy  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Oncology</span><span> <strong>2012,</strong> <em>30 </em>
                                    (33)
                                     , 4161-4167. <a href="https://doi.org/10.1200/JCO.2012.42.5223" title="DOI URL">https://doi.org/10.1200/JCO.2012.42.5223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1200/JCO.2012.42.5223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1200%2FJCO.2012.42.5223%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Oncology%26atitle%3DPhase%252BI%252BStudy%252Bof%252Ba%252BNovel%252BOral%252BJanus%252BKinase%252B2%252BInhibitor%25252C%252BSB1518%25252C%252Bin%252BPatients%252BWith%252BRelapsed%252BLymphoma%25253A%252BEvidence%252Bof%252BClinical%252Band%252BBiologic%252BActivity%252Bin%252BMultiple%252BLymphoma%252BSubtypes%26aulast%3DYounes%26aufirst%3DAnas%26date%3D2012%26volume%3D30%26issue%3D33%26spage%3D4161%26epage%3D4167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuqi  Guo</span>, <span class="hlFld-ContribAuthor ">Feng  Xu</span>, <span class="hlFld-ContribAuthor ">TianJian  Lu</span>, <span class="hlFld-ContribAuthor ">Zhenfeng  Duan</span>, <span class="hlFld-ContribAuthor ">Zhan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Interleukin-6 signaling pathway in targeted therapy for cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Treatment Reviews</span><span> <strong>2012,</strong> <em>38 </em>
                                    (7)
                                     , 904-910. <a href="https://doi.org/10.1016/j.ctrv.2012.04.007" title="DOI URL">https://doi.org/10.1016/j.ctrv.2012.04.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ctrv.2012.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ctrv.2012.04.007%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Treatment%2520Reviews%26atitle%3DInterleukin-6%252Bsignaling%252Bpathway%252Bin%252Btargeted%252Btherapy%252Bfor%252Bcancer%26aulast%3DGuo%26aufirst%3DYuqi%26date%3D2012%26volume%3D38%26issue%3D7%26spage%3D904%26epage%3D910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T  Southworth</span>, <span class="hlFld-ContribAuthor ">A  Metryka</span>, <span class="hlFld-ContribAuthor ">S  Lea</span>, <span class="hlFld-ContribAuthor ">S  Farrow</span>, <span class="hlFld-ContribAuthor ">J  Plumb</span>, <span class="hlFld-ContribAuthor ">D  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">IFN-γ synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid-resistant STAT1 activation. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2012,</strong> <em>166 </em>
                                    (7)
                                     , 2070-2083. <a href="https://doi.org/10.1111/j.1476-5381.2012.01907.x" title="DOI URL">https://doi.org/10.1111/j.1476-5381.2012.01907.x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/j.1476-5381.2012.01907.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fj.1476-5381.2012.01907.x%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DIFN-%2525CE%2525B3%252Bsynergistically%252Benhances%252BLPS%252Bsignalling%252Bin%252Balveolar%252Bmacrophages%252Bfrom%252BCOPD%252Bpatients%252Band%252Bcontrols%252Bby%252Bcorticosteroid-resistant%252BSTAT1%252Bactivation%26aulast%3DSouthworth%26aufirst%3DT%26date%3D2012%26date%3D2012%26volume%3D166%26issue%3D7%26spage%3D2070%26epage%3D2083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jamie  Mallinson</span>, <span class="hlFld-ContribAuthor ">Ian  Collins</span>. </span><span class="cited-content_cbyCitation_article-title">Macrocycles in new drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2012,</strong> <em>4 </em>
                                    (11)
                                     , 1409-1438. <a href="https://doi.org/10.4155/fmc.12.93" title="DOI URL">https://doi.org/10.4155/fmc.12.93</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.12.93&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.12.93%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DMacrocycles%252Bin%252Bnew%252Bdrug%252Bdiscovery%26aulast%3DMallinson%26aufirst%3DJamie%26date%3D2012%26volume%3D4%26issue%3D11%26spage%3D1409%26epage%3D1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian L  Harry</span>, <span class="hlFld-ContribAuthor ">S. Gail  Eckhardt</span>, <span class="hlFld-ContribAuthor ">Antonio  Jimeno</span>. </span><span class="cited-content_cbyCitation_article-title">JAK2 inhibition for the treatment of hematologic and solid malignancies. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2012,</strong> <em>21 </em>
                                    (5)
                                     , 637-655. <a href="https://doi.org/10.1517/13543784.2012.677432" title="DOI URL">https://doi.org/10.1517/13543784.2012.677432</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543784.2012.677432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543784.2012.677432%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DJAK2%252Binhibition%252Bfor%252Bthe%252Btreatment%252Bof%252Bhematologic%252Band%252Bsolid%252Bmalignancies%26aulast%3DHarry%26aufirst%3DBrian%2BL%26date%3D2012%26date%3D2012%26volume%3D21%26issue%3D5%26spage%3D637%26epage%3D655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Anthony  William</span>, <span class="hlFld-ContribAuthor ">Stéphanie  Blanchard</span>, <span class="hlFld-ContribAuthor ">Angeline  Lee</span>, <span class="hlFld-ContribAuthor ">Harish  Nagaraj</span>, <span class="hlFld-ContribAuthor ">Haishan  Wang</span>, <span class="hlFld-ContribAuthor ">Eeling  Teo</span>, <span class="hlFld-ContribAuthor ">Evelyn  Tan</span>, <span class="hlFld-ContribAuthor ">Kee Chuan  Goh</span>, <span class="hlFld-ContribAuthor ">Brian  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3). </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2012,</strong> <em>26 </em>
                                    (4)
                                     , 437-450. <a href="https://doi.org/10.1007/s10822-012-9572-z" title="DOI URL">https://doi.org/10.1007/s10822-012-9572-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-012-9572-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-012-9572-z%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DStructure-based%252Bdesign%252Bof%252Boxygen-linked%252Bmacrocyclic%252Bkinase%252Binhibitors%25253A%252Bdiscovery%252Bof%252BSB1518%252Band%252BSB1578%25252C%252Bpotent%252Binhibitors%252Bof%252BJanus%252Bkinase%252B2%252B%252528JAK2%252529%252Band%252BFms-like%252Btyrosine%252Bkinase-3%252B%252528FLT3%252529%26aulast%3DPoulsen%26aufirst%3DAnders%26date%3D2012%26date%3D2012%26volume%3D26%26issue%3D4%26spage%3D437%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesco  Passamonti</span>, <span class="hlFld-ContribAuthor ">Margherita  Maffioli</span>, <span class="hlFld-ContribAuthor ">Domenica  Caramazza</span>. </span><span class="cited-content_cbyCitation_article-title">New generation small-molecule inhibitors in myeloproliferative neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Hematology</span><span> <strong>2012,</strong> <em>19 </em>
                                    (2)
                                     , 117-123. <a href="https://doi.org/10.1097/MOH.0b013e32834ff575" title="DOI URL">https://doi.org/10.1097/MOH.0b013e32834ff575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/MOH.0b013e32834ff575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FMOH.0b013e32834ff575%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Hematology%26atitle%3DNew%252Bgeneration%252Bsmall-molecule%252Binhibitors%252Bin%252Bmyeloproliferative%252Bneoplasms%26aulast%3DPassamonti%26aufirst%3DFrancesco%26date%3D2012%26volume%3D19%26issue%3D2%26spage%3D117%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mamatha M  Reddy</span>, <span class="hlFld-ContribAuthor ">Anagha  Deshpande</span>, <span class="hlFld-ContribAuthor ">Martin  Sattler</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting JAK2 in the therapy of myeloproliferative neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Targets</span><span> <strong>2012,</strong> <em>16 </em>
                                    (3)
                                     , 313-324. <a href="https://doi.org/10.1517/14728222.2012.662956" title="DOI URL">https://doi.org/10.1517/14728222.2012.662956</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/14728222.2012.662956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F14728222.2012.662956%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Targets%26atitle%3DTargeting%252BJAK2%252Bin%252Bthe%252Btherapy%252Bof%252Bmyeloproliferative%252Bneoplasms%26aulast%3DReddy%26aufirst%3DMamatha%2BM%26date%3D2012%26date%3D2012%26volume%3D16%26issue%3D3%26spage%3D313%26epage%3D324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anders  Poulsen</span>, <span class="hlFld-ContribAuthor ">Stéphanie  Blanchard</span>, <span class="hlFld-ContribAuthor ">Chang Kai  Soh</span>, <span class="hlFld-ContribAuthor ">Chaiping  Lee</span>, <span class="hlFld-ContribAuthor ">Meredith  Williams</span>, <span class="hlFld-ContribAuthor ">Haishan  Wang</span>, <span class="hlFld-ContribAuthor ">Brian  Dymock</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design of PDK1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2012,</strong> <em>22 </em>
                                    (1)
                                     , 305-307. <a href="https://doi.org/10.1016/j.bmcl.2011.11.006" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.11.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.11.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-based%252Bdesign%252Bof%252BPDK1%252Binhibitors%26aulast%3DPoulsen%26aufirst%3DAnders%26date%3D2012%26volume%3D22%26issue%3D1%26spage%3D305%26epage%3D307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S  Hart</span>, <span class="hlFld-ContribAuthor ">K C  Goh</span>, <span class="hlFld-ContribAuthor ">V  Novotny-Diermayr</span>, <span class="hlFld-ContribAuthor ">Y C  Tan</span>, <span class="hlFld-ContribAuthor ">B  Madan</span>, <span class="hlFld-ContribAuthor ">C  Amalini</span>, <span class="hlFld-ContribAuthor ">L C  Ong</span>, <span class="hlFld-ContribAuthor ">B  Kheng</span>, <span class="hlFld-ContribAuthor ">A  Cheong</span>, <span class="hlFld-ContribAuthor ">J  Zhou</span>, <span class="hlFld-ContribAuthor ">W J  Chng</span>, <span class="hlFld-ContribAuthor ">J M  Wood</span>. </span><span class="cited-content_cbyCitation_article-title">Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Blood Cancer Journal</span><span> <strong>2011,</strong> <em>1 </em>
                                    (11)
                                     , e44-e44. <a href="https://doi.org/10.1038/bcj.2011.43" title="DOI URL">https://doi.org/10.1038/bcj.2011.43</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/bcj.2011.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fbcj.2011.43%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%2520Cancer%2520Journal%26atitle%3DPacritinib%252B%252528SB1518%252529%25252C%252Ba%252BJAK2%25252FFLT3%252Binhibitor%252Bfor%252Bthe%252Btreatment%252Bof%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DHart%26aufirst%3DS%26date%3D2011%26date%3D2011%26volume%3D1%26issue%3D11%26spage%3De44%26epage%3De44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S  Hart</span>, <span class="hlFld-ContribAuthor ">K C  Goh</span>, <span class="hlFld-ContribAuthor ">V  Novotny-Diermayr</span>, <span class="hlFld-ContribAuthor ">C Y  Hu</span>, <span class="hlFld-ContribAuthor ">H  Hentze</span>, <span class="hlFld-ContribAuthor ">Y C  Tan</span>, <span class="hlFld-ContribAuthor ">B  Madan</span>, <span class="hlFld-ContribAuthor ">C  Amalini</span>, <span class="hlFld-ContribAuthor ">Y K  Loh</span>, <span class="hlFld-ContribAuthor ">L C  Ong</span>, <span class="hlFld-ContribAuthor ">A D  William</span>, <span class="hlFld-ContribAuthor ">A  Lee</span>, <span class="hlFld-ContribAuthor ">A  Poulsen</span>, <span class="hlFld-ContribAuthor ">R  Jayaraman</span>, <span class="hlFld-ContribAuthor ">K H  Ong</span>, <span class="hlFld-ContribAuthor ">K  Ethirajulu</span>, <span class="hlFld-ContribAuthor ">B W  Dymock</span>, <span class="hlFld-ContribAuthor ">J W  Wood</span>. </span><span class="cited-content_cbyCitation_article-title">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. </span><span class="cited-content_cbyCitation_journal-name">Leukemia</span><span> <strong>2011,</strong> <em>25 </em>
                                    (11)
                                     , 1751-1759. <a href="https://doi.org/10.1038/leu.2011.148" title="DOI URL">https://doi.org/10.1038/leu.2011.148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/leu.2011.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fleu.2011.148%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%26atitle%3DSB1518%25252C%252Ba%252Bnovel%252Bmacrocyclic%252Bpyrimidine-based%252BJAK2%252Binhibitor%252Bfor%252Bthe%252Btreatment%252Bof%252Bmyeloid%252Band%252Blymphoid%252Bmalignancies%26aulast%3DHart%26aufirst%3DS%26date%3D2011%26date%3D2011%26volume%3D25%26issue%3D11%26spage%3D1751%26epage%3D1759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Inception of macrocyclization from an in-house library screening hit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,2-dimethoxyethane, water, 80 °C, 52–64%. (b) Allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 38–68%. (c) 4-Bromobut-1-ene, CsCO<sub>3</sub>, DMF, 40 °C, 52–64%. (d) Fe powder, NH<sub>4</sub>Cl, EtOH, water, 80 °C, 71–96%. (e) 4 M HCl, <i>n</i>-butanol, 80–100 °C, 21–56%. (f) Grubbs second generation catalyst, HCl, CH<sub>2</sub>Cl<sub>2</sub>, 40–45 °C, 43–51%. (g) NaSEt, DMF, 120 °C, 30%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, quantitative. (b) NaBH<sub>4</sub>, THF, water, 0 °C, quantitative. (c) Allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 38–68%. (d) Fe powder, NH<sub>4</sub>Cl, EtOH, water, 80 °C, 71–96%. (e) 1,2-Dichloroethane, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 54–72%. (f) Fmoc-Cl, DIEA, 1,4-dioxane, rt, 95%. (g) 4 M HCl, <i>n</i>-butanol, 80–100 °C, 21–92%. (h) Either Grubbs second generation catalyst or Zhan catalyst-1B, HCl, CH<sub>2</sub>Cl<sub>2</sub>, 40–45 °C, 43–96%. (i) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 73%. (j) 2-Bromoethanol, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 34%. (k) Acetyl chloride, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, rt, 63%. (l) Ethanesulfonyl chloride, K<sub>2</sub>CO<sub>3</sub>, THF, 70 °C, 41%. (m) DMA, microwave 80 °C, 72–90%. (n) 20% v/v piperidine in CH<sub>2</sub>Cl<sub>2</sub>, rt, 82%. (o) 3-(Diethylamino)propionic acid hydrochloride, HOBt, EDCI, CH<sub>2</sub>Cl<sub>2</sub>, 55%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0013.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reactions and conditions: (a) 1,2-dichloroethane, K<sub>2</sub>CO<sub>3</sub>, DMF, 100 °C, 54–72%. (b) NaBH<sub>4</sub>, THF, water, 0 °C, quantitative. (c) Allyl bromide, KOH, TBAHSO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 38–68%. (d) Pyrrolidine, DMA, 90 °C, 66–76%. (e) Fe powder, NH<sub>4</sub>Cl, EtOH, water, 80 °C, 74–90%. (f) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, 1,2-dimethoxyethane, water, 80 °C, 40–66%. (g) DIBAL, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 48%. (h) 4 M HCl, <i>n</i>-butanol, 80–100 °C, 21–91%. (i) Either Grubbs second generation catalyst or Zhan catalyst-1B, HCl, CH<sub>2</sub>Cl<sub>2</sub>, 40–45 °C, 32–79%.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0016.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>16e</b> docked into the ATP-binding site of JAK2. Compound <b>16e</b> is shown as a thick tube with green carbon. Hydrogen bonds between <b>16e</b> and JAK2 are shown as purple/black dashed lines. (A) JAK2 is shown in thin tube with gray carbon. The backbone of Leu932 forms two hydrogen bonds with <b>16e</b> and the side chain of Ser936 hydrogen bonds with an ether-oxygen in the macrocyclic linker. Leu855, Val863, Ala880, and Leu983 (in the bottom of the binding site) have hydrophobic contacts with the aromatic rings of <b>16e</b>. (B) JAK2 is shown as a surface. The methoxy group of <b>16e</b> is pointing toward a groove on the JAK2 surface that may accommodate a solubility-tag enabling fine-tuning of molecular properties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compound <b>21c</b> docked into the ATP-binding site of JAK2. Compound <b>21c</b> forms the same hydrogen bonds with JAK2 as <b>16e</b>. In addition, the solubilizing pyrrolidine side-chain forms a salt bridge with Asp939. There are opportunities for hydrophobic interactions with (A) Met929 through derivatization of the 5′-pyrimidine position and (B) with Gly993/Asp994 and Lys857 accessible from the A-ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>22b</b> docked into the ATP-binding site of JAK2 (A) and with the surface shown (B). The solvent-accessible surface of JAK2 surrounding the methyl-pyrimidine substituent is shown in peach. The methyl is an excellent fit to this part of the binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>22f</b> docked into JAK2 (A) and CDK2 (B). The 4-methoxy substituent of the A-ring points up into the hydrophobic area in JAK2 while it is in the plane of the A-ring in the CDK2 pose making unfavorable contact with the charged side chains of Lys33 and Asp145.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>21c</b> reduces splenomegaly and hepatomegaly in a Ba/F3-JAK2<sup>V617F</sup> model of leukemia. Ba/F3-JAK2<sup>V617F</sup>-bearing nude mice were dosed p.o., b.i.d., with 75 and 150 mg/kg <b>21c</b> (HCl salt) for 13 consecutive days. On day 13, mice were sacrificed and spleen and liver weights determined (<i>n</i> = 8; * <i>p</i> < 0.05, **<i>p</i> < 0.01 ANOVA, Dunnett’s post test). The dotted line represents baseline weights.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/medium/jm-2011-00326p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>21c</b> is efficacious in a xenograft derived from a cell line harboring FLT3-ITD. MV4–11 tumor bearing nude mice were randomized into 4 groups of 8–10 animals each. Mice were treated orally (p.o.) once daily at doses of 25, 50, or 100 mg/kg of <b>21c</b> for 21 consecutive days, and median time to end point (= median survival) was determined on day 55. The figures given indicate doses calculated using the molecular weight of the free base. The Log-rank (Mantel-Cox) test was used for statistical analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-13/jm200326p/production/images/large/jm-2011-00326p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm200326p&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i152">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86100" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86100" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 57 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Yamaoka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saharinen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holt, V. E. T.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">The Janus kinases (Jaks)</span> <span class="citation_source-journal">Genome Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">253.1</span><span class="NLM_x">–</span> <span class="NLM_lpage">253.6</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=253.1-253.6&author=K.+Yamaokaauthor=P.+Saharinenauthor=M.+Pesuauthor=V.+E.+T.+Holtauthor=O.+Silvennoinenauthor=J.+J.+O%E2%80%99Shea&title=The+Janus+kinases+%28Jaks%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DHolt%26aufirst%3DV.%2BE.%2BT.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Janus%2520kinases%2520%2528Jaks%2529%26jtitle%3DGenome%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D253.1%26epage%3D253.6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Rane, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Janus kinases: components of multiple signaling pathways</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5662</span><span class="NLM_x">–</span> <span class="NLM_lpage">5679</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5662-5679&author=S.+G.+Raneauthor=E.+P.+Reddy&title=Janus+kinases%3A+components+of+multiple+signaling+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DJanus%2520kinases%253A%2520components%2520of%2520multiple%2520signaling%2520pathways%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5662%26epage%3D5679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Levine, R. L.</span><span> </span><span class="NLM_article-title">Mechanisms of mutations in myeloproliferative neoplasms</span> <span class="citation_source-journal">Best Pract. Res. Clin. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2Fj.beha.2009.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=19959098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFagsbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=489-494&author=R.+L.+Levine&title=Mechanisms+of+mutations+in+myeloproliferative+neoplasms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of mutations in myeloproliferative neoplasms</span></div><div class="casAuthors">Levine, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Haematology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">489-494</span>CODEN:
                <span class="NLM_cas:coden">BPRCA5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years, a series of studies have provided genetic insight into the pathogenesis of myeloproliferative neoplasms (MPNs).  It is now known that JAK2V617F mutations are present in 90% of patients with polycythemia vera (PV), 60% of patients with essential thrombocytosis (ET) and 50% of patients with myelofibrosis (MF).  Despite the high prevalence of JAK2V617F mutations in these three myeloid malignancies, several questions remain.  For example, how does one mutation contribute to the pathogenesis of three clin. distinct diseases, and how do some patients develop these diseases in the absence of a JAK2V617F mutation Single nucleotide polymorphisms at various loci and somatic mutations, such as those in MPLW515L/K, TET2 and in exon 12 of JAK2, may also contribute to the pathogenesis of these MPNs.  There are likely addnl. germline and somatic genetic factors important to the MPN phenotype.  Addnl. studies of large MPN and control cohorts with new techniques will help identify these factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYBRiT16nHFLVg90H21EOLACvtfcHk0ljpKVvvn7TcMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFagsbzJ&md5=5d3977a29c4a78be41201ca3a952c75c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.beha.2009.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.beha.2009.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26atitle%3DMechanisms%2520of%2520mutations%2520in%2520myeloproliferative%2520neoplasms%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Haematol.%26date%3D2009%26volume%3D22%26spage%3D489%26epage%3D494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadleigh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B. J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wlodarsaka, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelsperger, J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercher, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenberghe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">387</span><span class="NLM_x">–</span> <span class="NLM_lpage">397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2Fj.ccr.2005.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=15837627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFSku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=387-397&author=R.+L.+Levineauthor=M.+Wadleighauthor=J.+Coolsauthor=B.+L.+Ebertauthor=G.+Wernigauthor=B.+J.+P.+Huntlyauthor=T.+J.+Boggonauthor=I.+Wlodarsakaauthor=J.+J.+Clarkauthor=S.+Mooreauthor=J+Adelspergerauthor=S.+Kooauthor=J.+C.+Leeauthor=S.+Gabrielauthor=T.+Mercherauthor=A.+D%E2%80%99Andreaauthor=S.+Frohlingauthor=K.+Dohnerauthor=P.+Marynenauthor=P.+Vandenbergheauthor=R.+A.+Mesaauthor=A.+Tefferiauthor=J.+D.+Griffinauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=M.+Meyersonauthor=T.+R.+Golubauthor=S.+J.+Leeauthor=D.+G.+Gilliland&title=Activating+mutation+in+the+tyrosine+kinase+JAK2+in+polycythemia+vera%2C+essential+thrombocythemia%2C+and+myeloid+metaplasia+with+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</span></div><div class="casAuthors">Levine, Ross L.; Wadleigh, Martha; Cools, Jan; Ebert, Benjamin L.; Wernig, Gerlinde; Huntly, Brian J. P.; Boggon, Titus J.; Wlodarska, Iwona; Clark, Jennifer J.; Moore, Sandra; Adelsperger, Jennifer; Koo, Sumin; Lee, Jeffrey C.; Gabriel, Stacey; Mercher, Thomas; D'Andrea, Alan; Froehling, Stefan; Doehner, Konstanze; Marynen, Peter; Vandenberghe, Peter; Mesa, Ruben A.; Tefferi, Ayalew; Griffin, James D.; Eck, Michael J.; Sellers, William R.; Meyerson, Matthew; Golub, Todd R.; Lee, Stephanie J.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">387-397</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Polycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibrosis (MMM) are clonal disorders arising from hematopoietic progenitors.  An internet-based protocol was used to collect clin. information and biol. specimens from patients with these diseases.  High-throughput DNA re-sequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations.  Mol. and cytogenetic analyses demonstrated that homozygous mutations were due to duplication of the mutant allele.  JAK2V617F was also identified in granulocyte DNA samples from 37 of 115 ET and 16 of 46 MMM patients, but was not obsd. in 269 normal individuals.  In vitro anal. demonstrated that JAK2V617F is a constitutively active tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXJNzUFm3Q3bVg90H21EOLACvtfcHk0lgxsGu3Pm8ORg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFSku7o%253D&md5=2a3e893867b114e8749cd6f5e55990b7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DWadleigh%26aufirst%3DM.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DHuntly%26aufirst%3DB.%2BJ.%2BP.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DWlodarsaka%26aufirst%3DI.%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DAdelsperger%26aufirst%3DJ%26aulast%3DKoo%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DMercher%26aufirst%3DT.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DA.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DActivating%2520mutation%2520in%2520the%2520tyrosine%2520kinase%2520JAK2%2520in%2520polycythemia%2520vera%252C%2520essential%2520thrombocythemia%252C%2520and%2520myeloid%2520metaplasia%2520with%2520myelofibrosis%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D387%26epage%3D397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Baxter, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">East, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fourouclas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassiliou, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bench, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erber, W. N.</span><span> </span><span class="NLM_article-title">Green, A. R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1054</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=1054-1061&author=E.+J.+Baxterauthor=L.+M.+Scottauthor=P.+J.+Campbellauthor=C.+Eastauthor=N.+Fourouclasauthor=S.+Swantonauthor=G.+S.+Vassiliouauthor=A.+J.+Benchauthor=E.+M.+Boydauthor=N.+Curtinauthor=M.+A.+Scottauthor=W.+N.+Erber&title=Green%2C+A.+R.+Acquired+mutation+of+the+tyrosine+kinase+JAK2+in+human+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaxter%26aufirst%3DE.%2BJ.%26aulast%3DScott%26aufirst%3DL.%2BM.%26aulast%3DCampbell%26aufirst%3DP.%2BJ.%26aulast%3DEast%26aufirst%3DC.%26aulast%3DFourouclas%26aufirst%3DN.%26aulast%3DSwanton%26aufirst%3DS.%26aulast%3DVassiliou%26aufirst%3DG.%2BS.%26aulast%3DBench%26aufirst%3DA.%2BJ.%26aulast%3DBoyd%26aufirst%3DE.%2BM.%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DScott%26aufirst%3DM.%2BA.%26aulast%3DErber%26aufirst%3DW.%2BN.%26atitle%3DGreen%252C%2520A.%2520R.%2520Acquired%2520mutation%2520of%2520the%2520tyrosine%2520kinase%2520JAK2%2520in%2520human%2520myeloproliferative%2520disorders%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D1054%26epage%3D1061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">James, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Couédic, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staerk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delhommeau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacout, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garçon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raslova, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennacaur-Griscelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villeval, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Constantinescu, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadevall, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainchenker, W.</span><span> </span><span class="NLM_article-title">A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">1144</span><span class="NLM_x">–</span> <span class="NLM_lpage">1148</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=1144-1148&author=C.+Jamesauthor=V.+Ugoauthor=J.+P.+Le+Cou%C3%A9dicauthor=J.+Staerkauthor=F.+Delhommeauauthor=C.+Lacoutauthor=L.+Gar%C3%A7onauthor=H.+Raslovaauthor=R.+Bergerauthor=A.+Bennacaur-Griscelliauthor=J.+L.+Villevalauthor=S.+N.+Constantinescuauthor=N.+Casadevallauthor=W.+Vainchenker&title=A+unique+clonal+JAK2+mutation+leading+to+constitutive+signaling+causes+polycythemia+vera"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DC.%26aulast%3DUgo%26aufirst%3DV.%26aulast%3DLe%2BCou%25C3%25A9dic%26aufirst%3DJ.%2BP.%26aulast%3DStaerk%26aufirst%3DJ.%26aulast%3DDelhommeau%26aufirst%3DF.%26aulast%3DLacout%26aufirst%3DC.%26aulast%3DGar%25C3%25A7on%26aufirst%3DL.%26aulast%3DRaslova%26aufirst%3DH.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBennacaur-Griscelli%26aufirst%3DA.%26aulast%3DVilleval%26aufirst%3DJ.%2BL.%26aulast%3DConstantinescu%26aufirst%3DS.%2BN.%26aulast%3DCasadevall%26aufirst%3DN.%26aulast%3DVainchenker%26aufirst%3DW.%26atitle%3DA%2520unique%2520clonal%2520JAK2%2520mutation%2520leading%2520to%2520constitutive%2520signaling%2520causes%2520polycythemia%2520vera%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D1144%26epage%3D1148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title"><i>JAK</i> and <i>MPL</i> mutations in myeloid malignancies</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">388</span><span class="NLM_x">–</span> <span class="NLM_lpage">397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1080%2F10428190801895360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=18297515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXit1CmtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=388-397&author=A.+Tefferi&title=JAK+and+MPL+mutations+in+myeloid+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">JAK and MPL mutations in myeloid malignancies</span></div><div class="casAuthors">Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">388-397</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The Janus family of non-receptor tyrosine kinases (JAK1, JAK2, JAK3 and tyrosine kinase 2) transduces signals downstream of type I and II cytokine receptors via signal transducers and activators of transcription (STATs).  JAK3 is important in lymphoid and JAK2 in myeloid cell proliferation and differentiation.  The thrombopoietin receptor MPL is one of several JAK2 cognate receptors and is essential for myelopoiesis in general and megakaryopoiesis in particular.  Germline loss-of-function (LOF) JAK3 and MPL mutations cause severe combined immunodeficiency and congenital amegakaryocytic thrombocytopenia, resp.  Germline gain-of-function (GOF) MPL mutation (MPLS505N) causes familial thrombocytosis.  Somatic JAK3 (e.g. JAK3A572V, JAK3V722I, JAK3P132T) and fusion JAK2 (e.g. ETV6-JAK2, PCM1-JAK2, BCR-JAK2) mutations have resp. been described in acute megakaryocytic leukemia and acute leukemia/chronic myeloid malignancies.  However, current attention is focused on JAK2 (e.g. JAK2V617F, JAK2 exon 12 mutations) and MPL (e.g. MPLW515L/K/S, MPLS505N) mutations assocd. with myeloproliferative neoplasms (MPNs).  A JAK2 mutation, primarily JAK2V617F, is invariably assocd. with polycythemia vera (PV).  The latter mutation also occurs in the majority of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF).  MPL mutational frequency in MPNs is substantially less (<10%).  In general, despite a certain degree of genotype - phenotype correlations, the prognostic relevance of harbouring one of these mutations, or their allele burden when present, remains dubious.  Regardless, based on the logical assumption that amplified JAK-STAT signalling is central to the pathogenesis of PV, ET and PMF, several anti-JAK2 tyrosine kinase inhibitors have been developed and are currently being tested in humans with these disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqS8-lmJ2SY7Vg90H21EOLACvtfcHk0ljSDmjLkh3Nkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXit1CmtL8%253D&md5=fd37abba8a06abca87afae8bd478dfb0</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1080%2F10428190801895360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190801895360%26sid%3Dliteratum%253Aachs%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DJAK%2520and%2520MPL%2520mutations%2520in%2520myeloid%2520malignancies%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2008%26volume%3D49%26spage%3D388%26epage%3D397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Gangat, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caramazza, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaidya, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Begna, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwager, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervantes, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passamonti, F.</span><span> </span><span class="NLM_article-title">DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">2446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2010&pages=2446&author=N.+Gangatauthor=D.+Caramazzaauthor=R.+Vaidyaauthor=G.+Georgeauthor=K.+Begnaauthor=S.+Schwagerauthor=D.+Van+Dykeauthor=C.+Hansonauthor=W.+Wuauthor=A.+Pardananiauthor=F.+Cervantesauthor=F.+Passamonti&title=DIPSS+plus%3A+A+refined+dynamic+international+prognostic+scoring+system+for+primary+myelofibrosis+that+incorporates+prognostic+information+from+karyotype%2C+platelet+count%2C+and+transfusion+status"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangat%26aufirst%3DN.%26aulast%3DCaramazza%26aufirst%3DD.%26aulast%3DVaidya%26aufirst%3DR.%26aulast%3DGeorge%26aufirst%3DG.%26aulast%3DBegna%26aufirst%3DK.%26aulast%3DSchwager%26aufirst%3DS.%26aulast%3DVan%2BDyke%26aufirst%3DD.%26aulast%3DHanson%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DPassamonti%26aufirst%3DF.%26atitle%3DDIPSS%2520plus%253A%2520A%2520refined%2520dynamic%2520international%2520prognostic%2520scoring%2520system%2520for%2520primary%2520myelofibrosis%2520that%2520incorporates%2520prognostic%2520information%2520from%2520karyotype%252C%2520platelet%2520count%252C%2520and%2520transfusion%2520status%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D32%26spage%3D2446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Purandare, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorenzi, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span> </span><span class="NLM_article-title">Janus kinase 2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasms (MPN)</span> <span class="citation_source-journal">Ann. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2FS0065-7743%2810%2945013-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=210-227&author=A.+V.+Purandareauthor=M.+V.+Lorenziauthor=L.+J.+Lombardo&title=Janus+kinase+2+%28JAK2%29+inhibitors+for+the+treatment+of+myeloproliferative+neoplasms+%28MPN%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2810%2945013-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252810%252945013-7%26sid%3Dliteratum%253Aachs%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26atitle%3DJanus%2520kinase%25202%2520%2528JAK2%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%2520%2528MPN%2529%26jtitle%3DAnn.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D210%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes-Franco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson-Viitanen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis <i>N</i></span> <span class="citation_source-journal">Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis+N"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0ljSDmjLkh3Nkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%2520N%26jtitle%3DEngl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">Therapeutic potential of JAK2 inhibitors</span> <span class="citation_source-journal">Hematol. Am. Soc. Hematol. Educ. Prog.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span><span class="NLM_x">–</span> <span class="NLM_lpage">642</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1182%2Fasheducation-2009.1.636" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=20008249" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=636-642&author=S.+Verstovsek&title=Therapeutic+potential+of+JAK2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1182%2Fasheducation-2009.1.636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fasheducation-2009.1.636%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DTherapeutic%2520potential%2520of%2520JAK2%2520inhibitors%26jtitle%3DHematol.%2520Am.%2520Soc.%2520Hematol.%2520Educ.%2520Prog.%26date%3D2009%26spage%3D636%26epage%3D642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Santos, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">JAK2 inhibitors: What’s the true therapeutic potential?</span> <span class="citation_source-journal">Blood Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2Fj.blre.2010.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=21095048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitFKjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=53-63&author=F.+P.+Santosauthor=S.+Verstovsek&title=JAK2+inhibitors%3A+What%E2%80%99s+the+true+therapeutic+potential%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2 inhibitors: What's the true therapeutic potential?</span></div><div class="casAuthors">Santos, Fabio P. S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">53-63</span>CODEN:
                <span class="NLM_cas:coden">BLOREB</span>;
        ISSN:<span class="NLM_cas:issn">0268-960X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Physicians treating patients with the classic Philadelphia-neg. myeloproliferative neoplasms (Ph-neg. MPNs) (polycythemia vera [PV], essential thrombocythemia [ET] and primary myelofibrosis [PMF]) traditionally had few therapeutic drugs available.  Spurred by the discovery of activating mutation of the JAK2 tyrosine kinase (JAK2 V617F mutation) in patients with Ph-neg. MPNs several years ago, several JAK2 inhibitors were synthesized and are currently undergoing clin. trials in patients with PMF, PV and ET.  Initial results from these studies have shown that these drugs can markedly reduce spleen size and alleviate constitutional symptoms, increase wt. and improve exercise capacity in MF patients, thus improve quality of their life, which is significant clin. benefit.  In ET and PV JAK2 inhibitor therapy may efficiently control blood cell count, as well as improve splenomegaly and control disease related symptoms.  JAK2 inhibitors are a novel class of agents with promising results for treating patients with MF, PV and ET.  In this article we will review the current evidence regarding the role of JAK2 mutations in the pathogenesis of Ph-neg. MPNs and summarize results from the most recent clin. trials with JAK2 inhibitors in these disorders.  JAK2 inhibitors are a novel class of agents with promising results for treating patients with MF, PV and ET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjZb8q4WeXPbVg90H21EOLACvtfcHk0lga4EJKZAGPEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitFKjsbw%253D&md5=5e99d696b87a7523af5d1fb7c540f386</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.blre.2010.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.blre.2010.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DF.%2BP.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DJAK2%2520inhibitors%253A%2520What%25E2%2580%2599s%2520the%2520true%2520therapeutic%2520potential%253F%26jtitle%3DBlood%2520Rev.%26date%3D2011%26volume%3D25%26spage%3D53%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Verstovsek, S.; Odenike, O.; Scott, B.; Estrov, Z.; Cortes, J.; Thomas, D. A.; Wood, J.; Ethirajulu, K.; Lowe, A.; Zhu, H. J.; Kantarjian, H.; Deeg, H. J.</span><span> </span><span class="NLM_article-title">Phase I dose escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis</span>.  <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span>, Abstr.  <span class="NLM_fpage">3905</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=3905&author=S.+Verstovsek&author=O.+Odenike&author=B.+Scott&author=Z.+Estrov&author=J.+Cortes&author=D.+A.+Thomas&author=J.+Wood&author=K.+Ethirajulu&author=A.+Lowe&author=H.+J.+Zhu&author=H.+Kantarjian&author=H.+J.+Deeg&title=Phase+I+dose+escalation+trial+of+SB1518%2C+a+novel+JAK2%2FFLT3+inhibitor%2C+in+acute+and+chronic+myeloid+diseases%2C+including+primary+or+post-essential+thrombocythemia%2Fpolycythemia+vera+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPhase%2520I%2520dose%2520escalation%2520trial%2520of%2520SB1518%252C%2520a%2520novel%2520JAK2%252FFLT3%2520inhibitor%252C%2520in%2520acute%2520and%2520chronic%2520myeloid%2520diseases%252C%2520including%2520primary%2520or%2520post-essential%2520thrombocythemia%252Fpolycythemia%2520vera%2520myelofibrosis%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D3905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Verstovsek, S.; Deeg, H. J.; Odenike, O.; Zhu, H. J.; Kantarjian, H.; Estrov, Z.; Scott, B.; Cortes, J.; Thomas, D. A.</span><span> </span><span class="NLM_article-title">Phase 1/2 study of SB1518, a novel JAK2/FLT3 inhibitor, in the treatment of primary myelofibrosis</span>.  <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span>, Abstr.  <span class="NLM_fpage">3082</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=3082&author=S.+Verstovsek&author=H.+J.+Deeg&author=O.+Odenike&author=H.+J.+Zhu&author=H.+Kantarjian&author=Z.+Estrov&author=B.+Scott&author=J.+Cortes&author=D.+A.+Thomas&title=Phase+1%2F2+study+of+SB1518%2C+a+novel+JAK2%2FFLT3+inhibitor%2C+in+the+treatment+of+primary+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPhase%25201%252F2%2520study%2520of%2520SB1518%252C%2520a%2520novel%2520JAK2%252FFLT3%2520inhibitor%252C%2520in%2520the%2520treatment%2520of%2520primary%2520myelofibrosis%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D3082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Blanchard, S.; Lee, A. C.-H.; Nagaraj, H. K.-M.; Poulsen, A.; Sun, E. T.; Tan, E. Y.-L.; William, A. D.</span><span> </span><span class="NLM_article-title">Oxygen linked pyrimidine derivavtives</span>. WO 2007/058627 A,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+Blanchard&author=A.+C.-H.+Lee&author=H.+K.-M.+Nagaraj&author=A.+Poulsen&author=E.+T.+Sun&author=E.+Y.-L.+Tan&author=A.+D.+William&title=Oxygen+linked+pyrimidine+derivavtives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlanchard%26aufirst%3DS.%26atitle%3DOxygen%2520linked%2520pyrimidine%2520derivavtives%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Weniger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melzner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menz, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wegener, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bucur, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattfeldt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, T. F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moller, P.</span><span> </span><span class="NLM_article-title">Mutations of the tumor suppressor gene <i>SOCS-1</i> in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2679</span><span class="NLM_x">–</span> <span class="NLM_lpage">2684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=2679-2684&author=M.+A.+Wenigerauthor=I.+Melznerauthor=C.+K.+Menzauthor=S.+Wegenerauthor=A.+J.+Bucurauthor=K.+Dorschauthor=T.+Mattfeldtauthor=T.+F.+E.+Barthauthor=P.+Moller&title=Mutations+of+the+tumor+suppressor+gene+SOCS-1+in+classical+Hodgkin+lymphoma+are+frequent+and+associated+with+nuclear+phospho-STAT5+accumulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeniger%26aufirst%3DM.%2BA.%26aulast%3DMelzner%26aufirst%3DI.%26aulast%3DMenz%26aufirst%3DC.%2BK.%26aulast%3DWegener%26aufirst%3DS.%26aulast%3DBucur%26aufirst%3DA.%2BJ.%26aulast%3DDorsch%26aufirst%3DK.%26aulast%3DMattfeldt%26aufirst%3DT.%26aulast%3DBarth%26aufirst%3DT.%2BF.%2BE.%26aulast%3DMoller%26aufirst%3DP.%26atitle%3DMutations%2520of%2520the%2520tumor%2520suppressor%2520gene%2520SOCS-1%2520in%2520classical%2520Hodgkin%2520lymphoma%2520are%2520frequent%2520and%2520associated%2520with%2520nuclear%2520phospho-STAT5%2520accumulation%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D2679%26epage%3D2684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Navarro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pons, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Codony, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montserrat, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monzo, M.</span><span> </span><span class="NLM_article-title">Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">2945</span><span class="NLM_x">–</span> <span class="NLM_lpage">2951</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2945-2951&author=A.+Navarroauthor=T.+Diazauthor=A.+Martinezauthor=A.+Gayaauthor=A.+Ponsauthor=B.+Gelauthor=C.+Codonyauthor=G.+Ferrerauthor=C.+Martinezauthor=E.+Montserratauthor=M.+Monzo&title=Regulation+of+JAK2+by+miR-135a%3A+prognostic+impact+in+classic+Hodgkin+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DT.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DGaya%26aufirst%3DA.%26aulast%3DPons%26aufirst%3DA.%26aulast%3DGel%26aufirst%3DB.%26aulast%3DCodony%26aufirst%3DC.%26aulast%3DFerrer%26aufirst%3DG.%26aulast%3DMartinez%26aufirst%3DC.%26aulast%3DMontserrat%26aufirst%3DE.%26aulast%3DMonzo%26aufirst%3DM.%26atitle%3DRegulation%2520of%2520JAK2%2520by%2520miR-135a%253A%2520prognostic%2520impact%2520in%2520classic%2520Hodgkin%2520lymphoma%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2945%26epage%3D2951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Raia, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schilling, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böhm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahn, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowarsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sticht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saile, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Möller, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gretz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theis, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, W.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klingmüller, U.</span><span> </span><span class="NLM_article-title">Dynamic mathematical modeling of IL13-induced signaling in hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=693-704&author=V.+Raiaauthor=M.+Schillingauthor=M.+B%C3%B6hmauthor=B.+Hahnauthor=A.+Kowarschauthor=A.+Raueauthor=C.+Stichtauthor=S.+Bohlauthor=M.+Saileauthor=P.+M%C3%B6llerauthor=N.+Gretzauthor=J.+Timmerauthor=F.+Theisauthor=W.-D.+Lehmannauthor=P.+Lichterauthor=U.+Klingm%C3%BCller&title=Dynamic+mathematical+modeling+of+IL13-induced+signaling+in+hodgkin+and+primary+mediastinal+B-cell+lymphoma+allows+prediction+of+therapeutic+targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaia%26aufirst%3DV.%26aulast%3DSchilling%26aufirst%3DM.%26aulast%3DB%25C3%25B6hm%26aufirst%3DM.%26aulast%3DHahn%26aufirst%3DB.%26aulast%3DKowarsch%26aufirst%3DA.%26aulast%3DRaue%26aufirst%3DA.%26aulast%3DSticht%26aufirst%3DC.%26aulast%3DBohl%26aufirst%3DS.%26aulast%3DSaile%26aufirst%3DM.%26aulast%3DM%25C3%25B6ller%26aufirst%3DP.%26aulast%3DGretz%26aufirst%3DN.%26aulast%3DTimmer%26aufirst%3DJ.%26aulast%3DTheis%26aufirst%3DF.%26aulast%3DLehmann%26aufirst%3DW.-D.%26aulast%3DLichter%26aufirst%3DP.%26aulast%3DKlingm%25C3%25BCller%26aufirst%3DU.%26atitle%3DDynamic%2520mathematical%2520modeling%2520of%2520IL13-induced%2520signaling%2520in%2520hodgkin%2520and%2520primary%2520mediastinal%2520B-cell%2520lymphoma%2520allows%2520prediction%2520of%2520therapeutic%2520targets%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D693%26epage%3D704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Hart, S.; Goh, K. C.; Novotny-Diermayr, V.; Hu, C. Y.; Hentze, H.; Tan, Y. C.; Madan, B.; Amalini, C.; Loh, Y. K.; Ong, L. C.; William, A.; Lee, A.; Poulsen, A.; Jayaraman, R.; Ethirajulu, K.; Dymock, B.; Wood, J.</span><span> </span><span class="NLM_article-title">SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</span>. Leukemia<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">, </span>not supplied. </span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Hart&author=K.+C.+Goh&author=V.+Novotny-Diermayr&author=C.+Y.+Hu&author=H.+Hentze&author=Y.+C.+Tan&author=B.+Madan&author=C.+Amalini&author=Y.+K.+Loh&author=L.+C.+Ong&author=A.+William&author=A.+Lee&author=A.+Poulsen&author=R.+Jayaraman&author=K.+Ethirajulu&author=B.+Dymock&author=J.+Wood&title=SB1518%2C+a+novel+macrocyclic+pyrimidine-based+JAK2+inhibitor+for+the+treatment+of+myeloid+and+lymphoid+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26atitle%3DSB1518%252C%2520a%2520novel%2520macrocyclic%2520pyrimidine-based%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloid%2520and%2520lymphoid%2520malignancies%26jtitle%3DLeukemia%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favata, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi., J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeleswaram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">184</span><span class="NLM_x">, </span> <span class="NLM_fpage">5298</span><span class="NLM_x">–</span> <span class="NLM_lpage">307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shi.author=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0lisFe2C8GXoWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi.%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Mesa, R. A.</span><span> </span><span class="NLM_article-title">Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis</span> <span class="citation_source-journal">IDrugs.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">394</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=20506062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1yltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=394-403&author=R.+A.+Mesa&title=Ruxolitinib%2C+a+selective+JAK1+and+JAK2+inhibitor+for+the+treatment+of+myeloproliferative+neoplasms+and+psoriasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis</span></div><div class="casAuthors">Mesa, Ruben A.</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-403</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and JAK2 of the JAK-STAT signaling pathway, being developed by Incyte Corp and Novartis AG.  Ruxolitinib was initially developed to target the constitutive activation of the JAK-STAT pathway in patients with myeloproliferative neoplasms (MPNs).  Meaningful redns. in spleen size and constitutional symptoms have been noted in patients with myelofibrosis (both primary and post-essential thrombocythemia/polycythemia vera).  Data from a phase I/II clin. trial led to ongoing registration trials in the US and Europe.  Toxicity (primarily decreased erythropoiesis and thrombocytopoiesis) has been managed by close control of dosing.  The inhibition of inflammatory cytokine signaling through JAK1 inhibition has led to intriguing results in patients with rheumatoid arthritis and psoriasis (using a topical cream formulation).  Ruxolitinib is a well tolerated, first-in-class JAK2 inhibitor with various potential clin. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5yUMfeRYwE7Vg90H21EOLACvtfcHk0lhYtaCkcmUKCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1yltr0%253D&md5=9f89b13c71527c112b797375c93ccbff</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26atitle%3DRuxolitinib%252C%2520a%2520selective%2520JAK1%2520and%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%2520and%2520psoriasis%26jtitle%3DIDrugs.%26date%3D2010%26volume%3D13%26spage%3D394%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Nosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Deursen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripp, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierfelder., W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witthuhn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMickle, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosveld, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">Defective lymphoid development in mice lacking Jak3</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">800</span><span class="NLM_x">–</span> <span class="NLM_lpage">802</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=800-802&author=T.+Nosakaauthor=J.+M.+van+Deursenauthor=R.+A.+Trippauthor=W.+E.+Thierfelder.author=B.+A.+Witthuhnauthor=A.+P.+McMickleauthor=P.+C.+Dohertyauthor=G.+C.+Grosveldauthor=J.+N.+Ihle&title=Defective+lymphoid+development+in+mice+lacking+Jak3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNosaka%26aufirst%3DT.%26aulast%3Dvan%2BDeursen%26aufirst%3DJ.%2BM.%26aulast%3DTripp%26aufirst%3DR.%2BA.%26aulast%3DThierfelder.%26aufirst%3DW.%2BE.%26aulast%3DWitthuhn%26aufirst%3DB.%2BA.%26aulast%3DMcMickle%26aufirst%3DA.%2BP.%26aulast%3DDoherty%26aufirst%3DP.%2BC.%26aulast%3DGrosveld%26aufirst%3DG.%2BC.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DDefective%2520lymphoid%2520development%2520in%2520mice%2520lacking%2520Jak3%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D800%26epage%3D802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors</span> <span class="citation_source-journal">Best Prac. Res. Clin. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2FS1521-6926%2803%2900063-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=12935959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVCgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2003&pages=409-417&author=D.+G.+Gilliland&title=FLT3-activating+mutations+in+acute+promyelocytic+leukaemia%3A+a+rationale+for+risk-adapted+therapy+with+FLT3+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors</span></div><div class="casAuthors">Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Haematology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-417</span>CODEN:
                <span class="NLM_cas:coden">BPRCA5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Our understanding of the genetic basis of acute myeloid leukemias has been enhanced through cloning of recurring chromosomal translocation breakpoints.  However, the remarkable observation, more than a decade ago, that all-trans retinoic acid (ATRA) induced remission in patients with t(15;17) acute promyelocytic leukemia (APL) was a driving force in the subsequent cloning and characterization of the PML-RARα fusion that is causally implicated in the pathogenesis of this disease.  Major improvements in treatment and outcome of APL patients have been made since that time by incorporating ATRA in conventional chemotherapy but 30% of APL patients still succumb to complications of their disease or their therapy.  Recent information that the hematopoietic receptor tyrosine kinase FLT3 is mutated in about 30% of APL patients suggests strategies for further improving treatment and outcome in this subset of APL patients using small-mol. inhibitors of FLT3.  The role of FLT3 mutations in APL and other AML is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo4Lxfsmnh9rVg90H21EOLACvtfcHk0lgi8dhgpOuXLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVCgu7s%253D&md5=f7b4d39e56a475225ab3fb7cb09e082b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS1521-6926%2803%2900063-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1521-6926%252803%252900063-X%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DFLT3-activating%2520mutations%2520in%2520acute%2520promyelocytic%2520leukaemia%253A%2520a%2520rationale%2520for%2520risk-adapted%2520therapy%2520with%2520FLT3%2520inhibitors%26jtitle%3DBest%2520Prac.%2520Res.%2520Clin.%2520Haematol.%26date%3D2003%26volume%3D16%26spage%3D409%26epage%3D417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Naoe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span> </span><span class="NLM_article-title">Oncogenic protein kinases: normal and oncogenic FLT3</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2932</span><span class="NLM_x">–</span> <span class="NLM_lpage">2938</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1007%2Fs00018-004-4274-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=15583855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXot1agtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2004&pages=2932-2938&author=T.+Naoeauthor=H.+Kiyoi&title=Oncogenic+protein+kinases%3A+normal+and+oncogenic+FLT3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Normal and oncogenic FLT3</span></div><div class="casAuthors">Naoe, T.; Kiyoi, H.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2932-2938</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  FLT3, a member of the class III receptor tyrosine kinases (RTKs), is preferentially expressed on the cell surface of hematopoietic progenitors, and the ligand of FLT3 (FL) is expressed as a membrane-bound or sol. form by bone marrow stroma cells.  It has been disclosed that FL-FLT3 interaction plays an important role in the maintenance, proliferation and differentiation of hematopoiesis.  FLT3 is also expressed in a high proportion of acute myeloid leukemia (AML) and B-lineage acute lymphoblastic leukemia cells.  Activating mutations of FLT3 are the most frequent genetic lesions in AML, and AML patients with FLT3 mutations have a worse prognosis than those with normal FLT3.  Exploring the mechanism by which FLT3 mutations cause autoactivation and uncontrolled signaling might lead to a better understanding of how FLT3 becomes oncogenic and provide insights for the development of new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojXMnqCiA_ZrVg90H21EOLACvtfcHk0lgXC9qvMkgTvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXot1agtg%253D%253D&md5=902c59f9824b5e4d44cbe9372b1e1f35</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs00018-004-4274-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-004-4274-x%26sid%3Dliteratum%253Aachs%26aulast%3DNaoe%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DOncogenic%2520protein%2520kinases%253A%2520normal%2520and%2520oncogenic%2520FLT3%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2004%26volume%3D61%26spage%3D2932%26epage%3D2938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Kottaridis, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linch, D. C.</span><span> </span><span class="NLM_article-title">Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">913</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1080%2F1042819031000067503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=12854887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1yqsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=905-913&author=P.+D.+Kottaridisauthor=R.+E.+Galeauthor=D.+C.+Linch&title=Prognostic+implications+of+the+presence+of+FLT3+mutations+in+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic Implications of the Presence of FLT3 Mutations in Patients with Acute Myeloid Leukemia</span></div><div class="casAuthors">Kottaridis, Panagiotis D.; Gale, Rosemary E.; Linch, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">905-913</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Several studies have shown that mutations in the FLT3 gene are common events in AML, with approx. one third of adult patients harboring either an internal tandem duplication in the juxtramembrane domain or a D835 mutation in the kinase domain.  The majority of studies in pediatric and adult AML have shown that FLT3 mutations are powerful prognostic factors predicting for increased relapse risk and adverse overall survival.  Some reports have suggested that loss of the wild type allele might be assocd. with an even worse prognosis.  Changes in the pattern of FLT3 mutations between disease presentation and relapse restrict their value as a marker of minimal residual disease, and have significant implications for therapy.  The optimum treatment for patients with FLT3 mutations remains unknown and large prospective studies are warranted to evaluate the efficacy of various treatment modalities such as bone marrow transplantation and targeted therapy with tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQTwjPfq-GmbVg90H21EOLACvtfcHk0lh-a8ojN1o_Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1yqsLY%253D&md5=a8e8475402ecf5d5600a0e4ed7a5fdb3</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1080%2F1042819031000067503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1042819031000067503%26sid%3Dliteratum%253Aachs%26aulast%3DKottaridis%26aufirst%3DP.%2BD.%26aulast%3DGale%26aufirst%3DR.%2BE.%26aulast%3DLinch%26aufirst%3DD.%2BC.%26atitle%3DPrognostic%2520implications%2520of%2520the%2520presence%2520of%2520FLT3%2520mutations%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2003%26volume%3D44%26spage%3D905%26epage%3D913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Reilly, J. T.</span><span> </span><span class="NLM_article-title">FLT3 and its role in the pathogenesis of acute myeloid leukaemia</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1080%2F1042819021000040233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=12691136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVCkurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=1-7&author=J.+T.+Reilly&title=FLT3+and+its+role+in+the+pathogenesis+of+acute+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 and its Role in the Pathogenesis of Acute Myeloid Leukaemia</span></div><div class="casAuthors">Reilly, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  FLT3, a tyrosine kinase receptor class III (RTK), and its ligand (FL) are important for normal hematopoiesis and the development of the immune system.  Recently, internal tandem duplications (FLT3 ITDs) in exons 14 and/or 15 that lead to constitutive receptor activation, have been described in 20-25% of adults with acute myeloid leukemia (AML).  The FLT ITD mutations, which are thought to disrupt a repressor sequence in the juxtamembrane region, confer a poor prognosis in AML, esp. in patients under the age of 60 yr.  Furthermore, FLT3 "activating loop" mutations involving exon 20 have been reported in 7 of AML cases, making FLT3 the most commonly mutated gene in AML.  FLT3, therefore, is a potentially important mol. target for AML therapy and already phase I clin. trials have been initiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-7XEr7cYqRrVg90H21EOLACvtfcHk0lhL3-2bDfS0iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVCkurw%253D&md5=4cd59dcba4c00464b5a06bf1cc7196cf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1080%2F1042819021000040233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1042819021000040233%26sid%3Dliteratum%253Aachs%26aulast%3DReilly%26aufirst%3DJ.%2BT.%26atitle%3DFLT3%2520and%2520its%2520role%2520in%2520the%2520pathogenesis%2520of%2520acute%2520myeloid%2520leukaemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2003%26volume%3D44%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Role of FLT3 in leukemia</span> <span class="citation_source-journal">Curr. Opin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">274</span><span class="NLM_x">–</span> <span class="NLM_lpage">281</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1097%2F00062752-200207000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=12042700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A280%3ADC%252BD38zgtFSgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=274-281&author=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Role+of+FLT3+in+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Role of FLT3 in leukemia</span></div><div class="casAuthors">Gilliland D Gary; Griffin James D</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in hematology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">274-81</span>
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    </div><div class="casAbstract">FLT3 is the most frequently mutated gene in cases of acute myelogenous leukemia (AML).  About 30 to 35% of patients have either internal tandem duplications (ITDs) in the juxtamembrane domain or mutations in the activating loop of FLT3.  FLT3 mutations occur in a broad spectrum of FAB subtypes in adult and pediatric AML and are particularly common in acute promyelocytic leukemia (APL).  FLT3 mutations confer a poor prognosis in most retrospective studies.  The consequence of either FLT3-ITD or activating loop mutations, which occur predominantly at position D835, is constitutive activation of the tyrosine kinase; FLT3 mutants confer factor-independent growth to Ba/F3 and 32D cells and activate similar transduction pathways as the native receptor in response to ligand, including the STAT, RAS/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3; kinase (PI3K)/AKT pathways.  Injection of FLT3-ITD transformed cells, such as Ba/F3 or 32D, into syngeneic recipient mice results in a leukemia-like syndrome, and expression in primary murine bone marrow cells in a retroviral transduction assay results in a myeloproliferative disorder.  Mutations that abrogate FLT3 kinase activity result in loss of transforming properties in these assays.  Further, FLT3-selective inhibitors impair transformation of primary AML cells that harbor these mutations, and also inhibit FLT3 transformed hematopoietic cell lines, and leukemias induced by activated FLT3 mutants in murine models.  Collectively, these data indicate that FLT3 may be a viable therapeutic target for treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFpKjX-b8FPb0AGQpJZWpJfW6udTcc2eYo4ZaNf33PtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zgtFSgsQ%253D%253D&md5=5a3742936355291f8a13f6f7eaf35cbf</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1097%2F00062752-200207000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00062752-200207000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DRole%2520of%2520FLT3%2520in%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2002%26volume%3D9%26spage%3D274%26epage%3D281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Younes, A.; Fanale, M. A.; McLaughlin, P.; Copeland, A.; Zhu, J.; Faria, S. C.</span><span> </span><span class="NLM_article-title">Phase 1 study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: Evidence of clinical and biological activity in multiple lymphoma subtypes</span>.  <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span>, Abstr.  <span class="NLM_fpage">2830</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=2830&author=A.+Younes&author=M.+A.+Fanale&author=P.+McLaughlin&author=A.+Copeland&author=J.+Zhu&author=S.+C.+Faria&title=Phase+1+study+of+a+novel+oral+JAK-2+inhibitor+SB1518+in+patients+with+relapsed+lymphoma%3A+Evidence+of+clinical+and+biological+activity+in+multiple+lymphoma+subtypes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26atitle%3DPhase%25201%2520study%2520of%2520a%2520novel%2520oral%2520JAK-2%2520inhibitor%2520SB1518%2520in%2520patients%2520with%2520relapsed%2520lymphoma%253A%2520Evidence%2520of%2520clinical%2520and%2520biological%2520activity%2520in%2520multiple%2520lymphoma%2520subtypes%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D2830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Kiss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sayeski, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keserũ, G. M.</span><span> </span><span class="NLM_article-title">Recent developments on JAK2 inhibitors: a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">495</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1517%2F13543771003639436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=20205617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslalsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=471-495&author=R.+Kissauthor=P.+P.+Sayeskiauthor=G.+M.+Keser%C5%A9&title=Recent+developments+on+JAK2+inhibitors%3A+a+patent+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments on JAK2 inhibitors: a patent review</span></div><div class="casAuthors">Kiss, Robert; Sayeski, Peter P.; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-495</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: JAK2 is one of the most promising targets against neoplastic growth.  A somatic mutation (V617F) resulting in enhanced JAK2 kinase activity can be frequently found in patients with serious myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia and primary myelofibrosis.  Preclin. results strongly support that JAK2 inhibitors could be effectively used in these indications.  Pharmaceutical companies and academic groups have developed a no. of potent JAK2 inhibitors during the last decade.  Tolerability and effectiveness of the most promising compds. are currently being investigated in clin. trials.  Areas covered in this review: In this paper, we aim to give a comprehensive review of the currently available patent literature of JAK2 inhibitors.  What the reader will gain: We tried to collect the published core structures possessing JAK2 inhibitory potency including compds. developed by academic and industrial research groups.  We review the currently available patent literature as well as the key papers contg. addnl. information about the described JAK2 inhibitors.  Clin. status data were collected by searching the Prous Integrity and Pharmaprojects databases.  Take home message: The significant no. of JAK2 inhibitors published and numerous clin. trials involving these compds. suggest that some of them might be approved in the next few years and can serve as novel drugs for the treatment of JAK2-dependent pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJQgQopptoVrVg90H21EOLACvtfcHk0lhl8ekwz5XGkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslalsrY%253D&md5=2531795d8c66c3b7173a0c1a3b2738e1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1517%2F13543771003639436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543771003639436%26sid%3Dliteratum%253Aachs%26aulast%3DKiss%26aufirst%3DR.%26aulast%3DSayeski%26aufirst%3DP.%2BP.%26aulast%3DKeser%25C5%25A9%26aufirst%3DG.%2BM.%26atitle%3DRecent%2520developments%2520on%2520JAK2%2520inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D471%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Grubbs, R. H.</span> <span class="citation_source-book">Handbook of Metathesis</span>; <span class="NLM_publisher-name">Wiley- VCH</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span><span class="NLM_x">; </span>Vols.  <span class="NLM_volume">1–3</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1002%2F9783527619481" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=R.+H.+Grubbs&title=Handbook+of+Metathesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2F9783527619481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527619481%26sid%3Dliteratum%253Aachs%26aulast%3DGrubbs%26aufirst%3DR.%2BH.%26btitle%3DHandbook%2520of%2520Metathesis%26pub%3DWiley-%2520VCH%26date%3D2003%26volume%3D1%25E2%2580%25933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Quincheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manfred, H.</span><span> </span><span class="NLM_article-title">Ring closure methods in the synthesis of macrocyclic natural products</span> <span class="citation_source-journal">Top. Curr. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">161</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=1992&pages=107-176&author=M.+Quinchengauthor=H.+Manfred&title=Ring+closure+methods+in+the+synthesis+of+macrocyclic+natural+products"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuincheng%26aufirst%3DM.%26aulast%3DManfred%26aufirst%3DH.%26atitle%3DRing%2520closure%2520methods%2520in%2520the%2520synthesis%2520of%2520macrocyclic%2520natural%2520products%26jtitle%3DTop.%2520Curr.%2520Chem.%26date%3D1992%26volume%3D161%26spage%3D107%26epage%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Deiters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. F.</span><span> </span><span class="NLM_article-title">Synthesis of oxygen- and nitrogen-containing heterocycles by ring-closing metathesis</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2199</span><span class="NLM_x">–</span> <span class="NLM_lpage">2238</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr0200872" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVSltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=2199-2238&author=A.+Deitersauthor=S.+F.+Martin&title=Synthesis+of+oxygen-+and+nitrogen-containing+heterocycles+by+ring-closing+metathesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of oxygen- and nitrogen-containing heterocycles by ring-closing metathesis</span></div><div class="casAuthors">Deiters, Alexander; Martin, Stephen F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2199-2238</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the synthesis of oxygen- and nitrogen-contg. heterocycles by ring-closing metathesis (RCM).  Applications of olefin and alkyne RCM, enyne RCM, and tandem processes in which these reactions are combined with ring-opening metathesis (ROM) to construct O- and N-heterocycles are presented with a particular emphasis on natural product synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxORod8gOrIrVg90H21EOLACvtfcHk0ljFWK_UIMO_eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVSltb0%253D&md5=93d648a549ce629a402b4849c15c577c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fcr0200872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0200872%26sid%3Dliteratum%253Aachs%26aulast%3DDeiters%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26atitle%3DSynthesis%2520of%2520oxygen-%2520and%2520nitrogen-containing%2520heterocycles%2520by%2520ring-closing%2520metathesis%26jtitle%3DChem.%2520Rev.%26date%3D2004%26volume%3D104%26spage%3D2199%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Tsantrizos, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonneau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goudreau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukolj, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaPlante, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llinàs-Brunet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamarre, D.</span><span> </span><span class="NLM_article-title">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1356</span><span class="NLM_x">–</span> <span class="NLM_lpage">1360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1002%2Fanie.200390347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=1356-1360&author=Y.+S.+Tsantrizosauthor=G.+Bolgerauthor=P.+Bonneauauthor=D.+R.+Cameronauthor=N.+Goudreauauthor=G.+Kukoljauthor=S.+R.+LaPlanteauthor=M.+Llin%C3%A0s-Brunetauthor=H.+Narauthor=D.+Lamarre&title=Macrocyclic+inhibitors+of+the+NS3+protease+as+potential+therapeutic+agents+of+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection</span></div><div class="casAuthors">Tsantrizos, Youla S.; Bolger, Gordon; Bonneau, Pierre; Cameron, Dale R.; Goudreau, Nathalie; Kukolj, George; LaPlante, Steven R.; Llinas-Brunet, Montse; Nar, Herbert; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1356-1360</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel class of selective inhibitors of the hepatitis C virus NS3 protease, an enzyme which is essential for viral replication in vivo, was developed.  The inhibitors are based on the structure-activity relationship between a substrate-based peptidomimetic ligand and the HCV NS3 serine protease.  The designed HCV inhibitor and its satd. analogs are the first inhibitors of the NS3 protease which inhibit HCV RNA replication in the cell-based replicon assay.  In addn., they are orally absorbed and stable to metabolic breakdown.  Thus, these compds. show many of the desirable properties of a druglike archetype and could lead t a clin. useful antiviral agent for the treatment of hepatitis C viral infections in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCij3shP5tmLVg90H21EOLACvtfcHk0lhgNxmYOpm0YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtlygsrc%253D&md5=e0a3c98ee0096bfc3d058bf0b92b81c3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fanie.200390347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200390347%26sid%3Dliteratum%253Aachs%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DMacrocyclic%2520inhibitors%2520of%2520the%2520NS3%2520protease%2520as%2520potential%2520therapeutic%2520agents%2520of%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D1356%26epage%3D1360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Graziani, E. I.</span><span> </span><span class="NLM_article-title">Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs</span> <span class="citation_source-journal">Nat. Prod. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">602</span><span class="NLM_x">–</span> <span class="NLM_lpage">609</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1039%2Fb804602f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=19387497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvValsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2009&pages=602-609&author=E.+I.+Graziani&title=Recent+advances+in+the+chemistry%2C+biosynthesis+and+pharmacology+of+rapamycin+analogs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs</span></div><div class="casAuthors">Graziani, Edmund I.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">602-609</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  In the period 1998 to 2003, a no. of reviews have appeared evaluating the potential of rapamycin and other immunophilin ligands as therapies for cancer, organ transplantation, restenosis prevention, autoimmune disorders, and neurodegenerative diseases.  This review aims to evaluate advances in the field since that time, specifically detailing progress in: (i) the role of rapamycin in inhibiting its principal cellular target, the mammalian target of rapamycin (mTOR) in both of its protein complexes, (ii) understanding the role of specific genes in the mechanism of rapamycin biosynthesis, (iii) the prodn. of novel analogs of rapamycin via precursor-directed biosynthesis, (iv) the enzymol. of the pipecolate incorporating enzyme (RapL) in vitro, and (v) the pharmacol. and mechanistic chem. biol. of rapamycin analog mediated neuroprotection and neuroregeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4t3kBQAAJ67Vg90H21EOLACvtfcHk0liEf0GGwCjndg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvValsrY%253D&md5=5df618a99547a56784d74bac6cbfdaf0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2Fb804602f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb804602f%26sid%3Dliteratum%253Aachs%26aulast%3DGraziani%26aufirst%3DE.%2BI.%26atitle%3DRecent%2520advances%2520in%2520the%2520chemistry%252C%2520biosynthesis%2520and%2520pharmacology%2520of%2520rapamycin%2520analogs%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2009%26volume%3D26%26spage%3D602%26epage%3D609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Driggers, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terret, N. K.</span><span> </span><span class="NLM_article-title">The exploration of macrocycles for drug discovery—an underexploited structural class</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">608</span><span class="NLM_x">–</span> <span class="NLM_lpage">624</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=608-624&author=E.+M.+Driggersauthor=S.+P.+Haleauthor=J.+Leeauthor=N.+K.+Terret&title=The+exploration+of+macrocycles+for+drug+discovery%E2%80%94an+underexploited+structural+class"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDriggers%26aufirst%3DE.%2BM.%26aulast%3DHale%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTerret%26aufirst%3DN.%2BK.%26atitle%3DThe%2520exploration%2520of%2520macrocycles%2520for%2520drug%2520discovery%25E2%2580%2594an%2520underexploited%2520structural%2520class%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D608%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Joshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maikap, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Titirmare, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurjar, M. K.</span><span> </span><span class="NLM_article-title">An improved synthesis of etravirine</span> <span class="citation_source-journal">Org. Proc. Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">657</span><span class="NLM_x">–</span> <span class="NLM_lpage">660</span></span><div class="citationLinks">[<a href="/doi/10.1021/op9003289" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=657-660&author=S.+Joshiauthor=G.+C.+Maikapauthor=S.+Titirmareauthor=A.+Chaudhariauthor=M.+K.+Gurjar&title=An+improved+synthesis+of+etravirine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fop9003289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop9003289%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DMaikap%26aufirst%3DG.%2BC.%26aulast%3DTitirmare%26aufirst%3DS.%26aulast%3DChaudhari%26aufirst%3DA.%26aulast%3DGurjar%26aufirst%3DM.%2BK.%26atitle%3DAn%2520improved%2520synthesis%2520of%2520etravirine%26jtitle%3DOrg.%2520Proc.%2520Res.%2520Dev.%26date%3D2010%26volume%3D14%26spage%3D657%26epage%3D660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Schmidt, B.</span><span> </span><span class="NLM_article-title">Ruthenium-catalyzed cyclizations: more than just olefin metathesis!</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">4996</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=4996-4999&author=B.+Schmidt&title=Ruthenium-catalyzed+cyclizations%3A+more+than+just+olefin+metathesis%21"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DB.%26atitle%3DRuthenium-catalyzed%2520cyclizations%253A%2520more%2520than%2520just%2520olefin%2520metathesis%2521%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D4996%26epage%3D4999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, S.-L.</span><span> </span><span class="NLM_article-title">Asymmetric construction of polycyclic indoles through olefin cross- metathesis/intramolecular Friedel–Crafts alkylation under sequential catalysis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7428</span><span class="NLM_x">–</span> <span class="NLM_lpage">7431</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=7428-7431&author=Q.+Caiauthor=Z.-A.+Zhaoauthor=S.-L.+You&title=Asymmetric+construction+of+polycyclic+indoles+through+olefin+cross-+metathesis%2Fintramolecular+Friedel%E2%80%93Crafts+alkylation+under+sequential+catalysis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DZ.-A.%26aulast%3DYou%26aufirst%3DS.-L.%26atitle%3DAsymmetric%2520construction%2520of%2520polycyclic%2520indoles%2520through%2520olefin%2520cross-%2520metathesis%252Fintramolecular%2520Friedel%25E2%2580%2593Crafts%2520alkylation%2520under%2520sequential%2520catalysis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2009%26volume%3D48%26spage%3D7428%26epage%3D7431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Suzuki, A.</span><span> </span><span class="NLM_article-title">Synthetic studies via the cross-coupling reaction of organoboron derivatives with organic halides</span> <span class="citation_source-journal">Pure Appl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1991&pages=419-422&author=A.+Suzuki&title=Synthetic+studies+via+the+cross-coupling+reaction+of+organoboron+derivatives+with+organic+halides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DSynthetic%2520studies%2520via%2520the%2520cross-coupling%2520reaction%2520of%2520organoboron%2520derivatives%2520with%2520organic%2520halides%26jtitle%3DPure%2520Appl.%2520Chem.%26date%3D1991%26volume%3D63%26spage%3D419%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Miyaura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, A.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed cross-coupling reactions of organoboron compounds</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">2457</span><span class="NLM_x">–</span> <span class="NLM_lpage">2483</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-catalyzed+cross-coupling+reactions+of+organoboron+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0lgxql6NEfFKRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-catalyzed%2520cross-coupling%2520reactions%2520of%2520organoboron%2520compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26spage%3D2457%26epage%3D2483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Rao, P. S-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senthilkumar, S. P.</span><span> </span><span class="NLM_article-title">A convenient procedure for the synthesis of allyl and benzyl ethers from alcohols and phenols</span> <span class="citation_source-journal">Proc. Indian Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1007%2FBF02704069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmslSjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2001&pages=191-196&author=P.+S-H.+Raoauthor=S.+P.+Senthilkumar&title=A+convenient+procedure+for+the+synthesis+of+allyl+and+benzyl+ethers+from+alcohols+and+phenols"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient procedure for the synthesis of allyl and benzyl ethers from alcohols and phenols</span></div><div class="casAuthors">Rao, H. Surya Prakash; Senthilkumar, S. P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings - Indian Academy of Sciences, Chemical Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-196</span>CODEN:
                <span class="NLM_cas:coden">PIAADM</span>;
        ISSN:<span class="NLM_cas:issn">0253-4134</span>.
    
            (<span class="NLM_cas:orgname">Indian Academy of Sciences</span>)
        </div><div class="casAbstract">Allyl and benzyl ethers of alcs. can be prepd. conveniently and in high yield with allyl and benzyl bromide in the presence of solid potassium hydroxide without use of any solvent.  Phenols can be converted to allyl ethers but are inert to benzylation under above conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2t9aaL_hdt7Vg90H21EOLACvtfcHk0liKnKFSZUt8CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmslSjs7s%253D&md5=6ffb92097143c2371b533e6cfd27de8d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2FBF02704069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02704069%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DP.%2BS-H.%26aulast%3DSenthilkumar%26aufirst%3DS.%2BP.%26atitle%3DA%2520convenient%2520procedure%2520for%2520the%2520synthesis%2520of%2520allyl%2520and%2520benzyl%2520ethers%2520from%2520alcohols%2520and%2520phenols%26jtitle%3DProc.%2520Indian%2520Acad.%2520Sci.%26date%3D2001%26volume%3D113%26spage%3D191%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Koehling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eilbracht, P.</span><span> </span><span class="NLM_article-title">Tandem hydroformylation/Fischer indole synthesis: a novel and convenient approach to indoles from olefins</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3213</span><span class="NLM_x">–</span> <span class="NLM_lpage">3216</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=3213-3216&author=P.+Koehlingauthor=A.+M.+Schmidtauthor=P.+Eilbracht&title=Tandem+hydroformylation%2FFischer+indole+synthesis%3A+a+novel+and+convenient+approach+to+indoles+from+olefins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoehling%26aufirst%3DP.%26aulast%3DSchmidt%26aufirst%3DA.%2BM.%26aulast%3DEilbracht%26aufirst%3DP.%26atitle%3DTandem%2520hydroformylation%252FFischer%2520indole%2520synthesis%253A%2520a%2520novel%2520and%2520convenient%2520approach%2520to%2520indoles%2520from%2520olefins%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D3213%26epage%3D3216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Ramadas, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasan, N.</span><span> </span><span class="NLM_article-title">Iron-ammonium chloride: a convenient and inexpensive reductant</span> <span class="citation_source-journal">Synth. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3189</span><span class="NLM_x">–</span> <span class="NLM_lpage">3195</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1080%2F00397919208021132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1ykt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1992&pages=3189-3195&author=K.+Ramadasauthor=N.+Srinivasan&title=Iron-ammonium+chloride%3A+a+convenient+and+inexpensive+reductant"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Iron-ammonium chloride - a convenient and inexpensive reductant</span></div><div class="casAuthors">Ramadas, Krishnamurthy; Srinivasan, Natarajan</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3189-95</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    </div><div class="casAbstract">The redn. of nitro arom. compds., I (R1 = H, NH2, Me, Cl, R2 = H, NH2, NO2, R3 = H, CH2CN, CH2CO2H, Me, OH, NHAc, Br, Cl, NH2, R4 = NO2), contg. other susceptible groups is reinvestigated to provide a viable economic route from the point of view of quant. transformation, reduced reaction times, and simple work up using iron powder and ammonium chloride soln. in neutral medium.  Thus, using Fe/NH4Cl on I gave I (R4 = NH2) in 67-90% yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD_QX8c0Gcx7Vg90H21EOLACvtfcHk0ljIkS48cUQWbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1ykt7k%253D&md5=7b3830ad2efaf09a30cbff04b89eb32a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F00397919208021132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919208021132%26sid%3Dliteratum%253Aachs%26aulast%3DRamadas%26aufirst%3DK.%26aulast%3DSrinivasan%26aufirst%3DN.%26atitle%3DIron-ammonium%2520chloride%253A%2520a%2520convenient%2520and%2520inexpensive%2520reductant%26jtitle%3DSynth.%2520Commun.%26date%3D1992%26volume%3D22%26spage%3D3189%26epage%3D3195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Hardcastle, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlands, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houghton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parr, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laughton, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trent, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neidle, S.</span><span> </span><span class="NLM_article-title">Rationally designed analogs of tamoxifen with improved calmodulin antagonism</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00002a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=241-248&author=I.+R.+Hardcastleauthor=M.+G.+Rowlandsauthor=J.+Houghtonauthor=I.+B.+Parrauthor=G.+A.+Potterauthor=M.+Jarmanauthor=K.+J.+Edwardsauthor=C.+A.+Laughtonauthor=J.+O.+Trentauthor=S.+Neidle&title=Rationally+designed+analogs+of+tamoxifen+with+improved+calmodulin+antagonism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm00002a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00002a005%26sid%3Dliteratum%253Aachs%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DRowlands%26aufirst%3DM.%2BG.%26aulast%3DHoughton%26aufirst%3DJ.%26aulast%3DParr%26aufirst%3DI.%2BB.%26aulast%3DPotter%26aufirst%3DG.%2BA.%26aulast%3DJarman%26aufirst%3DM.%26aulast%3DEdwards%26aufirst%3DK.%2BJ.%26aulast%3DLaughton%26aufirst%3DC.%2BA.%26aulast%3DTrent%26aufirst%3DJ.%2BO.%26aulast%3DNeidle%26aufirst%3DS.%26atitle%3DRationally%2520designed%2520analogs%2520of%2520tamoxifen%2520with%2520improved%2520calmodulin%2520antagonism%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D241%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Dodge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocksdale, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahey, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. D.</span><span> </span><span class="NLM_article-title">Regioselectivity in the alkaline thiolate deprotection of aryl methyl ethers</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">741</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00108a046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1995&pages=739-741&author=J.+A.+Dodgeauthor=M.+G.+Stocksdaleauthor=K.+J.+Faheyauthor=C.+D.+Jones&title=Regioselectivity+in+the+alkaline+thiolate+deprotection+of+aryl+methyl+ethers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjo00108a046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00108a046%26sid%3Dliteratum%253Aachs%26aulast%3DDodge%26aufirst%3DJ.%2BA.%26aulast%3DStocksdale%26aufirst%3DM.%2BG.%26aulast%3DFahey%26aufirst%3DK.%2BJ.%26aulast%3DJones%26aufirst%3DC.%2BD.%26atitle%3DRegioselectivity%2520in%2520the%2520alkaline%2520thiolate%2520deprotection%2520of%2520aryl%2520methyl%2520ethers%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1995%26volume%3D60%26spage%3D739%26epage%3D741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Niu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumey, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagirath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subrath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eid, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhary, D.</span><span> </span><span class="NLM_article-title">First generation 5-vinyl-3-pyridinecarbonitrile PKCθ inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5829</span><span class="NLM_x">–</span> <span class="NLM_lpage">5832</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5829-5832&author=C.+Niuauthor=D.+H.+Boschelliauthor=L.+N.+Tumeyauthor=N.+Bhagirathauthor=J.+Subrathauthor=J.+Shimauthor=Y.+Wangauthor=B.+Wuauthor=C.+Eidauthor=J.+Leeauthor=X.+Yangauthor=A.+Brennanauthor=D.+Chaudhary&title=First+generation+5-vinyl-3-pyridinecarbonitrile+PKC%CE%B8+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DTumey%26aufirst%3DL.%2BN.%26aulast%3DBhagirath%26aufirst%3DN.%26aulast%3DSubrath%26aufirst%3DJ.%26aulast%3DShim%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DEid%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBrennan%26aufirst%3DA.%26aulast%3DChaudhary%26aufirst%3DD.%26atitle%3DFirst%2520generation%25205-vinyl-3-pyridinecarbonitrile%2520PKC%25CE%25B8%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5829%26epage%3D5832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasho, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1441</span><span class="NLM_x">–</span> <span class="NLM_lpage">1445</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1441-1445&author=A.+Pardananiauthor=T.+Lashoauthor=G.+Smithauthor=C.+J.+Burnsauthor=E+Fantinoauthor=A.+Tefferi&title=CYT387%2C+a+selective+JAK1%2FJAK2+inhibitor%3A+in+vitro+assessment+of+kinase+selectivity+and+preclinical+studies+using+cell+lines+and+primary+cells+from+polycythemia+vera+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DLasho%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DFantino%26aufirst%3DE%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DCYT387%252C%2520a%2520selective%2520JAK1%252FJAK2%2520inhibitor%253A%2520in%2520vitro%2520assessment%2520of%2520kinase%2520selectivity%2520and%2520preclinical%2520studies%2520using%2520cell%2520lines%2520and%2520primary%2520cells%2520from%2520polycythemia%2520vera%2520patients%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D1441%26epage%3D1445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="note"><p class="first last">For latest trials in Myelofibrosis, Advanced Myeloid Malignancies and Advanced Lymphoid Malignancies see <a href="http://clinicaltrials.gov" class="extLink">http://clinicaltrials.gov</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span>Maestro, Ligprep, Macromodel, Glide and QikProp; <span class="NLM_publisher-name">Schrodinger, LLC</span>, <span class="NLM_publisher-loc">New York, NY</span>.<span class="NLM_x"> </span><span class="NLM_year">2011</span>. <a href="http://www.schrodinger.com" class="extLink">http://www.schrodinger.com</a></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maestro%2C+Ligprep%2C+Macromodel%2C+Glide+and+QikProp%3B+Schrodinger%2C+LLC%2C+New+York%2C+NY.+2011.+http%3A%2F%2Fwww.schrodinger.com"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMaestro%252C%2520Ligprep%252C%2520Macromodel%252C%2520Glide%2520and%2520QikProp%26pub%3DSchrodinger%252C%2520LLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Jorgensen, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxwell, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado-Rives, J.</span><span> </span><span class="NLM_article-title">Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">118</span><span class="NLM_x">, </span> <span class="NLM_fpage">11225</span><span class="NLM_x">–</span> <span class="NLM_lpage">11236</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja9621760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADyaK28XmtlOitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=11225-11236&author=W.+L.+Jorgensenauthor=D.+S.+Maxwellauthor=J.+Tirado-Rives&title=Development+and+testing+of+the+OPLS+all-atom+force+field+on+conformational+energetics+and+properties+of+organic+liquids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids</span></div><div class="casAuthors">Jorgensen, William L.; Maxwell, David S.; Tirado-Rives, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">11225-11236</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The parametrization and testing of the OPLS all-atom force field for org. mols. and peptides are described.  Parameters for both torsional and nonbonded energetics have been derived, while the bond stretching and angle bending parameters have been adopted mostly from the AMBER all-atom force field.  The torsional parameters were detd. by fitting to rotational energy profiles obtained from ab initio MO calcns. at the RHF/6-31G*//RHF/6-31G* level for more than 50 org. mols. and ions.  The quality of the fits was high with av. errors for conformational energies of less than 0.2 kcal/mol.  The force-field results for mol. structures are also demonstrated to closely match the ab initio predictions.  The nonbonded parameters were developed in conjunction with Monte Carlo statistical mechanics simulations by computing thermodn. and structural properties for 34 pure org. liqs. including alkanes, alkenes, alcs., ethers, acetals, thiols, sulfides, disulfides, aldehydes, ketones, and amides.  Av. errors in comparison with exptl. data are 2% for heats of vaporization and densities.  The Monte Carlo simulations included sampling all internal and intermol. degrees of freedom.  It is found that such non-polar and monofunctional systems do not show significant condensed-phase effects on internal energies in going from the gas phase to the pure liqs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhGotSev_b1LVg90H21EOLACvtfcHk0ljXAFoCrhh_yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtlOitrs%253D&md5=fef2924a69421881390282aa309ae91b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fja9621760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9621760%26sid%3Dliteratum%253Aachs%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DMaxwell%26aufirst%3DD.%2BS.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26atitle%3DDevelopment%2520and%2520testing%2520of%2520the%2520OPLS%2520all-atom%2520force%2520field%2520on%2520conformational%2520energetics%2520and%2520properties%2520of%2520organic%2520liquids%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26spage%3D11225%26epage%3D11236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Hasel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendrickson, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Still, W. C.</span><span> </span><span class="NLM_article-title">A rapid approximation to the solvent accessible surface areas of atoms</span> <span class="citation_source-journal">Tetrahedron Comput. Method</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2F0898-5529%2888%2990015-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1988&pages=103-116&author=W.+Haselauthor=T.+F.+Hendricksonauthor=W.+C.+Still&title=A+rapid+approximation+to+the+solvent+accessible+surface+areas+of+atoms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A rapid approximation to the solvent-accessible surface areas of atoms</span></div><div class="casAuthors">Hasel, Winnfried; Hendrickson, Thomas F.; Still, W. Clark</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Computer Methodology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-16</span>CODEN:
                <span class="NLM_cas:coden">TCMTE6</span>;
        ISSN:<span class="NLM_cas:issn">0898-5529</span>.
    </div><div class="casAbstract">An anal. expression for approx. at. and mol. van der Waals and solvent accessible surface areas is described.  The treatment is based on the probabilistic method of Wodak and Janin (1980) but with modifications which allow it to be applied to the calcn. of at. surface areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEtlzGPkwT_7Vg90H21EOLACvtfcHk0li_az6h3SMnXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXltFCms7s%253D&md5=98b3e7fab9432dccb1ff22f726d54fbf</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2F0898-5529%2888%2990015-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0898-5529%252888%252990015-2%26sid%3Dliteratum%253Aachs%26aulast%3DHasel%26aufirst%3DW.%26aulast%3DHendrickson%26aufirst%3DT.%2BF.%26aulast%3DStill%26aufirst%3DW.%2BC.%26atitle%3DA%2520rapid%2520approximation%2520to%2520the%2520solvent%2520accessible%2520surface%2520areas%2520of%2520atoms%26jtitle%3DTetrahedron%2520Comput.%2520Method%26date%3D1988%26volume%3D1%26spage%3D103%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Williams, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walden, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn., J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucet, I. S.</span><span> </span><span class="NLM_article-title">Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">387</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2Fj.jmb.2009.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=19361440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2009&pages=219-232&author=N.+K.+Williamsauthor=R.+S.+Bamertauthor=O.+Patelauthor=C.+Wangauthor=P.+M.+Waldenauthor=A.+F.+Wilksauthor=E.+Fantinoauthor=J.+Rossjohn.author=I.+S.+Lucet&title=Dissecting+specificity+in+the+Janus+kinases%3A+the+structures+of+JAK-specific+inhibitors+complexed+to+the+JAK1+and+JAK2+protein+tyrosine+kinase+domains"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains</span></div><div class="casAuthors">Williams, Neal K.; Bamert, Rebecca S.; Patel, Onisha; Wang, Christina; Walden, Patricia M.; Wilks, Andrew F.; Fantino, Emmanuelle; Rossjohn, Jamie; Lucet, Isabelle S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity assocd. with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders.  Whereas the structures of the JAK2 and JAK3 PTK domains have been detd., the structure of the JAK1 PTK domain is unknown.  Here, we report the high-resoln. crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes.  Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1.  As expected, the mode of inhibitor binding in JAK1 was very similar to that obsd. in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site.  Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQDLkMkCgiLbVg90H21EOLACvtfcHk0li_az6h3SMnXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVegtbo%253D&md5=79957755d04323057b5acf7e9d2c56ca</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2009.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2009.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BK.%26aulast%3DBamert%26aufirst%3DR.%2BS.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWalden%26aufirst%3DP.%2BM.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DRossjohn.%26aufirst%3DJ.%26aulast%3DLucet%26aufirst%3DI.%2BS.%26atitle%3DDissecting%2520specificity%2520in%2520the%2520Janus%2520kinases%253A%2520the%2520structures%2520of%2520JAK-specific%2520inhibitors%2520complexed%2520to%2520the%2520JAK1%2520and%2520JAK2%2520protein%2520tyrosine%2520kinase%2520domains%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D387%26spage%3D219%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Lucet, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Styles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bamert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broughton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treutlein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossjohn, J.</span><span> </span><span class="NLM_article-title">The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">176</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=176-183&author=I.+S.+Lucetauthor=E.+Fantinoauthor=M.+Stylesauthor=R.+Bamertauthor=O.+Patelauthor=S.+E.+Broughtonauthor=M.+Walterauthor=C.+J.+Burnsauthor=H.+Treutleinauthor=A.+F.+Wilksauthor=J.+Rossjohn&title=The+structural+basis+of+Janus+kinase+2+inhibition+by+a+potent+and+specific+pan-Janus+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLucet%26aufirst%3DI.%2BS.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DStyles%26aufirst%3DM.%26aulast%3DBamert%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DO.%26aulast%3DBroughton%26aufirst%3DS.%2BE.%26aulast%3DWalter%26aufirst%3DM.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DTreutlein%26aufirst%3DH.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DRossjohn%26aufirst%3DJ.%26atitle%3DThe%2520structural%2520basis%2520of%2520Janus%2520kinase%25202%2520inhibition%2520by%2520a%2520potent%2520and%2520specific%2520pan-Janus%2520kinase%2520inhibitor%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D176%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Crystal structure of the JAK3 kinase domain in complex with a staurosporine analog</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">996</span><span class="NLM_x">–</span> <span class="NLM_lpage">1002</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1182%2Fblood-2005-02-0707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=15831699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVSmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=996-1002&author=T.+J.+Boggonauthor=Y.+Liauthor=P.+W.+Manleyauthor=M.+J.+Eck&title=Crystal+structure+of+the+JAK3+kinase+domain+in+complex+with+a+staurosporine+analog"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog</span></div><div class="casAuthors">Boggon, Titus J.; Li, Yiqun; Manley, Paul W.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">996-1002</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Jak (Janus kinase) family nonreceptor tyrosine kinases are central mediators of cytokine signaling.  The Jak kinases exhibit distinct cytokine receptor assocn. profiles and so transduce different signals.  Jak3 expression is limited to the immune system, where it plays a key role in signal transduction from cytokine receptors contg. the common gamma chain, γc.  Patients unable to signal via γc present with severe combined immunodeficiency (SCID).  The finding that Jak3 mutations result in SCID has made it a target for development of lymphocyte-specific immunosuppressants.  Here, we present the crystal structure of the Jak3 kinase domain in complex with staurosporine analog AFN941.  The kinase domain is in the active conformation, with both activation loop tyrosine residues phosphorylated.  The phosphate group on pTyr981 in the activation loop is in part coordinated by an arginine residue in the regulatory C-helix, suggesting a direct mechanism by which the active position of the C-helix is induced by phosphorylation of the activation loop.  Such a direct coupling has not been previously obsd. in tyrosine kinases and may be unique to Jak kinases.  The crystal structure provides a detailed view of the Jak3 active site and will facilitate computational and structure-directed approaches to development of Jak3-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ-bnI3-sVjLVg90H21EOLACvtfcHk0lhlmFXkdZ31Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVSmsr4%253D&md5=12f87a37a495559c6e34dde019578371</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-02-0707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-02-0707%26sid%3Dliteratum%253Aachs%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520JAK3%2520kinase%2520domain%2520in%2520complex%2520with%2520a%2520staurosporine%2520analog%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D996%26epage%3D1002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Lawrie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M. E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunnah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span> </span><span class="NLM_article-title">Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">796</span><span class="NLM_x">–</span> <span class="NLM_lpage">801</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1997&pages=796-801&author=A.+M.+Lawrieauthor=M.+E.+M.+Nobleauthor=P.+Tunnahauthor=N.+R.+Brownauthor=L.+A.+Johnsonauthor=J.+A.+Endicott&title=Protein+kinase+inhibition+by+staurosporine+revealed+in+details+of+the+molecular+interaction+with+CDK2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLawrie%26aufirst%3DA.%2BM.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26aulast%3DTunnah%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DN.%2BR.%26aulast%3DJohnson%26aufirst%3DL.%2BA.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26atitle%3DProtein%2520kinase%2520inhibition%2520by%2520staurosporine%2520revealed%2520in%2520details%2520of%2520the%2520molecular%2520interaction%2520with%2520CDK2%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D1997%26volume%3D4%26spage%3D796%26epage%3D801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Griffith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faerman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, K.</span><span> </span><span class="NLM_article-title">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+structural+basis+for+autoinhibition+of+FLT3+by+the+juxtamembrane+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0ljhK65goBcdpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520structural%2520basis%2520for%2520autoinhibition%2520of%2520FLT3%2520by%2520the%2520juxtamembrane%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D169%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Berman, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westbrook, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhat, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindyalov, I. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourne, P. E.</span><span> </span><span class="NLM_article-title">The Protein Data Bank</span> <span class="citation_source-journal">Nucleic Acids Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm200326p&amp;key=10.1093%2Fnar%2F28.1.235" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm200326p&amp;key=10592235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm200326p&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=235-242&author=H.+M.+Bermanauthor=J.+Westbrookauthor=Z.+Fengauthor=G.+Gillilandauthor=T.+N.+Bhatauthor=H.+Weissigauthor=I.+N.+Shindyalovauthor=P.+E.+Bourne&title=The+Protein+Data+Bank"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Data Bank</span></div><div class="casAuthors">Berman, Helen M.; Westbrook, John; Feng, Zukang; Gilliland, Gary; Bhat, T. N.; Weissig, Helge; Shindyalov, Ilya N.; Bourne, Philip E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Protein Data Bank (PDB; http://www.rcsb.org/pdb/)is the single worldwide archive of structural data of biol. macromols.  This paper describes the goals of the PDB, the systems in place for data deposition and access, how to obtain further information, and near-term plans for the future development of the resource.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpStGCxT8QzirVg90H21EOLACvtfcHk0ljWKdzO_GE5uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhvVKjt7w%253D&md5=227fb393f754be2be375ab727bfd05dc</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1093%2Fnar%2F28.1.235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252F28.1.235%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DWestbrook%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DGilliland%26aufirst%3DG.%26aulast%3DBhat%26aufirst%3DT.%2BN.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DShindyalov%26aufirst%3DI.%2BN.%26aulast%3DBourne%26aufirst%3DP.%2BE.%26atitle%3DThe%2520Protein%2520Data%2520Bank%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2000%26volume%3D28%26spage%3D235%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EYG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EYG','PDB','3EYG'); return false;">PDB: 3EYG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2B7A" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2B7A','PDB','2B7A'); return false;">PDB: 2B7A</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YVJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YVJ','PDB','1YVJ'); return false;">PDB: 1YVJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1AQ1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1AQ1','PDB','1AQ1'); return false;">PDB: 1AQ1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB','PDB','1RJB'); return false;">PDB: 1RJB</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i149"><a href="/doi/suppl/10.1021/jm200326p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_24257"></div></div></div></div></div><hr /></hr><p class="last">Explanation for CDK2 potency of <b>17h</b>, Western blots showing intracellular target inhibition by <b>21c</b>, and structures of the RCM catalysts employed. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm200326p/suppl_file/jm200326p_si_001.pdf">jm200326p_si_001.pdf (181.25 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm200326p&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Fjm200326p%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2011.54.issue-13%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm200326p" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e11e061ebc1252","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
